--- a
+++ b/clusters/9knumclustersv2/centers.txt
@@ -0,0 +1,3000 @@
+Cluster 0: substrates cypa inhibitors inducers sensitive narrow prescription strong therapeutic moderate
+Cluster 1: requiring infection systemic active therapy intravenous patient patients evidence enrollment
+Cluster 2: transaminase aminotransferase serum glutamic pyruvate oxaloacetic glutamate sgot sgpt aspartate
+Cluster 3: mcl neutrophil absolute count registration days cohort weeks prior phase
+Cluster 4: eastern cooperative oncology ecog group status performance days registration prior
+Cluster 5: alopecia aes resolved grade events adverse anticancer therapy prior cancer
+Cluster 6: document willingness understand sign ability written informed consent subjects assent
+Cluster 7: bilirubin protease mg dl direct total fraction inhibitor felt atazanavir
+Cluster 8: childbearing pregnancy negative test women potential registration days prior serum
+Cluster 9: pneumonitis infectious non active steroids history required evidence known requiring
+Cluster 10: expectancy life investigator opinion months determined weeks judgment greater assessed
+Cluster 11: mm axis lymph diameter short measurable lesion node recist longest
+Cluster 12: hepatitis virus indicating sag hcv hbv ribonucleic surface positive antigen
+Cluster 13: lactating women pregnant excluded study eligible childbearing intending potential cohort
+Cluster 14: jellies sponge vaginal ring study cream diaphragm transdermal spermicidal double
+Cluster 15: previously treated patients received treatment therapy subjects study eligible prior
+Cluster 16: creatinine clearance grade patients normal greater serum individuals ineligible set
+Cluster 17: locally recurrent metastatic disease breast cancer advanced histologically prior inoperable
+Cluster 18: bilirubin upper normal limit registration uln total days obtained prior
+Cluster 19: cardiovascular currently clinically significant disease active infarction myocardial months history
+Cluster 20: liver function adequate defined demonstrated subjects bilirubin organ participant following
+Cluster 21: contraception willing use study adequate implement drug appropriate days dose
+Cluster 22: heart ventricular sustained tachycardia nyha block york class association iii
+Cluster 23: mcl platelets cells cohort weeks phase randomization discretion greater plts
+Cluster 24: trial screening expecting projected conceive father children visit breastfeeding starting
+Cluster 25: radiotherapy chemotherapy surgery prior cancer received therapy treatment investigational patient
+Cluster 26: carcinoma cell squamous adenocarcinoma histologically confirmed adenosquamous patients hepatocellular primary
+Cluster 27: si units mm platelets international anc hemoglobin count neutrophil absolute
+Cluster 28: immunodeficiency virus hiv human infection patients uncontrolled active infected immunosuppressed
+Cluster 29: pr cr disease relapsed refractory progression need cytoreduction demonstrates defined
+Cluster 30: lansky karnofsky performance status pediatric adult patients years fossa posterior
+Cluster 31: composition compounds attributed similar irinotecan chemical allergic reactions biologic oxaliplatin
+Cluster 32: aminotransferase uln ast alt alanine aspartate upper normal limit liver
+Cluster 33: trial confound best abnormality results interfere participate laboratory duration current
+Cluster 34: nervous central metastases symptomatic cns requiring presence neurologically stable patients
+Cluster 35: evaluable response criteria solid recist evaluation tumors measurable disease version
+Cluster 36: transplantation allogeneic organ marrow bone prior allograft allogenic autologous immunosuppressives
+Cluster 37: existing high conventional pre regimen conditions myeloablative related age risk
+Cluster 38: age years lansky karnofsky performance status patients scale children subjects
+Cluster 39: hemoglobin dl administration days transfusion study drug measured week preceding
+Cluster 40: sbrt aptt activated intended anticoagulant anticoagulants ptt thromboplastin pt range
+Cluster 41: albumin dl serum registration days arm decreased cohort prior prothrombin
+Cluster 42: bilirubin total upper limit normal stenting biliary institution laboratory age
+Cluster 43: cytotoxic chemotherapy prior weeks days therapy treatment received patients agents
+Cluster 44: signed approved informed consent patients irb written voluntary form patient
+Cluster 45: pd durvalumab inhibitor including previous tremelimumab ctla treatment anti pdl
+Cluster 46: willing written able provide consent informed trial review understand patient
+Cluster 47: illness situations intercurrent social pectoris exclusion arrhythmia compliance ongoing psychiatric
+Cluster 48: medication ability oral receive orally swallowed tube dasatinib feeding familial
+Cluster 49: agents investigational receiving patients ineligible study treatment days cancer therapy
+Cluster 50: white cells ul wbc blood wbcs days cell obtained prior
+Cluster 51: breastfeeding women female patient study currently ineligible current patients lactating
+Cluster 52: low warfarin lmwh heparin dose thrombin xa clopidogrel aspirin therapeutic
+Cluster 53: leukemia lymphoma hodgkin acute chronic lymphocytic myeloid lymphoblastic myeloma non
+Cluster 54: day prior days weeks cigarettes study smoke therapy treatment use
+Cluster 55: diameter mm longest lesion injectable lesions measurable cutaneous subcutaneous tumor
+Cluster 56: alkaline phosphatase uln days equal registration institutional obtained iuln prior
+Cluster 57: major surgery enrollment days prior immunotherapy chemotherapy month patients craniotomy
+Cluster 58: ms qtc prolongation qt corrected interval greater ecg males females
+Cluster 59: ul anc neutrophil absolute count peripheral days prior registration treatment
+Cluster 60: metastases participants brain known excluded untreated require clinical corticosteroids imaging
+Cluster 61: gi vomiting nausea alter bowel diarrhea significantly malabsorption disease absorption
+Cluster 62: tissue excisional biopsy obtained newly core tumor sample archival lesion
+Cluster 63: infections hepatitis active known hiv patients including viral treatment aside
+Cluster 64: limits bilirubin upper normal total uln institutional serum registration gilberts
+Cluster 65: bp mmhg hypertension pressure diastolic blood systolic uncontrolled medication controlled
+Cluster 66: inr normalized international ratio anticoagulation range anticoagulant therapeutic desired normal
+Cluster 67: reaction monoclonal antibody severe hypersensitivity history mab infusion treatment prior
+Cluster 68: autoimmune past excluded disease years graves psoriasis endocrine vitiligo adequately
+Cluster 69: cancer cancers cell low metachronous situ carcinoma malignancy carcinoid prognosis
+Cluster 70: lvef left ejection fraction ventricular cardiac known equal patient baseline
+Cluster 71: bilirubin mg dl serum patients values level levels segmental standpoint
+Cluster 72: hematologic renal hepatic function adequate cardiac liver coagulation inadequate defined
+Cluster 73: exclusion criteria registration tnbc specific cohort patients treatment patient screening
+Cluster 74: ongoing infection recent grade including severity systemic days patients zydelig
+Cluster 75: elapsed therapy days completion biologic myelosuppressive agent prior weeks chemotherapy
+Cluster 76: platelet count ml enrollment days patient platelets greater baseline screening
+Cluster 77: comply unable requirements investigator unwilling study protocol opinion patient unlikely
+Cluster 78: steroid immunosuppressive therapy systemic form receiving days dose diagnosis prior
+Cluster 79: hematopoietic transplant stem cell prior hsct allogenic months received previous
+Cluster 80: mmol hemoglobin dl days transfusion registration assessment screening performed subjects
+Cluster 81: brain metastases radiation therapy prior patients treatment metastasis weeks eligible
+Cluster 82: autoimmune disease syndrome sclerosis guillain systemic barre granulomatosis vasculitis erythematosus
+Cluster 83: retain swallow oral medication able ability subject patient medications orally
+Cluster 84: diagnosed malignancy nonmelanoma residual type undergone resection situ skin complete
+Cluster 85: forced fev fvc expiratory vital volume capacity predicted second pulmonary
+Cluster 86: inability comply follow procedures study medical procedure adhere therapy judged
+Cluster 87: adenocarcinoma prostate biopsy confirmed histologically enrollment months year prior registration
+Cluster 88: eastern cooperative oncology group ecog performance status patients subject clinical
+Cluster 89: measurable lesion recist version target lytic predominantly present disease bone
+Cluster 90: live vaccine trial received dose days treatment prior run prohibited
+Cluster 91: conditions medical uncontrolled study affect severe investigator participation opinion concurrent
+Cluster 92: astrocytoma anaplastic grade oligodendroglioma glioma glioblastoma oligoastrocytoma diagnosis gliomas iii
+Cluster 93: ul cells platelets blood days prior thrombocytopenia treatment work biopsy
+Cluster 94: uncontrolled infection active systemic patients time subject significant transplantation clinically
+Cluster 95: neuropathy terminology common peripheral ctcae events adverse grade criteria existing
+Cluster 96: times upper limit normal creatinine serum uln institutional institution ast
+Cluster 97: hamster chinese ovary recombinant products antibodies hypersensitivity human cell known
+Cluster 98: replacement systemic thyroxine pituitary insulin modifying physiologic adrenal insufficiency therapy
+Cluster 99: tumor patients primary volume biopsy positive sample resection surgical patient
+Cluster 100: feeding breast pregnant patients patient currently subject subjects participant participation
+Cluster 101: stage breast cancer diagnosis iiia early ii clinical confirmed diagnosed
+Cluster 102: abnormality condition illness medical laboratory psychiatric prevent participating significant subject
+Cluster 103: intolerant progressed standard therapy regimen received prior refractory refused metastatic
+Cluster 104: immune acquired deficiency aids immunodeficiency syndrome hiv virus human known
+Cluster 105: dose study male contraception adequate agree use days starting method
+Cluster 106: hepatitis hiv infection known active history patients positive chronic uncontrolled
+Cluster 107: speaking english non patients participants caregiver assessments person emr read
+Cluster 108: undergone consecutive celibate orientation choice remaining sexual meets regardless months
+Cluster 109: corticosteroids exceed intranasal physiological inhaled prednisone equivalent doses immunosuppressive corticosteroid
+Cluster 110: alt uln prior iu screening age leukemic normal day patients
+Cluster 111: gross resection total hematuria tumor disease residual patients surgical surgery
+Cluster 112: setting line metastatic therapy prior received endocrine chemotherapy patients adjuvant
+Cluster 113: care medical consent prejudice voluntary withdrawn future understanding procedure written
+Cluster 114: concomitant protocol systemic therapy malignancies use uncontrolled disorder disease defined
+Cluster 115: follows function organ adequate defined marrow hematopoietic patient hepatic renal
+Cluster 116: hepatitis qualitative reactive detected hbsag rna ribonucleic hcv surface acid
+Cluster 117: expectancy life greater weeks years month patients participant date screening
+Cluster 118: tuberculosis tb bacillus active known history excluded patients mycobacterium patient
+Cluster 119: cytologically histologically confirmed diagnosis cancer carcinoma breast melanoma sclc metastatic
+Cluster 120: bleeding peptic ulcer active diathesis uncontrolled epistaxis disease patients spontaneous
+Cluster 121: seizure malformation arteriovenous dispose schwannomas meningiomas randomization stroke transient masses
+Cluster 122: radiation chemotherapy therapy prior cancer treatment immunotherapy surgery patients breast
+Cluster 123: function adequate renal pulmonary impaired hepatic immune cardiopulmonary liver physical
+Cluster 124: ecog performance status patients equal subject screening patient grade adequate
+Cluster 125: expectancy life months patients weeks patient anticipated subjects expected screening
+Cluster 126: accepted advised sexually males strongly effective contraception women method use
+Cluster 127: ng psa ml prostate specific antigen prostatectomy level serum nadir
+Cluster 128: donor leukapheresis factors risk increased place complications precluding csf undergo
+Cluster 129: hep hepatitis infection active hiv virus immunodeficiency known human acid
+Cluster 130: egfr mutation tm tki activating erlotinib inhibitor treatment progression patients
+Cluster 131: grade effects toxic alopecia acute resolved prior neuropathy therapy peripheral
+Cluster 132: cancer situ melanoma cervical malignancy skin non carcinoma years prostate
+Cluster 133: preclude opinion condition participation investigator trial medical study clinical participant
+Cluster 134: pugh score child hepatic patient liver class points severe cirrhotic
+Cluster 135: vaccines influenza live allowed seasonal intranasal inactivated injection attenuated flumist
+Cluster 136: investigational whichever half lives longer product agent prior days study
+Cluster 137: intolerance hypersensitivity known metformin investigation agents history fosbretabulin octreotide azoles
+Cluster 138: read english speak ability inability understand materials phase patients informed
+Cluster 139: hgb hemoglobin dl days registration prior starting anemia therapy obtained
+Cluster 140: pneumonitis interstitial lung history disease active radiation pulmonary glucocorticoids oral
+Cluster 141: older male female years age participants subjects patients consent obtained
+Cluster 142: pet ct fdg imaging mri patients scan disease scanning undergo
+Cluster 143: involving investigational participation clinical trial agent study drug product weeks
+Cluster 144: age years patients patient subject participants subjects months women participant
+Cluster 145: weeks prior therapy enrollment treatment dose study chemotherapy patients randomization
+Cluster 146: syndrome history patients sarcoidosis stevens johnson serotonin shwachman serotonergic kostmann
+Cluster 147: glomerular filtration gfr rate ml min gault cockcroft estimated creatinine
+Cluster 148: infarction myocardial heart congestive arrhythmias failure significant uncontrolled months cardiovascular
+Cluster 149: creatinine mg dl serum equal registration days prior levels renal
+Cluster 150: evidence disease metastatic radiographic clinical patients imaging radiological residual bone
+Cluster 151: classical hodgkin lymphoma hl confirmed diagnosis refractory histologically relapsed patients
+Cluster 152: ib weeks earlier bevacizumab monoclonal administered antibody events phase adverse
+Cluster 153: clearance min ml creatinine estimated renal serum cr clcr measured
+Cluster 154: cord blood umbilical units donor unit ucb recipient unrelated graft
+Cluster 155: anti pd agonists cd blockade therapeutic checkpoint immune ctla programmed
+Cluster 156: failed therapy standard patients line prior regimen systemic chemotherapy disease
+Cluster 157: carcinomatosis leptomeningeal history meningeal cns metastases lymphangitic brain diagnosed metastasis
+Cluster 158: equivalents prednisone daily mg immunosuppressive corticosteroids medications inhaled systemic adrenal
+Cluster 159: target lesion measurable lesions radiation size disease radiotherapy recist criteria
+Cluster 160: antiretroviral combination hiv ineligible positive immunodeficiency virus human therapy patients
+Cluster 161: nursing excluded pregnant women study patients mothers step teratogenic effects
+Cluster 162: investigational study participated therapy device participating currently agent used receiving
+Cluster 163: therapy biologic chemotherapy immunotherapy hormonal cancer concurrent radiation treatment investigational
+Cluster 164: therapeutic trial clinical participation current concurrent treatment enrollment exclusion enrolled
+Cluster 165: cancer cell free years cervical squamous situ skin basal disease
+Cluster 166: milk stored future mother breastfeeding note pregnant breast treated use
+Cluster 167: disorder bipolar schizophrenia psychiatric major depression history psychosis depressive diagnosis
+Cluster 168: suspected autoimmune known active disease subjects participants patients exclusionary excluded
+Cluster 169: hospitalization bacteremia infection pneumonia active tuberculosis signs complications antibiotics cycle
+Cluster 170: azacitidine mannitol hypersensitivity suspected known ingredient constituents components used monoclonal
+Cluster 171: pembrolizumab nivolumab prior treatment therapy dose received ipilimumab mk weeks
+Cluster 172: procedure surgical major anticipation need course study diagnosis weeks initiation
+Cluster 173: receptor american asco cap er negative college pathologists society guidelines
+Cluster 174: subfamily cytochrome polypeptide family cypa cypc substrates inhibitors medications strong
+Cluster 175: pregnant inform suspect immediately bearing woman participating study barrier child
+Cluster 176: males females potential use child bearing agree contraception effective partners
+Cluster 177: metastases brain carcinomatous meningitis nervous cns central participate stable treated
+Cluster 178: mannitol hypersensitivity known allergy history sensitivity bendamustine ofatumumab quizartinib aza
+Cluster 179: leukocytes ul secondary days treatment obtained radiotherapy prior cells performed
+Cluster 180: histologically metastatic advanced locally confirmed unresectable cytologically patients nsclc breast
+Cluster 181: monitoring safety comply opinion requirements able investigator study eligible patients
+Cluster 182: tracheoesophageal fistula abdominal perforation gastrointestinal months history gi abscess prior
+Cluster 183: hemoglobin dl gr phase hg treatment minimum weeks enrollment screening
+Cluster 184: nervous central primary lymphoma malignancy metastatic history cns known pcnsl
+Cluster 185: kg donor weight haplo cd bw dose bmi wt recommended
+Cluster 186: evaluable recist measurable disease criteria non according radiographically version participants
+Cluster 187: bilateral breast orchiectomy cancer unilateral patients occlusion simultaneous primaries tubal
+Cluster 188: healing wound surgery allow major postoperative site randomization prior surgical
+Cluster 189: cns metastasis nervous central brain treated stable patients metastases eligible
+Cluster 190: major surgery weeks dose prior study day radiation therapy past
+Cluster 191: contraception methods abstinence effective highly use partner intrauterine acceptable male
+Cluster 192: carcinoma skin cell situ curative potentially basal undergone cervical squamous
+Cluster 193: corrected limits calcium albumin normal potassium magnesium serum phosphorus supplements
+Cluster 194: creatinine uln equal cohort baseline greater age biopsy kinase prior
+Cluster 195: visits comply procedures willing able scheduled tests study laboratory plans
+Cluster 196: examination physical registration history days prior complete patients digital rectal
+Cluster 197: aminotransferase alanine aspartate ast alt upper limit normal uln serum
+Cluster 198: dl plasma bone myeloma serum mg light marrow lesions protein
+Cluster 199: platinum containing regimen progression chemotherapy disease prior metastatic treatment cisplatin
+Cluster 200: relapsed refractory disease therapy cell stem transplant following prior autologous
+Cluster 201: heart york association new class iii iv cardiac disease nyha
+Cluster 202: menopausal post pregnancy test women pre negative urine serum status
+Cluster 203: relapsed refractory disease patients aml therapy prior treatment regimen therapies
+Cluster 204: sterilized surgically potential childbearing pregnancy test year negative menses postmenopausal
+Cluster 205: transient attack ischemic heart stroke infarction myocardial angina unstable months
+Cluster 206: components program hypersensitivity allergic documented patient reaction chemotherapy known study
+Cluster 207: lesions bone patients measurable target disease treated lesion considered metastatic
+Cluster 208: hematocrit hct hb hemoglobin dl equal infusions developed cyclophosphamide apheresis
+Cluster 209: epo dependency erythropoietin mmol transfusion assessment hemoglobin days dl initiation
+Cluster 210: coronary artery disease heart symptomatic failure congestive myocardial infarction cardiac
+Cluster 211: expectancy life weeks patients subjects minimum subject patient anticipated time
+Cluster 212: bmi kg mass index body obese overweight greater equal weight
+Cluster 213: echo muga lvef fraction ejection left ventricular scan cardiac normal
+Cluster 214: receipt investigational days prior therapy dose anticancer study weeks treatment
+Cluster 215: leukocytes mcl days registration phase obtained initiation ii treatment prior
+Cluster 216: cervix situ melanoma malignancy cancer skin carcinoma non years free
+Cluster 217: women potential childbearing pregnancy birth study men control test method
+Cluster 218: primary original histologic peritoneal epithelial fallopian ovarian tube report documentation
+Cluster 219: institute national nci common terminology ctcae events adverse grade criteria
+Cluster 220: phase ii patients portion criteria prior disease inclusion treatment ecog
+Cluster 221: proper prescribed inappropriate morbid illnesses make significantly judgment regimens safety
+Cluster 222: radiotherapy previous chemotherapy brain temozolomide therapy line treatment toxicity persistence
+Cluster 223: block bundle branch left right complete bifascicular hemiblock anterior lbbb
+Cluster 224: hypersensitivity known agents study used patients drug ingredients compounds dacarbazine
+Cluster 225: platelets mm cu wbc weeks enrollment count support day plts
+Cluster 226: provision existing safety pre interfere unstable condition psychiatric medical consent
+Cluster 227: cardiac impaired function clinically significant diseases disease following including heart
+Cluster 228: graft versus host disease active chronic grade acute treatment cgvhd
+Cluster 229: ul platelet count cells untransfused days thrombocytopenia prior arm cohort
+Cluster 230: pembrolizumab excipients hypersensitivity severe known grade epacadostat substance active history
+Cluster 231: exercise week intensity moderate minutes program vigorous able musculoskeletal intervention
+Cluster 232: mass cm bulky renal effect tumor disease palpable defined patients
+Cluster 233: urine protein mg creatinine ratio spot dl reported mmol hour
+Cluster 234: retinal detachment macular degenerative degeneration history vein ophthalmologic occlusion neurosensory
+Cluster 235: infections bacterial fungal viral active uncontrolled systemic requiring therapy unresponsive
+Cluster 236: existing pre neuropathy grade peripheral greater conditions patients higher disorder
+Cluster 237: pelvic previous radiation prostate cancer therapy abdominal chemotherapy radiotherapy surgery
+Cluster 238: kinase tyrosine inhibitor inhibitors tki therapy prior treatment egfr received
+Cluster 239: beta chorionic gonadotropin hcg human negative test potential pregnancy childbearing
+Cluster 240: oxygen continuous use home requires formalin supplementary ibrutinib dependence treatment
+Cluster 241: brain metastases stable steroids treated weeks patients treatment dose eligible
+Cluster 242: breastfeeding pregnant female patients patient subject subjects currently intending participants
+Cluster 243: advanced metastatic received disease prior therapy systemic cancer chemotherapy patients
+Cluster 244: step registration prior days eligibility patients criteria status initial treatment
+Cluster 245: platelet mm count greater days randomization starting prior initiation weeks
+Cluster 246: formulations allergy components hypersensitivity identified previously study cobimetinib treatment component
+Cluster 247: traumatic injury open major procedure significant surgical biopsy days study
+Cluster 248: self report reported identify hispanic african american latino black identifies
+Cluster 249: phenobarbital carbamazepine phenytoin subfamily cypa cytochrome polypeptide wort rifampin family
+Cluster 250: anc neutrophil absolute count ml days study treatment administration prior
+Cluster 251: cns leukemia nervous central active involvement evidence presence extramedullary clinical
+Cluster 252: stage iv histologically confirmed melanoma braf ve iiic mutation mbc
+Cluster 253: amylase pancreatitis lipase history increased pancreatic symptoms uln cholecystitis suggestive
+Cluster 254: threatening dysfunction outcomes compromise safety undue organ life illness opinion
+Cluster 255: lactating pregnant patients eligible participation practicing breastfeeding registration known ineligible
+Cluster 256: medical condition problems study participation uncontrolled investigator psychiatric risk disease
+Cluster 257: pregnancy current known female test avoid patient asked active patients
+Cluster 258: effects recovered major undergone starting surgery weeks drug prior study
+Cluster 259: parp inhibitor prior treatment inhibitors patients received previously iniparib temozolomide
+Cluster 260: unwilling unable undergo discontinue study complete patients prohibited adhere follow
+Cluster 261: deems unsuitable candidate investigators opinion receive condition drug participant study
+Cluster 262: neutrophils ul days obtained registration randomization cells prior study dose
+Cluster 263: neutrophil count mm biopsy total prior ul specific enrollment cell
+Cluster 264: seizure dispose schwannoma malformation arteriovenous meningioma meningeal pre benign condition
+Cluster 265: plasma leukemia primary secondary cell screening time evidence known history
+Cluster 266: rems adhere program revlimid scheduled reproductive testing females pregnancy required
+Cluster 267: agree intercourse abstain heterosexual practice completely contraception surgically effective sterilized
+Cluster 268: bleeding diathesis active evidence patients known uncontrolled hemoptysis weeks gastrointestinal
+Cluster 269: organ function adequate defined following including demonstrates baseline protocol criteria
+Cluster 270: stage melanoma unresectable iv iii histologically confirmed metastatic diagnosis cutaneous
+Cluster 271: oxygen dlco saturation pulmonary room air function monoxide carbon diffusing
+Cluster 272: uncontrolled diabetes hypertension days prior randomization assessment toxicity conditions interfere
+Cluster 273: autoimmune requiring trigger recur hypothyroidism vitiligo mellitus psoriasis replacement diabetes
+Cluster 274: illicit alcohol abuse drugs use drug addiction marijuana current months
+Cluster 275: drugs investigational received enrollment days patient weeks prior study dose
+Cluster 276: gilberts bilirubin uln total syndrome disease unless subjects patients documented
+Cluster 277: drugs taking treatment patients study use prior drug concomitant flecainide
+Cluster 278: comply willing able requirements protocol study trial instructions subject follow
+Cluster 279: creatinine cockcroft gault clearance formula mg dl ml min calculated
+Cluster 280: autoimmune disease active history known patients documented treatment requiring disorders
+Cluster 281: provide written consent informed patients procedures screening prior study participate
+Cluster 282: dmso sulfoxide dimethyl chemically idiosyncrasy delayed immediate excipients hypersensitivity reaction
+Cluster 283: recipients transplant organ allogeneic bone marrow immunodeficiency eligible pembrolizumab syndromes
+Cluster 284: situations social compliance illness psychiatric requirements limit study patients uncontrolled
+Cluster 285: myocardial angina infarction unstable months history prior day enrollment study
+Cluster 286: treatment study days dose investigational prior drug weeks chemotherapy agents
+Cluster 287: risk high intermediate patients disease defined neuroblastoma following criteria factors
+Cluster 288: schedule adhere visit requirements protocol able study willing ability patient
+Cluster 289: slides tissue unstained available block tumor archival blocks paraffin biopsy
+Cluster 290: zubrod performance status patients ps karnofsky score criteria scale equal
+Cluster 291: survival estimated months expectation gpa median year weeks medical patients
+Cluster 292: recist measurable defined disease criteria patients non unidimensionally presence imaging
+Cluster 293: normalized inr international ratio uln anticoagulants warfarin coagulopathy registration days
+Cluster 294: distant metastases evidence metastatic disease patients documented regional clinical known
+Cluster 295: pregnancy fcbp effective method commit days agree begin lenalidomide continued
+Cluster 296: alcohol drinks consumption drug addiction abuse day use excessive oz
+Cluster 297: qt msec congenital long corrected syndrome qtc interval fridericia history
+Cluster 298: venous thrombosis deep thromboembolism embolism arterial history pulmonary months prior
+Cluster 299: substance abuse alcohol history active psychiatric known mental addiction predisposes
+Cluster 300: metastasis brain known patients untreated active suspected history treated parenchymal
+Cluster 301: return follow institution enrolling monitoring willing phase active mayo clinic
+Cluster 302: pneumonitis organizing fibrosis idiopathic pneumonia induced chest pulmonary history bronchiolitis
+Cluster 303: compression cord spinal leptomeningeal brain metastases disease carcinomatosis uncontrolled symptomatic
+Cluster 304: brachytherapy beam external pelvic radiation radiotherapy prostate prior therapy received
+Cluster 305: nsclc squamous cell predominantly diagnosis histological histologic non predominance carcinoma
+Cluster 306: hsct allogeneic autologous prior allo undergoing previous cgs received patients
+Cluster 307: hiv antibodies immunodeficiency virus human known history testing required cohort
+Cluster 308: tomography ct positron emission imaging pet resonance magnetic mri computed
+Cluster 309: interpretation results interfere safety condition evaluation study opinion investigator patient
+Cluster 310: oxygen saturation pulse oximetry rest resting hypoxemia baseline supplemental pao
+Cluster 311: muga ventricular multi lvef equal acquisition gated scan left ejection
+Cluster 312: neoadjuvant chemotherapy therapy planned received surgery patients cancer prior breast
+Cluster 313: seizure disorder medication requiring patients antiepileptic seizures brain history metastases
+Cluster 314: patients disease men zydelig fanca fascia farber fap fanconi fancd
+Cluster 315: informed indicating consent board irb risks nature sign review approved
+Cluster 316: equivalent doses prednisone steroids suppression immune mg medications day discontinued
+Cluster 317: post operative transplant surgery treatment months pre operatively residual patients
+Cluster 318: surgically childbearing potential abstain heterosexual activity sterile sterilized study subjects
+Cluster 319: women pregnant planning nursing participate study eligible breastfeed ineligible donor
+Cluster 320: interpret confounds places unacceptable data study condition abnormalities participate ability
+Cluster 321: transfusion dependent blood days thrombocytopenia anemia prior draw eligibility patients
+Cluster 322: alk egfr ros rearrangement nsclc mutation mutations patients positive translocation
+Cluster 323: metastases meningitis carcinomatous brain evidence stability trial enlarging returned regardless
+Cluster 324: malignancy active treatment relapse requiring underlying uncontrolled meningeal patients cerebral
+Cluster 325: mab weeks earlier monoclonal administered antibody prior recovered adverse events
+Cluster 326: neck head squamous carcinoma cell histologically confirmed scchn cancer hnscc
+Cluster 327: bilirubin total mg dl serum days equal uln ml study
+Cluster 328: recovered grade note therapy prior qualify molecule criterion complications targeted
+Cluster 329: history bilateral reproductive menopausal ligation menses tubal oophorectomy hysterectomy potential
+Cluster 330: whichever shorter half lives therapy days anticancer investigational drug prior
+Cluster 331: grade persisting toxicity sensory related alopecia nci neuropathy ctcae constituting
+Cluster 332: urine hour proteinuria collection protein quantitative urinalysis hours participants undergo
+Cluster 333: total bilirubin upper limit normal uln age equal days level
+Cluster 334: toxicities receives recovered preparative grade elapsed weeks minor regimen vitiligo
+Cluster 335: potentially completion interfere psychiatric illness opinion according medical investigators protocol
+Cluster 336: cirrhosis liver chronic disease hepatitis patients history steatohepatitis nonalcoholic known
+Cluster 337: response working international imwg myeloma criteria group iwg partial uniform
+Cluster 338: hepatitis positive hbsag dna hbv negative hbcab test antibody surface
+Cluster 339: strong inducers cypa inhibitors medications treatment cytochrome study prior discontinued
+Cluster 340: contraception study abstinence adequate agree male lifestyle usual preferred use
+Cluster 341: ul platelets days prior registration obtained treatment weeks plts untransfused
+Cluster 342: cooperation substance abuse disorders interfere requirements psychiatric trial known study
+Cluster 343: chronic use immunosuppressants corticosteroids myopathy conditions history disease therapy glucocorticoids
+Cluster 344: strong inhibitor cypa cytochrome ibrutinib continuous require cyp subjects treatment
+Cluster 345: medications able oral orally patients patient tube willing feeding retain
+Cluster 346: start treatment prior study weeks days radiation therapy patients chemotherapy
+Cluster 347: effective contraception highly use agree study conception treatment male protocol
+Cluster 348: glucose fasting mg dl mmol plasma diabetes blood serum mellitus
+Cluster 349: nursing women pregnant lactating mothers plan following breastfeeding exclusion arm
+Cluster 350: aptt activated thromboplastin time partial uln prothrombin pt normal upper
+Cluster 351: steroidal inflammatory anti non aspirin drugs nsaids use agents nsaid
+Cluster 352: shortening fraction echocardiogram radionuclide ejection gated cardiac study function muga
+Cluster 353: creatinine clearance ml min upper limit normal calculated uln serum
+Cluster 354: world organization health aml leukemia acute promyelocytic apl diagnosis myeloid
+Cluster 355: abiraterone acetate enzalutamide treatment prior ketoconazole consumed cohort stomach aminoglutethimide
+Cluster 356: abdomen pelvis ct chest imaging scan tomography computed mri resonance
+Cluster 357: age signing consent years time informed form icf day subject
+Cluster 358: previous treatment therapy chemotherapy months radiation received treatments cancer prior
+Cluster 359: primary immunodeficiency history active tuberculosis known subject investigation patients sjcar
+Cluster 360: ovulation agree practice methods abstinence contraception post periodic true symptothermal
+Cluster 361: prolonging switched medication pointes different qt inducing discontinued interval risk
+Cluster 362: ctcae neuropathy grade peripheral nci version presence institute national higher
+Cluster 363: histologic cytologic confirmation diagnosis proof solid adenocarcinoma tumor advanced malignancy
+Cluster 364: samples correlative purposes research provide willing blood tissue mandatory marrow
+Cluster 365: biopsy tumor amenable core undergo patients tissue treatment patient study
+Cluster 366: donors donor apheresis meet related marrow guidelines pbsc selection unrelated
+Cluster 367: anaphylactic monoclonal antibody reactions allergic history severe reaction humanized therapy
+Cluster 368: obtained registration uln days prior creatinine bilirubin arm total serum
+Cluster 369: catheter venous central donor leukapheresis apheresis access peripheral adequate placement
+Cluster 370: agonist lhrh antagonist prior treatment ctla orchiectomy ipilimumab therapy inhibitor
+Cluster 371: wheelchair score ambulatory paralysis performance walk assessing purpose considered lansky
+Cluster 372: bowel inflammatory disease history active gastrointestinal chronic diarrhea colitis fibrosis
+Cluster 373: exist longer standard palliative curative effective measures lymphoma hodgkin patients
+Cluster 374: health authorization accountability portability insurance hipaa act release information personal
+Cluster 375: myeloid leukemia acute aml blasts relapsed marrow refractory remission patients
+Cluster 376: anc neutrophil absolute mm count peripheral randomization days weeks day
+Cluster 377: swallow able tube absorb medication capsule ability nasogastric capsules gastrostomy
+Cluster 378: document willingness understand sign ability written informed consent subject patients
+Cluster 379: carcinomas basal malignancies squamous cell skin adequately treated years past
+Cluster 380: guardians parents legal sign consent informed written patients assent benefits
+Cluster 381: cm dimension tumor lesion greatest tumors measurable disease lesions margin
+Cluster 382: illness situations pectoris social intercurrent compliance arrhythmia requirements psychiatric unstable
+Cluster 383: anti programmed pd death cell ligand lymphocyte ctla antibody cytotoxic
+Cluster 384: bilirubin serum uln institutional gilberts pretreatment institutions equal levels level
+Cluster 385: stage criteria inclusion eligibility zydelig fanca farber fap fanconi fancd
+Cluster 386: cancer cell carcinoma lung small colorectal melanoma non ovarian neck
+Cluster 387: approved investigational treatment day drug indication days therapy non receiving
+Cluster 388: therapy prior patients days targeted treatment receiving trastuzumab radiation dose
+Cluster 389: bladder cancer invasive muscle tumor turbt transurethral prior radiation non
+Cluster 390: absorption gastrointestinal interfere disease oral drug condition impair orally conditions
+Cluster 391: rendering understanding prohibit altered informed dementia condition consent mental psychiatric
+Cluster 392: hbv hcv infection hepatitis virus cleared hiv known active chronic
+Cluster 393: carcinoma cell basal cervix local resection exception squamous skin treated
+Cluster 394: space fluid drainage controlled presence collections significant clinically pleural effusion
+Cluster 395: bisphosphonates denosumab treatment allowed therapy prior bone started patients stable
+Cluster 396: initiation treatment therapy prior study days weeks investigational drug radiation
+Cluster 397: number regimens prior treatment chemotherapy limit allowed patients unlimited therapy
+Cluster 398: informed federal authorized legally accordance nature representative guidelines sign consent
+Cluster 399: unwillingness swallow inability pills capsules enteral medications oral malabsorption absorption
+Cluster 400: cancer remission complete cervix unless minimum situ melanoma skin years
+Cluster 401: male female age years patients time consent subjects creatinine informed
+Cluster 402: inability consent informed provide understand written obtain assent voluntary document
+Cluster 403: albumin allergy patients zydelig fascicular fascia farber fap fanconi fancd
+Cluster 404: capsules lenalidomide swallow opened isotretinoin able inability false familial falls
+Cluster 405: pelvic radiotherapy prior chemotherapy previous patients history received rectal malignancy
+Cluster 406: lln potassium lower phosphorus serum normal limit magnesium calcium sodium
+Cluster 407: cerebrovascular sequelae event significant symptoms ongoing past history disease months
+Cluster 408: investigational therapy prior month weeks entry study treatment days patients
+Cluster 409: effusion pericardial pleural ascites significant ejection fraction clinically evidence cardiac
+Cluster 410: iva stage ivb iii carcinoma squamous patients disease hnscc ivc
+Cluster 411: white wbc cells blood mm mcl cell bil days ml
+Cluster 412: oximetry pulse room air oxygen saturation pulmonary infusion patients gas
+Cluster 413: prisoners excluded vulnerable study eligible considered individuals pregnant populations children
+Cluster 414: regimen chemotherapy prior containing received patients treatment therapy disease metastatic
+Cluster 415: identity ensure entered process order approval open board date network
+Cluster 416: clinically significant history bleeding months past hemorrhagic event thromboembolic increases
+Cluster 417: kps karnofsky performance status score patients patient lansky greater ecog
+Cluster 418: weeks adverse events recovered administered prior agents entering study earlier
+Cluster 419: uln liver alt ast metastases metastasis present bilirubin patients subjects
+Cluster 420: ventricular fibrillation tachycardia atrial arrhythmia flutter inotropic cardiac uncontrolled contractions
+Cluster 421: giving capable consent informed written patient restrictions voluntarily mental prevents
+Cluster 422: creatinine glomerular filtration rate gfr min ml serum normal uln
+Cluster 423: bilirubin uln total direct initiation levels serum days subjects performed
+Cluster 424: prostate biopsy cancer proven trus prior core psa cores guided
+Cluster 425: current use malignancy smoker history treatment diagnosis study inter prior
+Cluster 426: docetaxel sensitive prostate cancer castrate metastatic treatment hormone chemotherapy mcrpc
+Cluster 427: excluded patients study subjects treatment women basis pregnant racial background
+Cluster 428: old females males years age older ethnicity race greater provide
+Cluster 429: pregnancy test positive lactating period female screening serum patients breastfeeding
+Cluster 430: donor selection nmdp pregnant eligibility identical pregnancy cell chimerism twin
+Cluster 431: version recist solid response evaluation tumors measurable criteria disease defined
+Cluster 432: fda food met nci institute national studies administration institutional human
+Cluster 433: continuing birth include method control condom barrier final acceptable partner
+Cluster 434: creatinine mg dl equal cr renal considered unless tumor related
+Cluster 435: aspirin heparin prophylactic anticoagulation molecular daily weight low asa intolerant
+Cluster 436: antifungals antivirals antibiotics infection parenteral requiring uncontrolled week prophylactic active
+Cluster 437: creatinine gault cockcroft clearance institutional normal min ml levels formula
+Cluster 438: ps performance ecog status score karnofsky scale group eastern operative
+Cluster 439: creatinine cockcroft gault clearance formula calculated min ml uln serum
+Cluster 440: allogenic transplantation stem organ cell prior including history hematopoietic transplants
+Cluster 441: antibiotics oral iv weeks prior therapeutic treatment day cycle received
+Cluster 442: aspartate aminotransferase ast uln hepatic days laboratory iu involvement unless
+Cluster 443: sign willing consent informed able understand comply protocol patients written
+Cluster 444: iii stage breast cancer ii diagnosed diagnosis newly histologically history
+Cluster 445: prolong interval qt qtc known medications drugs concomitant use medication
+Cluster 446: clips metal aneurysm devices mri implants pacemakers implanted shrapnel metallic
+Cluster 447: pathology review central report diagnosis confirmed tissue slides biopsy reviewed
+Cluster 448: lansky score karnofsky performance dependent patients years scores age inclusion
+Cluster 449: radiotherapy completed weeks prior therapy deferred chemotherapy enrollment study date
+Cluster 450: crcl cockcroft creatinine gault clearance min calculated ml formula using
+Cluster 451: females method males birth effective control agreed reproductive contraceptive potential
+Cluster 452: vegf endothelial growth vascular factor bevacizumab vegfr prior receptor anti
+Cluster 453: antibiotics infection requiring active iv controlled patients systemic uncomplicated chronic
+Cluster 454: bearing child pregnancy test women negative potential serum urine days
+Cluster 455: mri scan tumor ct performed evidence baseline imaging days prior
+Cluster 456: fruits herbal medications include gingko yohimbe grapefruit ephedra kava dehydroepiandrosterone
+Cluster 457: times limits normal bilirubin upper institutional total uln enzymes function
+Cluster 458: english read understand fluent able fluency language questionnaires complete speakers
+Cluster 459: malabsorption condition enteral syndrome absorption route interfere precludes problem administration
+Cluster 460: gog gynecologic oncology group performance status patients protocol priority rare
+Cluster 461: gene therapy prior mutation idh product modified treatment mutated tumor
+Cluster 462: msec qtc interval ecg screening prolongation males females electrocardiogram baseline
+Cluster 463: consent informed patients capacity willingness documented refuses assent patient understand
+Cluster 464: recover reversible effects fully regardless failure acute interval prior chemotherapy
+Cluster 465: day surgery major days cycle prior study weeks completely recovered
+Cluster 466: breastfeeding pregnant women childbearing potential intend plan currently months pregnancy
+Cluster 467: vaccination attenuated receipt live days durvalumab entry receiving tremelimumab prior
+Cluster 468: paclitaxel carboplatin hypersensitivity cremophor weekly known history chemotherapy reaction treatment
+Cluster 469: gvhd host graft versus transplant allogeneic stem disease cell sct
+Cluster 470: hemoptysis hemorrhage history gross pulmonary weeks months prior study month
+Cluster 471: treated adequately evidence lentigo maligna disease malignancy situ cancer melanoma
+Cluster 472: resonance magnetic imaging mri brain contrast undergo patients able gadolinium
+Cluster 473: chest radiation prior therapy received patients neck abdomen ray history
+Cluster 474: airway enlargement obstruction location cause tumor lymphodepletion procurement exclusion fixed
+Cluster 475: older years patients women old men japan korea participants south
+Cluster 476: geographical psychological familial permit sociological compliance protocol conditions follow unwillingness
+Cluster 477: sgot oxaloacetic glutamic transaminase aspartate aminotransferase ast upper limit normal
+Cluster 478: trial trials included participation agents clinical duration investigational start days
+Cluster 479: histology cytology neuroendocrine adenocarcinoma tumor confirmed grade mixed carcinoma sarcomatoid
+Cluster 480: authorized legally irb representative board applicable review approved document understand
+Cluster 481: stage metastatic iv disease distant patients iii evidence cancer unresectable
+Cluster 482: moderate severe disease cardiovascular ascites stenosis cardiac fatigue cgvhd nih
+Cluster 483: abstinent remain agreement men women consuming potential childbearing use alcohol
+Cluster 484: immunotherapy prior chemotherapy treatment received weeks previous days allowed patients
+Cluster 485: institutional creatinine upper limit normal uln serum equal days ctcae
+Cluster 486: examinations visits including undergoing scheduled comply willing duration follow able
+Cluster 487: increase study associated interpretation participation results medical interfere condition psychiatric
+Cluster 488: prostate cancer diagnosis therapy ketoconazole previous prior volume localized metastatic
+Cluster 489: finding metabolic reasonable suspicion contraindicates examination render dysfunction physical giving
+Cluster 490: bisphosphonate therapy denosumab hypercalcemia osteoporosis symptomatic use allowed reasons bone
+Cluster 491: autologous transplantation stem cell allogeneic prior eligible patients undergone asct
+Cluster 492: woman potential pregnancy test childbearing negative urine serum prior wocbp
+Cluster 493: anemia hemolytic thrombocytopenia autoimmune uncontrolled active immune itp aiha patients
+Cluster 494: chimeric humanized fusion anaphylactic proteins antibodies reactions allergic hypersensitivity severe
+Cluster 495: vomiting nausea preclude malabsorption absorption bowel significant shunt resection biliary
+Cluster 496: cigarette smoked past use week days tobacco month smoking study
+Cluster 497: platelets dl consent days chemistry documented total hepatocellular enrollment months
+Cluster 498: thyroid cancer patients replacement papillary hypothyroidism differentiated hormone medullary anaplastic
+Cluster 499: lymphoma cell mantle large leukemia diagnosis patients therapy nk nhl
+Cluster 500: incarcerated prisoners involuntarily subjects individuals patients persons prisoner likely person
+Cluster 501: clinical concerns study safety contraindicate procedures participation condition judgment compliance
+Cluster 502: individuals malignancy years circumstances following cell eligible recurrence history deemed
+Cluster 503: node lymph involvement dissection disease biopsy cm regional tumor patients
+Cluster 504: adenocarcinoma cytologically histologically prostate confirmed breast small cell proven diagnosis
+Cluster 505: medications systemic azathioprine tnf methotrexate thalidomide necrosis anti mineralocorticoids cyclophosphamide
+Cluster 506: invading vessel concern major invasion blood tumor carotid subject vessels
+Cluster 507: prolongation qtc qt interval history msec corrected syndrome known medications
+Cluster 508: dcis ductal breast carcinoma invasive situ cancer diagnosis history prior
+Cluster 509: surgery prior patients days weeks definitive patient chemotherapy undergo undergoing
+Cluster 510: medi small cohort lung cell cancer eligibility phase ii non
+Cluster 511: coagulation anti therapy therapeutic patients prophylactic aspirin venous currently dose
+Cluster 512: rems strategies mitigation program evaluation mandatory registered risk willing comply
+Cluster 513: hormone lhrh releasing luteinizing agonist therapy testosterone antagonist agonists androgen
+Cluster 514: ihc receptor staining immunohistochemistry estrogen er negative progesterone pr amplified
+Cluster 515: mmhg hypertension diastolic systolic uncontrolled pressure controlled despite poorly defined
+Cluster 516: accountability portability insurance act hipaa health authorization consent informed written
+Cluster 517: transplantation organ solid received eligible patients prior transplants subjects stratum
+Cluster 518: document sign written understand consent able informed willing comprehend patient
+Cluster 519: cohort expansion dose patients participants treatment prior inclusion criteria phase
+Cluster 520: anti pd antibody pathways targeting specifically ctla checkpoint stimulation cell
+Cluster 521: assistance questionnaire complete ability questionnaires english diary comprehend independently interpreter
+Cluster 522: ps eastern cooperative oncology ecog group performance status scale score
+Cluster 523: diagnosis cancer confirmed disease prior time history patients years malignancy
+Cluster 524: atrial fibrillation arrhythmia cardiac controlled uncontrolled arrhythmias requiring history excluded
+Cluster 525: trial clinical participation investigational drug days treatment prior participated agent
+Cluster 526: aminotransferase aspartate alanine ast alt uln institutional days registration unless
+Cluster 527: carcinomatous meningitis cns metastases active known brain lesions evidence ct
+Cluster 528: factors growth hematopoietic days transfusions prior platelet count allowed treatment
+Cluster 529: specific exclusions prevention study adhere applicable program bevacizumab available generate
+Cluster 530: sign informed consent patients form written document ability patient comprehend
+Cluster 531: cns nervous central disease active patients history malignancy symptomatic patient
+Cluster 532: hypertensive encephalopathy crisis history prior hypertension controlled inadequately years mmhg
+Cluster 533: organ marrow function adequate bone defined days patient patients prior
+Cluster 534: blast cml crisis myeloid leukemia chronic phase accelerated tyrosine kinase
+Cluster 535: contrast iodinated allergy mri media intravenous enhanced contraindication agent reaction
+Cluster 536: care standard patients patient therapy treatment receive supportive primary scheduled
+Cluster 537: cyclosporin azathioprine steroid immunosuppressive subjects therapy steroids premedication nasal enhanced
+Cluster 538: bowels stomach alter retain malabsorption absorption abnormalities swallow resection gastrointestinal
+Cluster 539: donate sperm agree study dose drug months male semen receiving
+Cluster 540: replacement autoimmune atopy intermittent injections bronchodilators systemic asthma syndrome childhood
+Cluster 541: tablets swallow able capsules intact inability patients ability ribociclib crushed
+Cluster 542: marrow bone function adequate defined evidenced subject lymphodepleting patient participants
+Cluster 543: autologous hematopoietic stem transplant cell allogeneic relapse prior hsct hodgkin
+Cluster 544: progressive disease rapidly evidence therapy patients treatment study time months
+Cluster 545: liver disease history chronic metastases function tests lfts patients burden
+Cluster 546: sgpt purpose transaminase alt uln pyruvate glutamate alanine aminotransferase serum
+Cluster 547: transplant allogeneic previous stem cell autologous aml months allo kind
+Cluster 548: hepatitis infection active known virus patients hiv clinically evidence including
+Cluster 549: bowel affecting significantly malabsorption small gastrointestinal stomach disease resection function
+Cluster 550: hemodialysis dialysis peritoneal renal patients failure requiring requirement replacement therapy
+Cluster 551: uncontrolled arrhythmias ventricular heart severe comorbidities angioplasty poorly atrial diastolic
+Cluster 552: weeks therapy nitrosoureas mitomycin prior study chemotherapy radiation treatment biologic
+Cluster 553: gilbert mg bilirubin dl syndrome total unless patients serum known
+Cluster 554: oxygen dependent patient chronic patients supplemental receiving therapy zydelig fancc
+Cluster 555: childbearing contraception potential effective use women men willing months forms
+Cluster 556: pre registration criteria eligibility exclusion step optional days post chemotherapy
+Cluster 557: source stem blood donor peripheral cell marrow bone cells hematopoietic
+Cluster 558: untreated nervous central metastases cns active known brain primary disease
+Cluster 559: immunosuppressant tacrolimus cyclosporine days concurrent systemic drug prednisone dose therapy
+Cluster 560: enrolled study patients currently trial clinical protocol previously treatment therapy
+Cluster 561: testosterone ng dl serum levels level castration androgen baseline hypogonadism
+Cluster 562: dysfunction significant cardiac organ renal history hepatic pulmonary clinically liver
+Cluster 563: creatinine clearance min hour ml urine calculated collection gault cockcroft
+Cluster 564: pt time anticoagulant intended anticoagulants prothrombin inr ptt range normalized
+Cluster 565: hemorrhage intracranial evidence mri intratumoral recent cns baseline grade patients
+Cluster 566: allergies intolerance known excipients hypersensitivity drug acetate subjects abiraterone prednisone
+Cluster 567: induction cr aml remission refractory relapse therapy patients complete chemotherapy
+Cluster 568: randomized phase trial ii arms clinical willing patients arm study
+Cluster 569: immunodeficiency test human virus positive hiv result known history screening
+Cluster 570: ul neutrophil absolute count days registration prior arm cohort phase
+Cluster 571: cytopathologically confirmed histologically pancreas adenocarcinoma infiltration myeloma multiple nervous cns
+Cluster 572: toxicity recovered grade prior therapy related acute baseline returned patients
+Cluster 573: weight loss months past program unintentional body prior watchers experienced
+Cluster 574: thrombosis vein deep embolism pulmonary months history embolus enrollment anticoagulation
+Cluster 575: time inr prothrombin ptt pt thromboplastin normalized partial ratio international
+Cluster 576: spermicide diaphragm condom uterine device abstinence birth acceptable control hormonal
+Cluster 577: composition chemical compounds attributed similar reactions allergic biologic used agents
+Cluster 578: confirmation histological breast cancer carcinoma metastatic tumor prostate required primary
+Cluster 579: contraindications known radiotherapy surgery patients mr radiation sensitivities excluded intended
+Cluster 580: diameter cm maximum lesion tumor longest measurable lesions largest maximal
+Cluster 581: resection surgical patients tumor prior weeks biopsy disease complete eligible
+Cluster 582: participant research study does received cell treatment household disease following
+Cluster 583: bevacizumab prior treatment received therapy patients weeks treated previously vegf
+Cluster 584: uncontrolled unacceptable risks cause compromise safety compliance concurrent severe medical
+Cluster 585: diffusion capacity dlco monoxide carbon predicted lung corrected pulmonary hemoglobin
+Cluster 586: microliter count neutrophil absolute platelet anc mcl leukocyte randomization obtained
+Cluster 587: cancer malignancies present invasive excluded melanoma contraindicates exception skin years
+Cluster 588: hg mm heart pressure uncontrolled hypertension systolic cardiac diastolic blood
+Cluster 589: myelodysplastic myeloid leukemia acute syndrome mds aml suggestive features patients
+Cluster 590: abnormalities laboratory following baseline chemistry patients hematologic serum significant grade
+Cluster 591: women employ unwilling nursing men contraception childbearing adequate potential pregnant
+Cluster 592: intercurrent severe infection patients procurement exclusion infusion treatment time infections
+Cluster 593: experimental drug therapy days use treatment weeks study prior baseline
+Cluster 594: sedation anesthesia require unable tolerate conscious patients general mri pet
+Cluster 595: prior study criteria therapy disease treatment patients history weeks inclusion
+Cluster 596: anti pd ctla antibody prior therapy treatment exposure checkpoint immune
+Cluster 597: ablation chemoembolization radiofrequency tace transarterial therapy embolization prior local arterial
+Cluster 598: white blood count cell ul hydroxyurea mcl criterion meet cells
+Cluster 599: barrier contraception method use study months double male effective condom
+Cluster 600: agent investigational weeks treatment study prior use days dose administration
+Cluster 601: doxorubicin cumulative mg epirubicin anthracycline dose equivalent exposure prior liposomal
+Cluster 602: metastatic disease patients known presence prior therapy cancer systemic chemotherapy
+Cluster 603: seizures uncontrolled history subjects patients controlled prior encephalitis epileptic past
+Cluster 604: lymphoblastic leukemia acute lymphoma cell patients relapsed refractory ll burkitts
+Cluster 605: lactating females pregnant donor exclusion intend breastfeeding criteria excluded group
+Cluster 606: second malignancy active currently requiring primary cancer therapy treatment concurrent
+Cluster 607: involvement nervous central known lymphoma active leukemia patients malignancy meningeal
+Cluster 608: vitamin supplementation iu folic antagonist supplements ng acid warfarin patients
+Cluster 609: proven biopsy histologically diagnosis pathologically cancer cytologically breast disease metastatic
+Cluster 610: tissue available tumor archived biopsy specimen correlative fresh studies testing
+Cluster 611: iaslc lung stage international staging association cancer disease th ajcc
+Cluster 612: embedded paraffin formalin fixed tissue ffpe tumor available biopsy availability
+Cluster 613: equal greater years performance lansky status karnofsky age participants old
+Cluster 614: thalidomide lenalidomide hypersensitivity known pomalidomide rash imids prior immunomodulatory applicable
+Cluster 615: creatinine upper limit normal uln age institution registration equal cr
+Cluster 616: cardiac heart unstable myocardial infarction congestive failure angina significant arrhythmia
+Cluster 617: milliliter minute creatinine ml clearance min cockcroft gault collection estimated
+Cluster 618: bilirubin origin rise hepatic gilberts unless syndrome non uln total
+Cluster 619: carcinomas malignancy situ carcinoma years concurrence basal squamous cervix cell
+Cluster 620: ascites effusion pleural symptomatic clinically fluid paracentesis stable significant conditions
+Cluster 621: escalation dose cohort phase patients portion disease segment treatment expansion
+Cluster 622: eligible patients disease treatment study therapy receive prior enrollment radiation
+Cluster 623: staff astrazeneca conduct applies planning study site involvement present previous
+Cluster 624: sensory motor common terminology ctcae neuropathy events adverse grade criteria
+Cluster 625: repair aortic aneurysm arterial vascular thrombosis recent surgical peripheral significant
+Cluster 626: fields overlap result region radiotherapy radiation prior therapy cancer study
+Cluster 627: assent provide willing written able trial informed consent study participation
+Cluster 628: daily mg aspirin activities use living dose able day smoker
+Cluster 629: daily prednisone equivalent mg corticosteroids immunosuppressive inhaled medications systemic condition
+Cluster 630: diarrhea symptom etiology gastrointestinal major malabsorption significant disorder crohn grade
+Cluster 631: transaminase uln aspartate ast alanine alt liver times involvement metastases
+Cluster 632: ipss intermediate prognostic scoring risk mds international high score revised
+Cluster 633: radical prostatectomy primary received prostate site oncologic adenocarcinoma treatment neo
+Cluster 634: infectious interstitial pneumonitis lung non evidence active disease history known
+Cluster 635: options available advanced solid curative tumor treatment therapies standard confirmed
+Cluster 636: support growth factor transfusion platelets days independent marrow screening prior
+Cluster 637: brain metastases treated previously radiation subjects surgery treatment epidural unless
+Cluster 638: cd sections express providing submitted staining cytometry paraffin cluster flow
+Cluster 639: events adverse aes ctcae alopecia terminology therapies common recovered baseline
+Cluster 640: wound healing dehiscence evidence surgical infection non unhealed fracture complications
+Cluster 641: lab central performed subjects amplification hla ngs tp immunohistochemistry egfr
+Cluster 642: leukemia chronic leukemias secretory burkitt accelerated myelogenous blast lymphocytic plasma
+Cluster 643: eastern cooperative oncology group ecog expectancy life weeks months participants
+Cluster 644: concurrent therapy study interventional observational clinical use enrollment treatment non
+Cluster 645: area radiation prior target months therapy relocate treatment houston treated
+Cluster 646: renal marrow function liver bone adequate assessed conducted following impaired
+Cluster 647: acute chronic infections infection skin active severe uncontrolled prostatitis therapy
+Cluster 648: decitabine azacitidine hypomethylating treatment cycles prior agent therapy hma previous
+Cluster 649: cmv end organ cytomegalovirus evidence randomization adoptive damage copies disease
+Cluster 650: muscular myopathies dystrophy neuromuscular amyotrophic atrophy lateral sclerosis ck spinal
+Cluster 651: immunodeficiency hiv virus positive human status known subjects disorder protease
+Cluster 652: cells platelets mm days randomization initiation enrollment weeks treatment fallopian
+Cluster 653: investigational start weeks treatment study received prior drug cycle days
+Cluster 654: ac hemoglobin diabetes hgb hbac defined uncontrolled hb mellitus glycosylated
+Cluster 655: results interfere interpretation likely medical participation laboratory investigator history including
+Cluster 656: creatinine serum uln concentration days equal age prior registration cr
+Cluster 657: analysis tissue tumor available biomarker results archival archived biopsy sample
+Cluster 658: compliance requirements illness limit uncontrolled intercurrent study psychiatric concurrent medical
+Cluster 659: unwilling follow unable requirements protocol consent instruction informed render instructions
+Cluster 660: patients prior history disease study subjects use treatment months known
+Cluster 661: potency manifestations psoriasis hydrocortisone arthritis patients oral autoimmune lichen chronicus
+Cluster 662: major anticipation traumatic injury surgery need significant procedure study surgical
+Cluster 663: chemotherapy prior weeks patients treatment systemic receive years days enrollment
+Cluster 664: seropositive hiv immunodeficiency virus human known patients active infection eligible
+Cluster 665: colony stimulating support factor anc neutrophil absolute count granulocyte mm
+Cluster 666: hepatitis infection chronic active acute known transmitting carrier fluids viral
+Cluster 667: criteria response evaluation solid recist tumors measurable lesion disease according
+Cluster 668: measurable disease criteria patients recist response defined evaluable non radiographically
+Cluster 669: cirrhosis viral hepatitis nonviral active liver known including disease clinically
+Cluster 670: antibiotic infection requiring therapy systemic days active study intravenous enrollment
+Cluster 671: mcl anc neutrophil absolute count days registration prior step phase
+Cluster 672: legally representative consent informed subject acceptable written procedures study patient
+Cluster 673: participants female patient study pregnant childbearing treated male use prior
+Cluster 674: angina new onset months heart rest anginal symptoms began unstable
+Cluster 675: neuropathy peripheral grade enrollment days patient applicable ahct ctcae initiation
+Cluster 676: noninvasive years ago melanomatous cancers cavity example cervix invasive minimum
+Cluster 677: lactation pregnancy breastfeeding test positive current year women standards time
+Cluster 678: receptor estrogen positive hormone progesterone breast selective cancer aromatase negative
+Cluster 679: contraception dose preferred lifestyle usual therapy abstinence study acceptable method
+Cluster 680: methods abstinence practice lactational spermicides agree ovulation postovulation contraception female
+Cluster 681: perforation fistula gastrointestinal history months abdominal prior fistulae gi ulceration
+Cluster 682: cabozantinib prior treatment dose days dl albumin platelets obtained hemoglobin
+Cluster 683: pneumonitis infectious interstitial non lung steroids required history disease evidence
+Cluster 684: superficial cancer bladder skin non melanoma malignancy years situ carcinoma
+Cluster 685: threatening maintenance arrhythmias ventricular infarction myocardial ongoing life congestive heart
+Cluster 686: unwilling comply unable protocol patients procedures study requirements patient reason
+Cluster 687: provide ability informed consent written willingness arm english follow read
+Cluster 688: board irb review approved willingness document understand sign ability institutional
+Cluster 689: ms qtcf qt interval corrected fridericia formula ecg screening mean
+Cluster 690: primary fallopian epithelial tube peritoneal ovarian cancer recurrent suspected biodistribution
+Cluster 691: compulsorily detained physical infectious illness psychiatric subjects treatment disease prisoners
+Cluster 692: pugh child impairment hepatic classification according currently clinically significant class
+Cluster 693: organ solid allogeneic tissue transplant history participant previous eligible prior
+Cluster 694: anticoagulation inr stable heparin normalized warfarin therapeutic molecular weight ratio
+Cluster 695: evaluable measurable subjects disease need dose metastatic marker escalation appropriate
+Cluster 696: brain metastases asymptomatic stable patients treated eligible symptomatic corticosteroids untreated
+Cluster 697: cockroft creatinine gault clearance min calculated ml formula equation serum
+Cluster 698: phosphate glucose deficiency dehydrogenase known pd history patients porphyria phosphatase
+Cluster 699: splenectomy prior undergone history patients having previous previously prtx sickle
+Cluster 700: potassium mmol serum registration supplementation days normal range institutional obtained
+Cluster 701: times bilirubin gilberts total uln upper normal limit syndrome patients
+Cluster 702: cdk cyclin dependent kinase inhibitor prior treatment received therapy previously
+Cluster 703: urine proteinuria random sample protein persistent grade ratio hrs measured
+Cluster 704: resected history completely malignancy melanoma years free skin cancer non
+Cluster 705: uncontrolled cardiac unstable respiratory pacer symptomatic dysrhythmia hepatic renal hematologic
+Cluster 706: effects recovered surgery radiotherapy prior recent antineoplastic chemotherapy therapy patients
+Cluster 707: neutrophil absolute mm count greater cu days weeks prior inclusion
+Cluster 708: embolic thrombotic attacks cerebrovascular accident transient events ischemic arterial thrombosis
+Cluster 709: heart class york association new failure iv congestive iii nyha
+Cluster 710: azd compounds composition chemical attributed similar reactions allergic biologic history
+Cluster 711: bilirubin normal total age institutional serum laboratory biopsy patients infusion
+Cluster 712: legal incapacity capacity limited subject providing patients granted authorization guardian
+Cluster 713: polyneuropathy organomegaly endocrinopathy poems changes monoclonal syndrome skin protein gammopathy
+Cluster 714: wocbp method contraception women use childbearing potential study men dose
+Cluster 715: equal platelet greater count mm mcl transfusion ul support turnstile
+Cluster 716: contraception adequate beginning signing icf associate definition designated agree judgment
+Cluster 717: albumin mg dl days supplementation serum obtained registration prior intravenous
+Cluster 718: weeks mitomycin nitrosoureas earlier entering administered adverse events recovered agents
+Cluster 719: contraceptive measures reproductive bilateral effective pregnancy celibacy potential chooses heterosexually
+Cluster 720: gpd phosphate deficiency dehydrogenase glucose known history patients hereditary normal
+Cluster 721: pregnancy test negative serum screening female prior day wocbp hours
+Cluster 722: superficial cancer bladder basal cell carcinoma squamous malignancy skin situ
+Cluster 723: contraindicate uncontrolled chronic pancreatitis judgment severe patient active concurrent participation
+Cluster 724: leptomeningeal history disease metastatic fda fascicular fascia farber fap fanconi
+Cluster 725: promyelocytic leukemia acute diagnosis aml patients classification subtype apml favorable
+Cluster 726: hepatitis antibody hiv virus surface antigen human immunodeficiency negative positive
+Cluster 727: signed written informed consent provide provided subjects study age granted
+Cluster 728: agent investigational received days enrollment prior treatment patients indication weeks
+Cluster 729: aged years males females female inclusive old consent patients informed
+Cluster 730: given signed informed consent registration study prior patients subjects participants
+Cluster 731: tumor primary brain metastatic resection diagnosis positive patients uncontrolled subject
+Cluster 732: gestation termination conception state hcg lactating nursing laboratory female pregnancy
+Cluster 733: elective planned major surgery course trial performed clinical patient subcutaneous
+Cluster 734: pills swallow phase ii able patient patients zydelig familial fancc
+Cluster 735: estimated glomerular filtration rate egfr min ml creatinine renal clearance
+Cluster 736: present previous enrollment study randomization enrolment assignment treatment family fap
+Cluster 737: heart uncontrolled electrocardiographic ischemia conduction arrhythmias angina nyha abnormalities ventricular
+Cluster 738: crcl min creatinine ml clearance calculated measured uln serum renal
+Cluster 739: lactating pregnant subject subjects patient intending non participant woman breastfeeding
+Cluster 740: inadequate function organ renal liver marrow hematologic bone evidenced following
+Cluster 741: meet criteria following patients inclusion subjects eligible exclusion study enrolled
+Cluster 742: classes excipients formulations hypersensitivity study drugs allergy suspected given drug
+Cluster 743: performance scale ecog eastern cooperative status oncology group karnofsky ps
+Cluster 744: transfused hemoglobin dl hgb meet patients level reach cut criterion
+Cluster 745: alkaline phosphatase upper uln normal limit institutional metastases times limits
+Cluster 746: apply criteria inclusion additional information contact investigator exclusions unable pembrolizumab
+Cluster 747: hypercalcemia calcium corrected bisphosphonate albumin normal serum limits allowed malignant
+Cluster 748: cognitive impairment consent preclude psychiatric informed significant hearing provide study
+Cluster 749: transaminase glutamic serum sgpt pyruvic sgot oxaloacetic uln alt alanine
+Cluster 750: glucose hbac intolerance met transient mellitus diabetes poorly corticosteroid exclusion
+Cluster 751: brain trial excluded metastases clinical known patients participants untreated active
+Cluster 752: feeding women breast pregnant currently study lactating excluded entered eligible
+Cluster 753: programmed death pd ligand cell prior tumor therapy protein lymphocyte
+Cluster 754: seropositivity hiv donor known htlv ebv history pending unrelated matched
+Cluster 755: greater hemoglobin dl equal gm turnstile screening values visit transfusion
+Cluster 756: infarction myocardial months entry study prior acute cardiac starting recent
+Cluster 757: obscure hazardous condition interpretation make underlying opinion frequent events adverse
+Cluster 758: vaccinated attenuated vaccines live weeks drug dose study starting tremelimumab
+Cluster 759: willingness sign understand ability written informed consent subjects registration patients
+Cluster 760: vitamin antagonists warfarin concomitant use anticoagulants concurrent days ibrutinib treatment
+Cluster 761: producing avoidance measures enrolled child immunization experimental agree contraception month
+Cluster 762: karnofsky eastern cooperative oncology performance ecog group status kps lansky
+Cluster 763: bilirubin uln gilbert level enrolled serum total known upper limit
+Cluster 764: gi tolerance swallowing absorption difficulty interfere gastrointestinal procedure oral known
+Cluster 765: irae grade event immune unresolved adverse related immunotherapy receiving previous
+Cluster 766: registration prior days weeks chemotherapy therapy patients study use biologic
+Cluster 767: rbc transfusion red hemoglobin units blood dl dependent cell weeks
+Cluster 768: ecg qtc qt interval electrocardiogram corrected msec screening lead ms
+Cluster 769: bilirubin uln direct total gilberts normal syndrome upper limit patients
+Cluster 770: donor locus typing hla haploidentical class match recipient serologic based
+Cluster 771: times bilirubin upper limit normal uln serum institutional age range
+Cluster 772: menopausal exogenous amenorrheic post cessation hormone women oophorectomy treatments bilateral
+Cluster 773: hcv rna hepatitis positive antibody negative ribonucleic acid virus pcr
+Cluster 774: hepatic renal function marrow bone adequate coagulation metabolic reserve participant
+Cluster 775: investigational currently receiving drug eligible patients drugs excluded participation subjects
+Cluster 776: hepatitis surface antigen positive antibody hbsag core infection active negative
+Cluster 777: mg dl years age creatinine male female serum gender gfr
+Cluster 778: positive hiv known patients donor test subject ineligible hepatitis status
+Cluster 779: nursing participants pregnant female volunteers breastfeed lactating period following dose
+Cluster 780: hepatitis indicating virus acute positive chronic test infection result known
+Cluster 781: heart functional classification congestive york association failure arrhythmia myocardial infarction
+Cluster 782: abbreviated diet mdrd formula glomerular filtration rate according renal min
+Cluster 783: clear rcc cell component histologically confirmed advanced histology metastatic sarcomatoid
+Cluster 784: creatinine mg ml clearance min dl adults estimated yrs levels
+Cluster 785: heart york association new cardiac failure myocardial iii infarction congestive
+Cluster 786: ability written informed consent sign understand signing initiation protocol participant
+Cluster 787: tumors patients primary brain eligible cavitary located solid germ necrotic
+Cluster 788: remains prior localized abdominal received years free completed provided recurrent
+Cluster 789: autoimmune past systemic required years active disease treatment requiring replacement
+Cluster 790: hepatitis virus surface hcv antigen positive hbsag known rna hiv
+Cluster 791: signed consent informed study provide patient provided participate protocol lab
+Cluster 792: neutrophil absolute count days enrollment microliters randomization patient dl cytokine
+Cluster 793: amyloidosis primary known systemic light patients chain organ suspected subjects
+Cluster 794: general health good donor medical provider determined evaluating permits psychological
+Cluster 795: liver function acceptable defined specified normal screening day days therapy
+Cluster 796: castrate resistant prostate cancer medi metastatic cohort eligibility phase ii
+Cluster 797: hepatic impairment severe cirrhosis existing moderate pre known bilirubin uln
+Cluster 798: heparin fondaparinux lmwh derived warfarin prophylaxis coumarin molecular weight low
+Cluster 799: institutional creatinine uln serum days registration clearance rep expanded window
+Cluster 800: forms medically sexually acceptable contraception willing able women use childbearing
+Cluster 801: ejection fraction cardiac echocardiogram ef normal function baseline echo heart
+Cluster 802: lenalidomide prior therapy treatment use cycles patients received refractory progression
+Cluster 803: bilateral females potential hysterectomy ligation tubal postmenopausal surgically oophorectomy childbearing
+Cluster 804: hcc hepatocellular diagnosis carcinoma systemic confirmed liver prior aasld patients
+Cluster 805: untreated brain metastases symptomatic known require symptoms control meningeal treated
+Cluster 806: urine test pregnancy negative serum hours female medication childbearing required
+Cluster 807: granulocyte absolute count mm agc platelets ul lymphocyte peripheral marrow
+Cluster 808: equal greater neutrophil absolute count anc mm mcl microl turnstile
+Cluster 809: study use contraception agree dose effective potential childbearing drug male
+Cluster 810: hospitalization requiring coagulation registration transmural jaundice protocol months exacerbation defects
+Cluster 811: female childbearing pregnancy test negative potential serum patients urine enrollment
+Cluster 812: myeloma multiple requiring treatment defined protocol symptomatic study participant mm
+Cluster 813: recist based measurable disease determined site criteria presence radiology patients
+Cluster 814: heart enrollment cerebral months accident stroke vascular cardiovascular arrhythmia infarction
+Cluster 815: transaminase aminotransferase serum pyruvate glutamate glutamic oxaloacetic sgot sgpt uln
+Cluster 816: tuberculosis history known active latent years preceding bacillus infection tb
+Cluster 817: karnofsky ecog poor health rating index screening time false fancc
+Cluster 818: bilirubin range normal total direct gilbert syndrome uln liver reference
+Cluster 819: allogeneic transplant organ history prior received subject previously chl primary
+Cluster 820: gadolinium contrast allergy mri contraindication known agents allergic intravenous based
+Cluster 821: hypercalcemia uncontrolled symptomatic bisphosphonate history continued related patient requiring pain
+Cluster 822: endometrial invasion figo serous cancer myometrial clear differentiated lymphatic federation
+Cluster 823: hemoglobin dl days registration prior study enrollment treatment step dose
+Cluster 824: dihydropyrimidine deficiency dehydrogenase dpd known fluoropyrimidine fluorouracil hypersensitivity capecitabine severe
+Cluster 825: hpv oropharynx squamous carcinoma associated cell positive papillomavirus oropharyngeal status
+Cluster 826: microliter platelets wbc transfusion randomization independent factors growth prior ul
+Cluster 827: strong moderate inhibitors cypa subfamily cytochrome family polypeptide prohibited medications
+Cluster 828: meeting criteria following disease measurable iwcll presence myeloma multiple laboratory
+Cluster 829: aminotransferase limits ast aspartate normal alanine upper alt times institutional
+Cluster 830: cml phase chronic accelerated leukemia myeloid blast blasts cp myelogenous
+Cluster 831: gi manifestations reason alter unknown malabsorption gastrointestinal absorption mln stomata
+Cluster 832: growth factor neutrophil absolute support count anc mm days mcl
+Cluster 833: adverse immune grade related events prior event ae immunotherapy mediated
+Cluster 834: xrt radiation elapsed craniospinal irradiation palliative local substantial pelvis weeks
+Cluster 835: ocular melanoma mucosal primary conditions patients melanomas metastatic disorders acuity
+Cluster 836: treatments agents concurrent anti use cancer experimental investigational prior study
+Cluster 837: signed procedures informed screening consent obtained prior comply icf able
+Cluster 838: amylase normal upper limit serum uln institutional obtained nserum registration
+Cluster 839: abdominal abscess fistula perforation intra gastrointestinal history months prior gi
+Cluster 840: infection improvement despite exhibiting signs bacterial fungal antibiotics viral appropriate
+Cluster 841: light chain protein free serum mg dl abnormal immunoglobulin ratio
+Cluster 842: hgb transfusion dl hemoglobin days blood allowed reach prior acceptable
+Cluster 843: access placement vascular starting major minimum surgery recent minor surgical
+Cluster 844: procedure surgical major traumatic injury open anticipation biopsy need course
+Cluster 845: heart failure congestive history symptomatic chf uncontrolled disease requiring arrhythmia
+Cluster 846: bearing child potential contraception use effective female agree male study
+Cluster 847: independent transfusion mm platelets platelet support count involvement marrow bone
+Cluster 848: gm albumin dl serum plasma neratinib trametinib arm enrolled infusion
+Cluster 849: hepatitis positive history known patients test hiv disease antibody result
+Cluster 850: retinal occlusion rvo vein history retinopathy current serous evidence risk
+Cluster 851: signs symptoms infection weeks prior study treatment day randomization initiation
+Cluster 852: antibiotics urinary prophylactic tract obstructive prevention pulmonary iv oral chronic
+Cluster 853: immunodeficiency acquired aids syndrome virus hiv human related illness known
+Cluster 854: rituximab containing prior therapy treatment months regimen received refractory cyclophosphamide
+Cluster 855: antifungal antiviral antibiotic infection requiring active systemic therapy iv treatment
+Cluster 856: ethics nature board committee independent legal review representative procedure approved
+Cluster 857: heart arterial thrombotic evidenced disease infarction myocardial measurement york unstable
+Cluster 858: calcium corrected uln serum normal albumin phosphate registration sub upper
+Cluster 859: mm ct axis measurable short scan diameter tomography accurately lymph
+Cluster 860: mm accurately longest dimension recorded diameter spiral measured techniques measurable
+Cluster 861: affecting disorder absorption gastrointestinal gastrectomy peptic ulcer negatively affects active
+Cluster 862: pregnant study inform suspect immediately bearing woman child participating barrier
+Cluster 863: radiosurgery stereotactic brain srs radiation prior metastases treated treatment radiotherapy
+Cluster 864: toxicity grade treatment previous prior alopecia related greater therapy residual
+Cluster 865: effects toxic recovered therapy prior grade acute alopecia patients previous
+Cluster 866: permitting release personal authorization information health approved signed informed consent
+Cluster 867: edition th ajcc joint stage committee american cancer staging iv
+Cluster 868: pregnant patient currently participants plan subjects study trying women non
+Cluster 869: revascularization ischemic coronary symptoms history cardiac events including acs mi
+Cluster 870: old years age patients male female patient lansky time consent
+Cluster 871: expectancy life greater months physician anticipated morbid treating attributed assessed
+Cluster 872: vessels invading encasing major blood tumor subject contact participant pulmonary
+Cluster 873: solid advanced tumors metastatic tumor histologically locally cytologically confirmed documented
+Cluster 874: prostate cancer carcinoma psa specific antigen situ skin malignancy treated
+Cluster 875: bclc barcelona stage clinic liver cancer locoregional amenable chemoembolization disease
+Cluster 876: oophorectomy appropriate bearing child considered case potential hysterectomy vasomotor reproductive
+Cluster 877: node axillary sentinel lymph dissection biopsy mastectomy nodes patients positive
+Cluster 878: warfarin anticoagulation receiving patients therapy inr anticoagulants currently permitted require
+Cluster 879: liver gallstones biliary asymptomatic disease gilbert exception syndrome chronic assessment
+Cluster 880: murine products containing hypersensitivity reactions protein history known humanized anaphylactic
+Cluster 881: neoplasm agent considered primary investigational receiving treatment registration currently prior
+Cluster 882: therapy steroid immunosuppressive form immunodeficiency diagnosis receiving systemic days trial
+Cluster 883: standard therapy available advanced refractory solid metastatic relapsed tumor treatment
+Cluster 884: hla positive allele patients expression phenotype express subject alleles restriction
+Cluster 885: breastfeeding women excluded pregnant discontinued study nursing prior mothers avoided
+Cluster 886: magnesium lln serum mg supplementation dl normal range wnl mmol
+Cluster 887: ancillary considered bisphosphonates supportive therapy concurrent care allowed note protocol
+Cluster 888: products investigational tobacco treatment drug study days cigarettes dose use
+Cluster 889: ischemic attack transient stroke months history prior day tia arterial
+Cluster 890: live vaccine planned start received days study therapy virus medication
+Cluster 891: creatinine renal cockcroft gault clearance function ml calculated min formula
+Cluster 892: lymphocytic leukemia chronic cll workshop iwcll diagnosis international criteria treatment
+Cluster 893: ethnic groups races members eligible trial men women racial background
+Cluster 894: entire length comply study procedures understand able ability requirements period
+Cluster 895: medication orally likely absorption swallow interfere unable disorders gastrointestinal administered
+Cluster 896: cns symptomatic metastases known uncontrolled steroids requiring disease subjects subject
+Cluster 897: stratum criteria patients inclusion eligible ii participants iii disease strata
+Cluster 898: kettering sloan memorial mskcc center cancer confirmed diagnosis msk pathology
+Cluster 899: lung small cell cancer non nsclc stage sclc diagnosis germ
+Cluster 900: conforms federal consent guidelines approved institutional form provide signed able
+Cluster 901: bleeding hemorrhage event grade ctcae weeks study dose drug pulmonary
+Cluster 902: adequately cancer treated melanoma skin non situ malignancy years free
+Cluster 903: voluntarily assessments conducted procedures related understand sign informed consent study
+Cluster 904: abide cooperate fully unwilling designee unable protocol investigator study subject
+Cluster 905: postmenopausal female participants defined patient family fap fanconi fancd fancc
+Cluster 906: cardiac angioplasty stenting infarction myocardial angina unstable heart months history
+Cluster 907: secondary malignancy active primary patients immunodeficiency form actively treated hormone
+Cluster 908: immunodeficiency virus human infection known hiv patients diagnosis subject eligible
+Cluster 909: rescue stem cell high autologous transplant dose chemotherapy marrow bone
+Cluster 910: genders practice birth control willing months time enrollment patients treatment
+Cluster 911: hours pregnancy test negative childbearing potential serum women urine prior
+Cluster 912: dysrhythmias cardiac ongoing atrial fibrillation ctcae nci grade msec interval
+Cluster 913: transplant stem allogeneic cell history autologous eligible antecedent spleen organ
+Cluster 914: turnstile ii infusion til patients criteria chemotherapy designee inclusion cell
+Cluster 915: telephone access number address reached working research engage nurse follow
+Cluster 916: platelets mcl initiation days performed treatment labs ul prior working
+Cluster 917: pressure blood systolic hypertension diastolic sbp uncontrolled dbp controlled greater
+Cluster 918: refractory primary disease therapy patients relapse defined progression mr myeloma
+Cluster 919: lipase uln upper normal limit times equal pancreatitis increased signs
+Cluster 920: lvef echocardiogram lln trastuzumab muga performed decline measured institution cardiomyopathy
+Cluster 921: tolerate illnesses compromise adequately therapy appropriate controlled ability opinion medical
+Cluster 922: wbc ul hydroxyurea white mm count blood cell counts prior
+Cluster 923: vaccines live attenuated study weeks days vaccination receipt treatment initiation
+Cluster 924: wbc white blood cell count mcl days ml microliter registration
+Cluster 925: activity physical cardiac ordinary heart limitation class association comfortable york
+Cluster 926: measurable disease non patients subjects presence site allowed metastatic required
+Cluster 927: lines setting metastatic chemotherapy prior cytotoxic received treatment therapy disease
+Cluster 928: spanish speak english read able patients inability understand caregiver phase
+Cluster 929: drugs hypersensitivity known study components analogs chemical similar contraindication patient
+Cluster 930: infection active systemic patients pericardial evidence pulmonary days time tract
+Cluster 931: qtcf msec qt interval fridericia corrected formula using ecg screening
+Cluster 932: uln bilirubin ast alt function total normal hepatic limit liver
+Cluster 933: pyruvate glutamate sgpt transaminase upper normal limit alanine alt aminotransferase
+Cluster 934: cytotoxic cytokines chemotherapy weeks antibodies biologic nitrosoureas mitomycin agents investigational
+Cluster 935: infusion lymphocyte donor dli days received enrollment cell prior infusions
+Cluster 936: anticonvulsants inducing enzyme seizure disorder controlled enrolled patients non seizures
+Cluster 937: immunocompromised hiv positive patients immunodeficiency known virus human antiretroviral currently
+Cluster 938: board review signed institutional approved irb informed consent written guidelines
+Cluster 939: premedication steroids injection articular intranasal inhaled topical intra reactions corticosteroids
+Cluster 940: mol mg dl creatinine serum bilirubin total si function male
+Cluster 941: menarchal girls agreed tests females pregnancy entered participate obtained males
+Cluster 942: place risk undue patient investigator condition unacceptable organ disease opinion
+Cluster 943: severe uncontrolled hypertension diseases disease disorders illnesses active cardiovascular systemic
+Cluster 944: similar composition compounds allergic chemical reactions attributed biologic history hypersensitivity
+Cluster 945: toxicities attributed cancer anti fatigue resolve version therapy resolved alopecia
+Cluster 946: following treatment diagnoses patients fulfill indications disease required prior status
+Cluster 947: fasting cholesterol triglycerides mg lipid dl lowering uln mmol triglyceride
+Cluster 948: steroid concurrent systemic therapy requirement inhaled need patient chronic patients
+Cluster 949: signs infection progressing attributable symptoms interpreted infections hemodynamic persisting fever
+Cluster 950: voluntary written consent informed donor research related performance procedures able
+Cluster 951: myelosuppressive weeks nitrosourea chemotherapy received prior study enrollment anticancer entry
+Cluster 952: values function laboratory adequate organ confirmed hematologic hematological biological defined
+Cluster 953: myelofibrosis vera polycythemia essential thrombocythemia myeloproliferative post mf primary pv
+Cluster 954: hamster chinese ovary produced biopharmaceuticals formulation atezolizumab hypersensitivity component cells
+Cluster 955: upcr protein urine ratio creatinine urinalysis hour cabozantinib spot proteinuria
+Cluster 956: level dl hemoglobin mg triglyceride serum patients creatinine greater plasma
+Cluster 957: heart symptomatic congestive angina failure unstable pectoris cardiac arrhythmia uncontrolled
+Cluster 958: organ transplant history requires immunosuppressive immunosuppressives use requiring major prior
+Cluster 959: subdural metastases brain corticosteroids starting discontinued local current unless treatment
+Cluster 960: impair receive disorder ability medical uncontrolled infection active protocol treatment
+Cluster 961: cva tia accident transient ischemic attack cerebrovascular history months stroke
+Cluster 962: echo gated muga echocardiogram acquisition multi fraction ejection scan left
+Cluster 963: prostatectomy prostate prior therapy radiation cancer cryosurgery cryotherapy neoadjuvant hyperthermia
+Cluster 964: agents receiving investigational subjects patient antineoplastic actively registration days prior
+Cluster 965: degrees celsius fever fahrenheit infection temperature active hours unexplained febrile
+Cluster 966: myeloma multiple measurable disease diagnosis confirmed documented active defined screening
+Cluster 967: thromboplastin partial ptt time uln upper normal limit activated institutional
+Cluster 968: bearing child women potential pregnant breastfeeding reliable means using contraception
+Cluster 969: anticancer receiving therapy agents patients currently investigational drug experimental concomitant
+Cluster 970: cancer adequately treated remission cell complete stage patient currently basal
+Cluster 971: fev expiratory forced diffusing dlco volume monoxide carbon second capacity
+Cluster 972: ast alt uln serum liver metastasis bilirubin patients hepatic institutional
+Cluster 973: grant inability compliance medical consent non history regimen regimens patient
+Cluster 974: feed breast females taking lactating agree feeding pregnant lenalidomide women
+Cluster 975: legal representative consent informed able written provide patient understand read
+Cluster 976: according recist measurable disease version criteria lesions prior non subject
+Cluster 977: precautions contraceptive medically reproductive approved potential study agree drug following
+Cluster 978: trials clinical participation enrolled treatment therapeutic patients allowed supportive investigational
+Cluster 979: weeks earlier monoclonal administered antibody recovered adverse prior events baseline
+Cluster 980: plt platelet count mm ul registration peripheral ctcae cumm days
+Cluster 981: stomach malabsorption absorption bowel resection small syndrome major affect gastrointestinal
+Cluster 982: sampling blood suitable access venous required study pk serial pharmacokinetic
+Cluster 983: makes unsuitable psychological reason investigators judgment according participation condition medical
+Cluster 984: menopausal sterilization bearing post child beta hcg potential surgical previous
+Cluster 985: protected dated authorization purpose information risks privacy signed regulations health
+Cluster 986: response evaluation recist solid tumors criteria measurable disease based defined
+Cluster 987: corticosteroids inhaled topical prednisone equivalent systemic mg immunosuppressive steroids day
+Cluster 988: malignancy currently considered active second melanoma skin non completed cancers
+Cluster 989: brca mutation deleterious germline cancer breast known mutations testing genes
+Cluster 990: ptt aptt anticoagulant intended activated anticoagulants range pt thromboplastin therapeutic
+Cluster 991: bi dimensionally measurable lesion cm disease dimension scan ct centimeters
+Cluster 992: cyclodextrin captisol solubilize derivative carfilzomib allergy used known history bendamustine
+Cluster 993: brentuximab vedotin refractory dose progression progressed prior failed relapsed finished
+Cluster 994: jeopardize compliance protocol condition opinion investigator safety concurrent subject investigators
+Cluster 995: creatinine gault cockcroft formula clearance crcl ml min using uln
+Cluster 996: signs cycle symptoms day infection weeks prior general team relevant
+Cluster 997: breastfeeding pregnancy current active women reported self planning possibility intention
+Cluster 998: authorized legally representative document sign understand consent written informed ability
+Cluster 999: transplantation stem cell allogeneic prior patients eligible undergone history transplant
+Cluster 1000: hepatitis known surface positive suspected antigen infection active status hiv
+Cluster 1001: nutrition parenteral hydration obstruction signs symptoms require tube clinical gastrointestinal
+Cluster 1002: institutional bilirubin upper normal uln limit total serum administration level
+Cluster 1003: rapamycins temsirolimus sirolimus everolimus hypersensitivity excipients known rad patients deforolimus
+Cluster 1004: lymphocyte count absolute mcl phase lower days limits equal anc
+Cluster 1005: meningitis carcinomatous subjects history known leptomeningeal participants presence patients disease
+Cluster 1006: protein reactive mg crp urinary mgps albumin excretion thrombophilic total
+Cluster 1007: institutional ast aspartate aminotransferase upper limit normal times obtained uln
+Cluster 1008: caregiver patient identified willing primary participate parent family person study
+Cluster 1009: intrauterine device iud ius placement releasing hormone established containing partner
+Cluster 1010: anticoagulants therapeutic use dose parenteral current aptt thrombolytic oral inr
+Cluster 1011: leptomeningeal metastases cns evidence known history patients disease presence dural
+Cluster 1012: angina unstable pectoris months requiring uncontrolled prior cardiac known arrhythmia
+Cluster 1013: hepatitis virus positive immunodeficiency human hiv active known chronic infectious
+Cluster 1014: contraception methods oophorectomy hormone women sterilization highly intrauterine partner child
+Cluster 1015: score karnofsky performance status higher patients greater adult adequate time
+Cluster 1016: alanine aminotransferase alt uln days hepatic laboratory unless prior obtained
+Cluster 1017: creatinine institutional normal limits clearance min levels ml patients serum
+Cluster 1018: sexual contact latex condom vasectomy successful agree use potential men
+Cluster 1019: illness social situations compliance uncontrolled psychiatric intercurrent requirements limited infection
+Cluster 1020: pulse oximetry dyspnea rest room air exercise intolerance evidence indication
+Cluster 1021: toxic effects recovered fully acute prior entering chemotherapy immunotherapy radiotherapy
+Cluster 1022: exempt azoospermic continuously heterosexually contraceptive wocbp males requirements undergo testing
+Cluster 1023: congenital qt diagnosed long syndrome suspected fanca fascia farber fap
+Cluster 1024: end stage disease renal liver kidney dialysis hemodialysis meld model
+Cluster 1025: platelet transfusions count receive rbc hemoglobin marrow bone red guidelines
+Cluster 1026: gi absorption gastrointestinal alter impairment significantly function disease panobinostat interfere
+Cluster 1027: creatinine upper normal limit serum uln institution age renal days
+Cluster 1028: rbc red transfusions hemoglobin blood dl cell receive accordance guidelines
+Cluster 1029: cardiovascular clinically significant disease including history impaired uncontrolled condition diseases
+Cluster 1030: weigh kg patients entry patient greater study kilogram time subject
+Cluster 1031: platelets ml cells surgery days equal fancc fascia farber fap
+Cluster 1032: intermittent antiherpetic acyclovir topical chronic intravenous drug use oral treatment
+Cluster 1033: utilize condom partner sexually birth effective concluded methods control willing
+Cluster 1034: aminotransferase times uln alanine aspartate alt ast liver hepatic serum
+Cluster 1035: daily equivalent prednisone mg corticosteroids dose steroids chronic treatment greater
+Cluster 1036: red transfusion blood hemoglobin dl packed cell prbc rbc days
+Cluster 1037: biologics devices investigational drugs plans study prior course days use
+Cluster 1038: cavity oropharynx larynx hypopharynx oral squamous carcinoma cell neck histologically
+Cluster 1039: type mellitus diabetes insulin controlled ii stable history eligible regimen
+Cluster 1040: hypertension uncontrolled despite arterial medical patients controlled treatment current grade
+Cluster 1041: higher neuropathy grade peripheral patients neurotoxicity current ii arm significant
+Cluster 1042: hcg units chorionic baseline test screening gonadotropin beta negative females
+Cluster 1043: platinum based chemotherapy regimen line received disease therapy prior progression
+Cluster 1044: qt long congenital syndrome history family sudden patients death screening
+Cluster 1045: psychological medical investigator opinion social condition compromise participation study safety
+Cluster 1046: pregnant patients excluded known currently time female included ineligible srs
+Cluster 1047: fcbp lenalidomide agree days effective pregnancy females contact method intercourse
+Cluster 1048: uveal melanoma metastatic ocular primary mucosal diagnosis confirmed histologically patients
+Cluster 1049: epithelial fallopian ovarian peritoneal tube primary cancer diagnosis carcinoma confirmed
+Cluster 1050: plt ul platelets registration thrombocytopenia obtained days transfusion prior sgn
+Cluster 1051: radioisotope gfr creatinine glomerular filtration clearance min ml rate gender
+Cluster 1052: cell cancers basal squamous skin malignancy malignancies exception curatively cancer
+Cluster 1053: substances medications inducers cypa inhibitors strong ineligible receiving new counter
+Cluster 1054: grade examination neuropathy peripheral pain clinical period screening patient initiation
+Cluster 1055: dr matched donor hla unrelated allele antigen dq loci leukocyte
+Cluster 1056: intracranial hemorrhage stroke months history enrollment prior cerebral randomization registration
+Cluster 1057: transplantation solid organ history prior tuberculosis allogeneic corneal primary hsct
+Cluster 1058: illness intercurrent uncontrolled including infection limited medical concurrent significant active
+Cluster 1059: surgery major dose days drug study prior complications fully abbv
+Cluster 1060: consecutive months potential naturally mature undergone hysterectomy postmenopausal childbearing preceding
+Cluster 1061: age creatinine patients normal diagnosis reproductive gender yrs enrollment irrespective
+Cluster 1062: logistics feasibility issues prospective comply procedures compliance opinion related able
+Cluster 1063: hla drb match donor resolution typing unrelated high antigen dna
+Cluster 1064: score eastern cooperative oncology group ecog performance karnofsky equal ps
+Cluster 1065: severity toxicity progressing alopecia grade anti ongoing cancer therapy prior
+Cluster 1066: fraction shortening ejection left ventricular fractional cardiac function cardiologist greater
+Cluster 1067: bsa level dose area body surface patients mg enrolled minimum
+Cluster 1068: ribose poly adp parp polymerase inhibitor adenosine diphosphate prior treatment
+Cluster 1069: unwilling unable participate evaluations procedures required study procedure related subject
+Cluster 1070: hepatitis virus immunodeficiency hiv human infection known active chronic history
+Cluster 1071: provide able written consent informed patients guardian patient understand study
+Cluster 1072: radiation prior therapy field gy treatment patients outside oncologist dose
+Cluster 1073: urea nitrogen bun blood mg dl normal times upper uln
+Cluster 1074: prohibited medication medications use current concomitant treatment currently study taking
+Cluster 1075: virus hepatitis infection active known hiv immunodeficiency human chronic evidence
+Cluster 1076: malignancy melanotic cancer cervix situ exceptions skin carcinoma specific non
+Cluster 1077: matched hla donor unrelated related sibling leukocyte antigen drb available
+Cluster 1078: beta pregnancy pregnant subject established hcg chorionic result confirmation gonadotropin
+Cluster 1079: synchronous bilateral cancer breast invasive primaries patients colon tumors disease
+Cluster 1080: threatening illness unrelated life cancer potentially opinion psychiatric medical interfere
+Cluster 1081: applications sprays drops eye injections airways topical rash inhaled articular
+Cluster 1082: attorney power durable sign willing dpa consented benefits consent written
+Cluster 1083: glutamic transaminase aminotransferase pyruvic serum uln sgpt sgot alt oxaloacetic
+Cluster 1084: reserve marrow adequate bone evidenced poor demonstrated organ mm anc
+Cluster 1085: breastfeeding pregnancy test negative pregnant entry days study childbearing women
+Cluster 1086: impair underlying ability receive medical condition protocol patient treatment infection
+Cluster 1087: aminotransferase uln ast alt alanine aspartate liver involvement metastasis subjects
+Cluster 1088: cells neutrophil absolute count mm anc days registration bil prior
+Cluster 1089: gvhd acute chronic active prophylaxis patients grade systemic overlap therapy
+Cluster 1090: coronary history heart evidence cardiac controlled angioplasty stenting current syndromes
+Cluster 1091: vascular peripheral disease significant collagen symptomatic arterial clinically active infarction
+Cluster 1092: nervous central metastases known active disease malignancy brain suspected history
+Cluster 1093: metastasis nervous central cns symptomatic untreated malignancy active brain history
+Cluster 1094: ecog patient screen enrolment better ii fanca farber fap fanconi
+Cluster 1095: delayed toxicity chemotherapy weekly days extensive biologic immunotherapy daily prior
+Cluster 1096: hb hemoglobin dl transfusion gm anemia level correct transfusions equal
+Cluster 1097: leukoencephalopathy multifocal pml progressive history meningeal cerebral participants confirmed cunningham
+Cluster 1098: complying outlined understanding parameters capable irb board specific approved review
+Cluster 1099: exposure prior previous household inhibitor inhibitors chemotherapy months enrollment ibrutinib
+Cluster 1100: leukocyte hla antigen human donor matched related identical positive sibling
+Cluster 1101: vomiting nausea formulated diseases bowel preclude gastrointestinal resection refractory swallow
+Cluster 1102: concurrent investigational agents use receiving therapy agent chemotherapeutics patients therapeutic
+Cluster 1103: illness infection uncontrolled active ongoing including patients limited medical concurrent
+Cluster 1104: threatening life infection visceral disease active severe uncontrolled patients concurrent
+Cluster 1105: lung cancer prior therapy patients radiation diagnosis primary screening metastatic
+Cluster 1106: condom drug seminal delivery vasectomized fluid order intercourse prevent father
+Cluster 1107: wound surgery dose cabozantinib healing complications treatment days study major
+Cluster 1108: feeding females breast pregnant excluded lactating eligible study actively menstruating
+Cluster 1109: immediate reaction hypersensitivity severe used history agents fludarabine study cyclophosphamide
+Cluster 1110: filgrastim support neutrophil absolute mm count greater anc equal gcsf
+Cluster 1111: transaminase serum sgpt pyruvate glutamate sgot glutamic oxaloacetic normal upper
+Cluster 1112: total bilirubin uln institutional age equal concentration liver days prior
+Cluster 1113: immunosuppressive medication use current prior days dose exceptions medi study
+Cluster 1114: metastasis alkaline phosphatase liver uln bone present absence upper limit
+Cluster 1115: board irb review approved form consent institutional understand informed sign
+Cluster 1116: detection interstitial management suspected pulmonary toxicity lung interfere related symptomatic
+Cluster 1117: iuln bilirubin total registration direct patients days prior arm cohort
+Cluster 1118: aptt intended anticoagulant activated anticoagulants thromboplastin partial ptt range pt
+Cluster 1119: women pregnancy test childbearing negative potential serum urine days prior
+Cluster 1120: calcium ionized serum lln normal albumin corrected limits phosphorus supplementation
+Cluster 1121: lymphoma nervous central cns known leptomeningeal active primary infiltration involving
+Cluster 1122: investigational drug days study device prior treatment weeks received dose
+Cluster 1123: subject study treatment following enrollment prior received disease therapy investigator
+Cluster 1124: substantially increase judgment risk associated participation investigator condition medical illness
+Cluster 1125: ventricular tachycardia fibrillation pointes arrhythmias history torsades significant clinically torsade
+Cluster 1126: guardian legal parent consent informed patient assent written able sign
+Cluster 1127: atezolizumab influenza attenuated live vaccine receive flumist dose months treatment
+Cluster 1128: brain metastases patients active history treated presence stable subjects eligible
+Cluster 1129: formulation components hypersensitivity allergy identified previously subject treatment study known
+Cluster 1130: immunocompromised patients splenectomy status including immunodeficiency allowed subjects known infection
+Cluster 1131: neuropathy grade baseline diabetic neurosensory patient pain patients significant dlbcl
+Cluster 1132: albumin serum concentration lln receipt urinary calcium absence abnormal gram
+Cluster 1133: strong inhibitors discontinued cypa inducers different isoenzyme treatment switched drugs
+Cluster 1134: feeding pregnancy breast test positive unwillingness women known urine pregnant
+Cluster 1135: white blood mm count cell cu cells cubic hydrea equal
+Cluster 1136: anticancer therapy prior weeks systemic investigational treatment received study days
+Cluster 1137: creatinine clearance mg ml dl min serum calculated measured renal
+Cluster 1138: practice male childbearing contraception adequate potential participants women agree treatment
+Cluster 1139: lipase pancreatitis radiologic clinical evidence uln upper limit normal cabozantinib
+Cluster 1140: tsh thyroid stimulating hormone normal limits free wnl thyroxine euthyroid
+Cluster 1141: autoimmune syndrome systemic disease patients immune history demyelinating recur phospholipid
+Cluster 1142: arbor ann stage iv ii iii disease staging bulky classification
+Cluster 1143: mellitus diabetes uncontrolled hypertension hyperthyroidism patients heart failure hypothyroidism subject
+Cluster 1144: minor placement procedure surgical access excluding biopsy core vascular device
+Cluster 1145: federal accordance guidelines institutional written informed consent local signed provide
+Cluster 1146: nursing pregnant patients harm infants potential regimen congenital non abnormalities
+Cluster 1147: mother breastfeeding potential discontinued risks study apply infants excluded women
+Cluster 1148: mri undergo unable contrast scans able patients brain inability imaging
+Cluster 1149: cord spinal compression untreated leptomeningeal brain symptomatic metastases disease metastasis
+Cluster 1150: read english able speak understand fluently language patients patient caregivers
+Cluster 1151: cardiac scan muga ejection fraction acquisition gated heart left ventricular
+Cluster 1152: measureable recist disease lesion version defined radiographically criteria presence according
+Cluster 1153: experimental planned study recent participation current drug weeks infusion genentech
+Cluster 1154: neuropathy peripheral grade patients greater preexisting excluded baseline ii equal
+Cluster 1155: alc lymphocyte absolute count ul mm cells cell blood product
+Cluster 1156: uncompensated morbidity participate lung interfere ability trial uncontrolled infection heart
+Cluster 1157: nodal lesions mm axis recorded short accurately longest dimension calipers
+Cluster 1158: opportunistic infections concurrent infection dosing cmv day previous viral active
+Cluster 1159: triglycerides fasting mg dl hypertriglyceridemia uncontrolled glucose mmol elevated metabolic
+Cluster 1160: contralateral breast invasive cancer synchronous dcis patients eligible previous lcis
+Cluster 1161: visits scheduled comply tests willingness plans procedures ability laboratory treatment
+Cluster 1162: communicate english able read spanish sensations exablate ability staff inability
+Cluster 1163: inr uln aptt anticoagulant anticoagulants coumadin therapy recent incb normalization
+Cluster 1164: cervix situ carcinoma uteri breast adequately treated noninvasive neoplasm fanca
+Cluster 1165: upper alt limit normal ast times uln institutional donor serum
+Cluster 1166: hepatitis reactive hbsag rna qualitative hcv detected known active determine
+Cluster 1167: immunotherapy radiotherapy chemotherapy investigational therapy concurrent days treatment agents cancer
+Cluster 1168: count neutrophil absolute platelet hemoglobin dl anc function marrow bone
+Cluster 1169: disorders gastrointestinal absorption interfere extensive drug surgery study medical significant
+Cluster 1170: existing interstitial pre lung known disease ild inflammatory current patient
+Cluster 1171: plt platelets mm transfusions mcl days ml obtained start registration
+Cluster 1172: end hematologic organ function adequate results obtained laboratory defined initiation
+Cluster 1173: informed federal accordance nature study guidelines procedures provide specific written
+Cluster 1174: resonance magnetic tomography imaging measurable computed ct mri recist disease
+Cluster 1175: bilirubin uln total direct levels serum subjects days registration upper
+Cluster 1176: pap smear intraepithelial cancer situ localized cervical curatively remission exempt
+Cluster 1177: blood pressure hg significant pulmonary hypertension qtc mm history qt
+Cluster 1178: obtained newly specimen inaccessible archived excisional concern biopsy tissue submit
+Cluster 1179: prolymphocytic transformation richter leukemia prolymphocytes richters history syndrome blood documented
+Cluster 1180: laboratory clia certified improvement mutation clinical amendments testing act tumor
+Cluster 1181: iron overload hemochromatosis parenteral subjects transferrin ferritin dextran saturation anemia
+Cluster 1182: sgot glutamic oxaloacetic transaminase aspartate ast uln serum aminotransferase equal
+Cluster 1183: decreasing stable corticosteroids dose days prior week receiving patients dexamethasone
+Cluster 1184: hepatitis serology cirrhosis fibrosis liver chronic positive stage evidence patients
+Cluster 1185: crohns colitis ulcerative disease history diverticulitis active absorption syndrome malabsorption
+Cluster 1186: karnofsky performance status patients ecog higher days registration prior better
+Cluster 1187: hbac glycosylated hemoglobin glycated screening measurement glucose diabetes hyperglycemia fasting
+Cluster 1188: wbc white ul blood cell count counts days obtained prior
+Cluster 1189: pneumonitis infectious steroids current required non history known evidence active
+Cluster 1190: mg doses corticosteroids prednisone equivalent day steroids physiologic systemic replacement
+Cluster 1191: wocbp partners birth control fertile using effective men sexually sexual
+Cluster 1192: ecg electrocardiogram abnormalities clinically significant abnormal investigator lead meaningful screening
+Cluster 1193: diagnosed newly cancer patients breast disease stage untreated histologically proven
+Cluster 1194: hematologic toxicity evaluable transfusions patients limiting provided enrolled observed red
+Cluster 1195: hla donor haploidentical recipient identical haplotype drb related loci antibodies
+Cluster 1196: hyperbilirubinemia hemolysis predominantly unconjugated persistent apply pathology absence consultation gilberts
+Cluster 1197: performed anc neutrophil mcl absolute initiation count days treatment registration
+Cluster 1198: fungal mycobacterial nail beds antibiotics infection infections excluding bacterial episode
+Cluster 1199: unsuitable makes opinion condition subject participation investigator trial investigators make
+Cluster 1200: regorafenib prior use treatment criteria sunitinib inclusion therapy patients received
+Cluster 1201: transformation richter cll aggressive richters lymphoma dlbcl hodgkin known biopsy
+Cluster 1202: nsclc stage iv prior metastatic recurrent advanced treatment therapy chemotherapy
+Cluster 1203: uncontrolled myocardial infarction angina heart congestive failure months unstable cardiac
+Cluster 1204: arrhythmias symptomatic cardiac uncontrolled ventricular ejection fraction left disease pressor
+Cluster 1205: product investigational clinical participation study weeks days prior medicinal ip
+Cluster 1206: daratumumab cd anti therapies received previously prior cluster sy differentiation
+Cluster 1207: permissible cavity melanomatous invasive free cervix minimum situ oral malignancy
+Cluster 1208: older age years men female women patients time subjects patient
+Cluster 1209: birth control pregnant effective unwilling feeding breast women use reproductive
+Cluster 1210: tacrolimus cyclosporine versus host post prevent transplant graft agents receiving
+Cluster 1211: hiv known infection history patients carrier infected subjects suspected active
+Cluster 1212: lactating female pregnant patients subject breastfeeding subjects patient non male
+Cluster 1213: bacterial fungal viral infection active uncontrolled systemic requiring treatment therapy
+Cluster 1214: hemoglobin dl hgb achieve transfusion intervention acceptable note use registration
+Cluster 1215: concurrent malignancy requiring active intervention therapy participants immediate treatment patient
+Cluster 1216: normal institution range upper limit ast alt bilirubin eosinophilia tenderness
+Cluster 1217: estimated expectancy life weeks investigator judgment participant permit sjcar judgement
+Cluster 1218: involvement platelets marrow unless bone lymphoma mcl cytopenias mm ul
+Cluster 1219: carcinoma malignancies adequately basal situ cell squamous treated skin cervix
+Cluster 1220: providing capable informed consent procedures written complying patient parent guardian
+Cluster 1221: growth factor acting days hematopoietic sargramostim filgrastim long forming neulasta
+Cluster 1222: verification original histologic diagnosis relapse tumors patients malignancy refractory cns
+Cluster 1223: blasts marrow bone leukemia relapse patients acute morphologic aml disease
+Cluster 1224: ketoconazole cypa itraconazole inhibitors strong ritonavir inducers carbamazepine clarithromycin phenytoin
+Cluster 1225: microliter leukocytes mcl fascial farber fap fanconi fancd fancc fanca
+Cluster 1226: healing wound non ulcer fracture presence bone dehiscing scalp fractures
+Cluster 1227: interstitial lung disease history evidence clinically active known patients induced
+Cluster 1228: inappropriate make study judgment investigator severe participation abnormality condition medical
+Cluster 1229: limits bilirubin total institutional normal upper gilberts registration cohort outside
+Cluster 1230: renal function adequate liver defined follows following cardiac days compromised
+Cluster 1231: cockcroft formula gault creatinine clearance min ml estimated according local
+Cluster 1232: injectables implants combined contraceptives devices partner iuds intrauterine condoms highly
+Cluster 1233: mastectomy lumpectomy breast surgery reconstruction patients conserving nipple sparing scheduled
+Cluster 1234: coagulopathy bleeding diathesis evidence history disorder significant clinically inherited known
+Cluster 1235: pregnancy wocbp minimized manner avoid risk using contraception method study
+Cluster 1236: nsclc cytologically histologically confirmed squamous stage iv diagnosis non metastatic
+Cluster 1237: thromboplastin time aptt partial activated inr normalized ratio international uln
+Cluster 1238: unresectable metastatic advanced locally disease cancer patients resectable sarcoma tumor
+Cluster 1239: hepatitis antibody hcv positive hbsag antigen infection hbc virus eligible
+Cluster 1240: agent investigational dose type days received study treatment subject drug
+Cluster 1241: dermatitis atopic cohort history vitiligo euthyroid skin patients grave childhood
+Cluster 1242: metastases brain administration weeks doses prednisone equivalents treated mri immunosuppressive
+Cluster 1243: disease inflammatory syndrome hashimoto celiac systemic following hypophysitis graves bowel
+Cluster 1244: altered mental understanding process precluding necessary psychiatric informed status consent
+Cluster 1245: lung small histologically cell cytologically confirmed non cancer nsclc stage
+Cluster 1246: past years psoriasis vitiligo disease autoimmune graves requiring systemic documented
+Cluster 1247: obtained hemoglobin dl registration days prior hgb mg creatinine study
+Cluster 1248: female childbearing potential male contraception partners use effective patients agree
+Cluster 1249: platelet help transfusions meet eligibility allowed criteria days count enrollment
+Cluster 1250: rems revlimid program registered mandatory comply requirements willing able participants
+Cluster 1251: gastrointestinal perforation abdominal risk disease bleeding colitis ulcerative peptic bowel
+Cluster 1252: hiv cd immunodeficiency haart antiretroviral load virus viral human positive
+Cluster 1253: anthracycline therapy prior chemotherapy taxane received based containing exposure regimen
+Cluster 1254: contraception lifestyle usual preferred course abstinence study acceptable medication method
+Cluster 1255: corticosteroids immunosuppressive inhaled chronic topical systemic treatment agents allowed receiving
+Cluster 1256: guardian informed explained consent copy understood patient signed given procurement
+Cluster 1257: live virus vaccination contain flu seasonal planned vaccines start received
+Cluster 1258: flc serum light mg chain abnormal protein free involved ratio
+Cluster 1259: heart hypertension history clinically significant labile qt ecg cardiac poor
+Cluster 1260: excipient hypersensitivity durvalumab history known medi ip substance component investigational
+Cluster 1261: morbidities active significant clinically disease compromise pulmonary uncontrolled participation condition
+Cluster 1262: heart york infarction myocardial association unstable iii new iv class
+Cluster 1263: requiring thoracentesis paracentesis effusions pleural ascites subjects days prior randomization
+Cluster 1264: informed federal accordance nature guidelines institutional consent investigational written sign
+Cluster 1265: performing subject meeting prevent compromise study opinion requirements condition investigator
+Cluster 1266: hg pressure blood mm systolic diastolic hypertension uncontrolled mercury defined
+Cluster 1267: therapy embolization biologic immunotherapy radiation surgery tumor chemotherapy anti cancer
+Cluster 1268: creatinine clearance gault cockcroft hour collection min ml urine formula
+Cluster 1269: administered recovered therapy previously molecule agent prior targeted adverse small
+Cluster 1270: gm hemoglobin dl hgb transfusion creatinine days equal permitted prior
+Cluster 1271: interferons immunostimulatory whichever lives half il shorter limited systemic drug
+Cluster 1272: angina cardiac new heart blockers arrhythmic months onset digoxin beta
+Cluster 1273: pulmonary hypertension disease significant cardiac severe patients history emphysema overt
+Cluster 1274: abdomen pelvis radiotherapy radiation upper prior therapy previous liver treatment
+Cluster 1275: bleeding disorder significant acquired unrelated history congenital diagnosed cancer viii
+Cluster 1276: brain metastasis ct exclude mri metastases neurological symptoms scan undergo
+Cluster 1277: medically fit undergo stable inoperable unfit patients surgical receive unstable
+Cluster 1278: sgot ast uln limits upper normal serum families fancd fancc
+Cluster 1279: projected expectancy life weeks participant cohort subject months families fanconi
+Cluster 1280: brain metastasis symptomatic steroids patients requiring uncontrolled doses treatment metastases
+Cluster 1281: valproic acid panobinostat need condition days treatment medical patients prior
+Cluster 1282: immunodeficiency known acquired aids testing syndrome positive virus human hiv
+Cluster 1283: block resting degree rhythm morphology important heart conduction abnormalities ecg
+Cluster 1284: entry surgery major study weeks prior days radiation recover failed
+Cluster 1285: spanish english speaking speaks fluent able consent french questionnaires informed
+Cluster 1286: aminotransferase alanine institutional aspartate ast alt upper normal limit uln
+Cluster 1287: age lansky years corresponding scores patients ecog eastern cooperative oncology
+Cluster 1288: fertile unwilling contraceptive practice methods men period study appropriate follow
+Cluster 1289: predicted fev dlco diffusion capacity expiratory forced volume carbon monoxide
+Cluster 1290: components hypersensitivity known drug talazoparib patients study niraparib analogs contraindication
+Cluster 1291: imaging ct mri tomography resonance computed magnetic contrast scan metastases
+Cluster 1292: neutrophil absolute anc count obtained registration days prior mm mcl
+Cluster 1293: rapamycin analogs temsirolimus everolimus sirolimus intolerance hypersensitivity known derivatives lenvatinib
+Cluster 1294: male female aged years subjects patients non gender pregnant greater
+Cluster 1295: representatives parents authorized legally assent guidelines appropriate according sign obtained
+Cluster 1296: intrinsic dyspnea resulting lung lungs extensive rest involvement symptomatic disease
+Cluster 1297: labs adequate screening performed organ function days demonstrate initiation treatment
+Cluster 1298: milliseconds qtc interval qt corrected prolongation baseline demonstration ms electrocardiogram
+Cluster 1299: objectives compromise opinion condition study investigator medical studys investigators adherence
+Cluster 1300: visit screening postmenopausal year months prior investigational weeks subjects study
+Cluster 1301: lymphoma follicular transformed grade dlbcl transformation confirmed marginal lymphocytic zone
+Cluster 1302: multigated acquisition muga fraction ejection echocardiogram left scan ventricular echo
+Cluster 1303: delayed toxicity therapy weeks chemotherapy anti immunotherapy cancer preceding dose
+Cluster 1304: bilirubin gilberts mg dl total syndrome patients unless uln equal
+Cluster 1305: polymerase chain pcr reaction immunohistochemistry reverse ihc rt tumor transcriptase
+Cluster 1306: severe uncontrolled systemic disease current metabolic cardiovascular pulmonary clinically significant
+Cluster 1307: anemia fanconi syndromes marrow aplastic failure inherited bone syndrome fa
+Cluster 1308: ct contrast mri scan chest imaging pet abdomen tomography enhanced
+Cluster 1309: outside device concurrent investigational drug signing use trial weeks form
+Cluster 1310: visits follow willing study attend able comply subject travel protocol
+Cluster 1311: auto immune disease active inflammatory history autoimmune requiring vitiligo thyroiditis
+Cluster 1312: hiv negative immunodeficiency virus human donor serology test antibody hepatitis
+Cluster 1313: iiib stage iv nsclc advanced histologically cytologically metastatic confirmed locally
+Cluster 1314: vaccines live vaccine influenza rabies rubella mumps measles yellow typhoid
+Cluster 1315: protein urine dipstick urinalysis urinary hour routine mg collection hours
+Cluster 1316: glucose mellitus diabetes closely antidiabetic dm monitored adjusted hbac necessary
+Cluster 1317: bilirubin uln equal conjugated institutional mla fractionated isolated direct needs
+Cluster 1318: seizure predispose condition history cortical stroke brain trauma significant prior
+Cluster 1319: females childbearing potential males contraception fcbp study agree effective use
+Cluster 1320: renal insufficiency creatinine failure gfr disease history patients acute ml
+Cluster 1321: icf form signed consent informed sign approved read ability irb
+Cluster 1322: oxaliplatin irinotecan fluorouracil fluoropyrimidine fu leucovorin bevacizumab prior containing chemotherapy
+Cluster 1323: target designated persistence irradiated field confirm tumors assess lesions response
+Cluster 1324: excipients hypersensitivity known ribociclib patient bkm nivolumab study formulation severe
+Cluster 1325: child bearing potential women men agree use contraception study adequate
+Cluster 1326: steroid prednisone therapy equivalent immunosuppressive immunodeficiency receiving mg form daily
+Cluster 1327: expectancy life years months physician patients treating anticipated month weeks
+Cluster 1328: effects toxic grade ctcae nci terminology resolution common institute events
+Cluster 1329: contraception methods intrauterine suppository film cream gel foam hormonal caps
+Cluster 1330: investigational concomitant drugs use agents days subjects receive therapy anticancer
+Cluster 1331: steroids systemic use patients treatment doses days prior replacement chronic
+Cluster 1332: protein electrophoresis monoclonal serum urine spep quantitative mg dl hour
+Cluster 1333: complying capable protocol understanding requirements opinion investigator participants procedures patient
+Cluster 1334: nursing female pregnant patients eligible subjects ineligible study intend intends
+Cluster 1335: enzyme antiepileptic inducing rifampin phenobarbital carbamazepine wort phenytoin rifapentine st
+Cluster 1336: cancer distinct treated curatively situ superficial carcinoma bladder years cervical
+Cluster 1337: likely procedures interfere results coexisting condition medical study psychiatric hazard
+Cluster 1338: sensory neuropathy grade peripheral preexisting baseline greater patients evidence equal
+Cluster 1339: children hospital parents fathering excluded age study prisoners vulnerable avoid
+Cluster 1340: transaminases normal upper limit uln liver times serum bilirubin hepatic
+Cluster 1341: comply written informed consent provide procedures study ability able requirements
+Cluster 1342: severe willebrands hemophilia von disorders bleeding known disease familial families
+Cluster 1343: secretory myeloma multiple non oligo symptomatic protein diagnosis ii mm
+Cluster 1344: shorter whichever therapy half lives weeks chemotherapy prior biologic radiotherapy
+Cluster 1345: world health organization performance status organisation deterioration weeks expectancy life
+Cluster 1346: revassist program mandatory registered comply willing requirements able participants study
+Cluster 1347: live vaccine receipt attenuated days dose prior study receive enrolled
+Cluster 1348: sorafenib prior treatment hcc therapy received systemic sunitinib patients progression
+Cluster 1349: mmhg rescreened minutes separate antihypertensive measurements apart pressure diastolic systolic
+Cluster 1350: antiretroviral combination undertaken indicated studies hiv appropriate immunodeficiency therapy virus
+Cluster 1351: strong cypa inducers inhibitors receiving cytochrome concomitant treatment days medications
+Cluster 1352: transfusions blood red platelet packed days cell prior cells entry
+Cluster 1353: antibody anti cd therapy prior treatment received weeks previous based
+Cluster 1354: area body surface bsa enrollment patients time study dose design
+Cluster 1355: allograft corneal organ transplant including history stem immunosuppression cell regardless
+Cluster 1356: site primary disease tumor patients radiation biopsy unknown measurable metastatic
+Cluster 1357: arrhythmia cardiac ventricular uncontrolled requiring history symptomatic inadequately controlled arrhythmias
+Cluster 1358: heart class functional classification disease cardiovascular arrhythmias york association infarction
+Cluster 1359: unl upper limit normal bilirubin total gilbert syndrome institutional serum
+Cluster 1360: scan ct bone imaging mri tomography resonance magnetic computed metastatic
+Cluster 1361: pump proton histamine antacids antagonists inhibitors antagonist constant enzymes inhibitor
+Cluster 1362: earlier weeks administered adverse events recovered agents entering radiotherapy chemotherapy
+Cluster 1363: pose safety risk consulted disorder opinion amgen condition investigator interfere
+Cluster 1364: prohibitions restrictions adhere specified willing protocol able schedule visit study
+Cluster 1365: adverse terminology common events ctcae grade criteria alopecia recovered toxicities
+Cluster 1366: forced capacity fvc vital dlco fev monoxide expiratory carbon volume
+Cluster 1367: sampling analyses specific provision consent procedures informed dated written signed
+Cluster 1368: scleroderma lupus active diagnosis disease radiation oncologist autoimmune history systemic
+Cluster 1369: agents investigational weeks use study treatment prior days patients receive
+Cluster 1370: hypertensive pressure controlled blood hypertension anti mmhg diastolic systolic history
+Cluster 1371: entry study prior time weeks months days received patients therapy
+Cluster 1372: immunostimulatory agents whichever lives systemic half treatment shorter weeks drug
+Cluster 1373: kg mg day prednisone equivalent gvhd corticosteroids dose methylprednisolone cgvhd
+Cluster 1374: thromboembolic event arterial history months events venous past anticoagulation prior
+Cluster 1375: childbearing potential female subjects non pregnant partner male enrolled woman
+Cluster 1376: malignancy carcinoma basal treated cell years skin eligible patients situ
+Cluster 1377: comply requirements study able swallow drug enzalutamide psychologically follow drugs
+Cluster 1378: risks benefits understand study basic elements research participant purpose able
+Cluster 1379: shorter whichever half lives investigational weeks prior drug days study
+Cluster 1380: stricture urethral dilatation proximal history requiring bladder neck biliary prostatic
+Cluster 1381: lower normal calcium limit lab values institution magnesium potassium hours
+Cluster 1382: purpura hemolytic thrombocytopenic idiopathic itp autoimmune anemia thrombotic uremic thrombocytopenia
+Cluster 1383: intravenous antibiotics infection requiring active iv registration oral bacterial fungal
+Cluster 1384: therapeutics intermittent continuous molecule monoclonal excluding antibodies effects small lives
+Cluster 1385: reaction allergic history prior hypersensitivity involved known protocol severe cisplatin
+Cluster 1386: eligible brain metastases fewer radiosurgery stereotactic diameter asymptomatic month cm
+Cluster 1387: signed form informed consent study written provide approved procedure patient
+Cluster 1388: load viral hepatitis negative hiv hcv virus positive antibody patients
+Cluster 1389: modifiers response biologic chemotherapy weeks therapy targeted colony therapies granulocyte
+Cluster 1390: msec qtcf ecg screening interval mean males females triplicate electrocardiogram
+Cluster 1391: estimated expectancy life months greater investigator years patients entry treating
+Cluster 1392: granulocytes ul mcl mm ml total equal anc bands greater
+Cluster 1393: threatening stroke cardiovascular arrhythmia unstable infarction myocardial life problems congestive
+Cluster 1394: healed surgery wound fully major incision weeks surgical dental incompletely
+Cluster 1395: pugh impairment hepatic child class severe moderate patients baseline liver
+Cluster 1396: hla typing drb resolution matched donor unrelated high donors dqb
+Cluster 1397: anticancer receipt medications drugs administration intervals investigational drug defined study
+Cluster 1398: carcinoma situ adequately treated evidence disease noninvasive cervical ductal papillary
+Cluster 1399: geographic compliance psychological follow familial hamper protocol proximity sociological adequate
+Cluster 1400: abdominal diverticulitis abscess obstruction intra carcinomatosis gastrointestinal gi perforation bowel
+Cluster 1401: measurable following defined disease measurements assessed mm randomization days patients
+Cluster 1402: oxygen supplemental requiring requirement saturation patients daily pulmonary require home
+Cluster 1403: platelet transfusions independent count mm transfusion solid involvement tumors marrow
+Cluster 1404: daunorubicin cytarabine liposomal products equivalents hypersensitivity mg received induction eligible
+Cluster 1405: neuropathy peripheral grade greater baseline presence patient equal severity current
+Cluster 1406: awareness indicating nature program signed informed investigational consent scheduling cct
+Cluster 1407: inr warfarin ptt exists heparin parameters underlying coagulation participate abnormality
+Cluster 1408: effects reversible recovered antineoplastic grade toxicity therapy prior anticancer alopecia
+Cluster 1409: females breastfeeding pregnant currently ineligible excluded childbearing current potential avoid
+Cluster 1410: myelogenous leukemia chronic cml acute aml patients phase lymphoblastic remission
+Cluster 1411: concomitant medications excluded therapies previous relating pharmacokinetics use study induce
+Cluster 1412: prostate adenocarcinoma histologically confirmed documented cancer diagnosis metastatic primary patients
+Cluster 1413: swallow inability pills medications absorb medication drug preclude absorption gastrointestinal
+Cluster 1414: urethra ureter bladder pelvis transitional renal urothelial carcinoma cell histologically
+Cluster 1415: female subject subjects patients sex eligible enter years patient participate
+Cluster 1416: dose therapy study male starting method contraception agree adequate use
+Cluster 1417: field palliation weeks radiation wide radiotherapy limited effects recovered starting
+Cluster 1418: stage disease clinical ib patients iiia ia ii figo iia
+Cluster 1419: corticosteroids permitted equivalents prednisone systemic mg autoimmune topical dye brief
+Cluster 1420: aml promyelocytic apl leukemia acute diagnosed newly excluding classification patients
+Cluster 1421: hepatitis seronegative antibody antigen tested rna rt pcr hcv reverse
+Cluster 1422: renal creatinine function adequate uln serum normal defined mg times
+Cluster 1423: hepatic renal function adequate defined cardiac baseline pulmonary pancreatic hematopoietic
+Cluster 1424: completed prior therapy radiation weeks chemotherapy enrollment treatment study days
+Cluster 1425: events adverse biologic extended occurring agent occur known days agents
+Cluster 1426: heart york association new congestive failure nyha ii class greater
+Cluster 1427: recist measurable criteria disease appendix assessed present patients inclusion participants
+Cluster 1428: hemophilia von bleeding willebrands disorders known willebrand disease diathesis predisposition
+Cluster 1429: retroviral combination anti hiv receiving immunodeficiency virus human undertaken therapy
+Cluster 1430: protein urine mg hours hour hr bence jones measured monoclonal
+Cluster 1431: infectious active disease process infection hepatitis uncontrolled candidiasis evidence aspergillus
+Cluster 1432: ritonavir clarithromycin saquinavir ketoconazole telithromycin itraconazole nelfinavir indinavir grapefruit nefazodone
+Cluster 1433: allergy known history hypersensitivity patients reaction suspected measles bovine products
+Cluster 1434: follow return visits required assess obtain studies toxicity protocol inability
+Cluster 1435: pelvis radiation prior radiotherapy therapy prostate bone outside marrow treatment
+Cluster 1436: comply willingness requirements ability protocol study guidelines informed consent written
+Cluster 1437: unable consent informed cognitively comprehend patients excluded subjects adults impaired
+Cluster 1438: antiviral hepatitis active therapy chronic infection requiring known treatment positive
+Cluster 1439: males mg dl females creatinine years age serum maximum gender
+Cluster 1440: time signing practice agree contraception effective childbearing potential consent informed
+Cluster 1441: times uln alt ast liver metastases bilirubin alanine normal aminotransferase
+Cluster 1442: provided consent informed written subject study participation prior activities participate
+Cluster 1443: proteinuria urine dipstick protein hour collection urinalysis demonstrate discovered undergo
+Cluster 1444: leukocytes mm ml registration obtained days microl prior cells equal
+Cluster 1445: myeloma multiple therapy treatment prior received patients mm smoldering systemic
+Cluster 1446: sexually contraception effective males childbearing potential active use method women
+Cluster 1447: rvo retinal csr hypercoagulability glaucoma hyperviscosity hypertension ocular history uncontrolled
+Cluster 1448: kidney functions liver adequate hematological marrow bone performance status function
+Cluster 1449: accident cerebrovascular infarction myocardial months history angina unstable severe enrollment
+Cluster 1450: indicative months dose teaspoon hemoptysis hemorrhage signs red pulmonary treatment
+Cluster 1451: voluntarily understand sign informed consent form able document ability icf
+Cluster 1452: iuln creatinine serum registration days prior clearance min ml level
+Cluster 1453: aminotransferase uln liver metastases alanine aspartate alt ast present subjects
+Cluster 1454: uln alkaline phosphatase involvement liver limit cancer subjects lymphoma direct
+Cluster 1455: durvalumab dose female days tremelimumab monotherapy reproductive effective birth employ
+Cluster 1456: pelvic radiation prior history therapy patients abdominal received surgery hip
+Cluster 1457: braf mutation ve nras melanoma kras oncogene raf tumor homolog
+Cluster 1458: transfusion meet inclusion neutrophil absolute blood anc count mm allowed
+Cluster 1459: excluded women pregnant study breastfeeding participating studied trial included pregnancy
+Cluster 1460: refrain agreement abstinent remain donating measures contraceptive sperm men intercourse
+Cluster 1461: rituxan chlorambucil cytokine cytoreduction imatinib cytarabine conditioning hydroxyurea tyrosine addition
+Cluster 1462: times bilirubin uln total serum greater plasma days equal performed
+Cluster 1463: virus htlv human lymphotropic hiv immunodeficiency hepatitis cell infection seropositive
+Cluster 1464: acute exercise uncontrolled pulmonary cardiopulmonary failure dissecting myocarditis hemodynamic aggravated
+Cluster 1465: granulocyte colony stimulating csf factor neutrophil absolute count anc days
+Cluster 1466: cr subsequent cri pr creatinine complete response leukemia relapse achieved
+Cluster 1467: deacetylase histone inhibitor valproic taken acid weeks vorinostat enrollment prior
+Cluster 1468: hct allogeneic autologous prior post patients days hematologic treatable time
+Cluster 1469: effusion drainage pleural pericardial ascites requiring recurrent uncontrolled procedures frequently
+Cluster 1470: interstitial fibrosis lung pulmonary pneumonitis disease history pneumonia extensive evidence
+Cluster 1471: cells anc mm cellular mcl marrow dendritic neutropenia killer involvement
+Cluster 1472: fsh hormone follicle stimulating miu postmenopausal ml menstrual months women
+Cluster 1473: subfamily polypeptide cytochrome cypa family inhibitors strong inducers concomitant use
+Cluster 1474: infectious pneumonitis evidence non known active history patient step years
+Cluster 1475: adherence interfere opinion ability condition investigators clinically medical protocol significant
+Cluster 1476: tuberculosis previous diagnosis clinical known history eligibility phase criteria active
+Cluster 1477: delirium memorial scale assessment rating cognitive score hours mixed cognition
+Cluster 1478: valid consent written informed able willing address general physiologic provide
+Cluster 1479: female interruptions contact successful vasectomy condom sexual abstinence true practice
+Cluster 1480: blood products transfusions receive transfusion willing patients donated samples donate
+Cluster 1481: setting metastatic adjuvant prior treatment therapy advanced received taxane neoadjuvant
+Cluster 1482: ctcae grade nci infection ongoing version uln clinically bilirubin baseline
+Cluster 1483: warrants term existing corticosteroid pre long condition excess use dose
+Cluster 1484: heart bypass coronary artery graft angioplasty infarction myocardial angina class
+Cluster 1485: pregnancy study potential test childbearing negative contraception dose effective use
+Cluster 1486: malignancies active years concurrent history expectant patients observation requiring study
+Cluster 1487: calcification mineralization ectopic calcified kidneys intestine tissue current soft evidence
+Cluster 1488: creatinine normal institutional levels clearance min upper ml limit patients
+Cluster 1489: limits institutional creatinine normal upper serum uln function platelets limit
+Cluster 1490: opinion investigator condition medical study patient interfere compromise psychiatric participation
+Cluster 1491: ixazomib treated participated previously bortezomib study treatment previous blinded patients
+Cluster 1492: ventricular atrial heart tachycardia degree fibrillation block lvef arrhythmias old
+Cluster 1493: survival expected months days weeks free greater infection time opinion
+Cluster 1494: radiation weeks therapy prior treatment dose study chemotherapy enrollment surgery
+Cluster 1495: tas prior treatment received regorafenib previously components known previous hypersensitivity
+Cluster 1496: bilirubin total gilbert mg syndrome dl uln subjects normal upper
+Cluster 1497: surgery recovered major fully prior weeks patients patient day study
+Cluster 1498: nature understand informed consent ability written study investigational trial provide
+Cluster 1499: fever infection unexplained active scheduled dosing day enrollment visits days
+Cluster 1500: marrow involvement bone neutrophil absolute anc count solid tumors peripheral
+Cluster 1501: ta tb stage clinical prostate incidental cancer tnm finding stages
+Cluster 1502: males females age years older time consent non obtained pregnant
+Cluster 1503: kidney function liver adequate bone marrow stones disease solitary renal
+Cluster 1504: thoracic radiotherapy radiation prior patients breast therapy surgeon chemotherapy lung
+Cluster 1505: bearing consecutive child undergone woman potential study celibate remaining orientation
+Cluster 1506: status performance adequate patients disease considered eligible solely better good
+Cluster 1507: gastric duodenal bypass cancer surgery ulcer history undifferentiated resection bowel
+Cluster 1508: herpetic keratitis encephalitis complications lesions skin active hsv infection prior
+Cluster 1509: procedures comply willing able study follow protocol patient reporting instructions
+Cluster 1510: curatively cancer treated skin non years situ melanoma melanomatous malignancy
+Cluster 1511: melanoma metastatic unresectable patients diagnosis prior cutaneous therapy primary treatment
+Cluster 1512: measured measurable lesion dimension accurately mm disease ct defined mri
+Cluster 1513: amenable curative metastatic advanced locally intent disease surgery recurrent resection
+Cluster 1514: boron mannitol bortezomib hypersensitivity velcade patient known containing compounds allergic
+Cluster 1515: bacterial fungal viral taking currently progression uncontrolled clinical medication symptoms
+Cluster 1516: mmhg pressure blood systolic diastolic hypertension controlled inadequately uncontrolled defined
+Cluster 1517: values laboratory following screening hematology days follows baseline adequate meet
+Cluster 1518: placement access venous days subcutaneous device major surgery prior randomization
+Cluster 1519: cc creatinine clearance min calculated mg dl measured estimated serum
+Cluster 1520: hdac histone deacetylase inhibitor inhibitors valproic prior acid treatment therapy
+Cluster 1521: write read english able speak understand spanish unable languages ability
+Cluster 1522: anesthesia general surgery requiring major study epidural risk contraindications administration
+Cluster 1523: acceptable status hematologic coagulation hematological support specified ecog screening zydelig
+Cluster 1524: enzalutamide abiraterone prior treatment ar androgen arn ketoconazole bicalutamide therapy
+Cluster 1525: conjugated sum unconjugated age bilirubin upper limit normal uln total
+Cluster 1526: gilberts syndrome history known disease patients diagnosis glucuronidation bilirubin deficiency
+Cluster 1527: ischemic revascularization artery event procedures including fibrillation attack cerebrovascular transient
+Cluster 1528: chronic hepatitis liver active cirrhosis disease viral symptomatic persistent known
+Cluster 1529: alcohol cirrhosis abuse current hepatitis liver clinically viral significant including
+Cluster 1530: chemical similar composition compounds biologic allergy known hypersensitivity tolerability drugs
+Cluster 1531: platinum resistant disease based refractory progression months therapy sensitive ovarian
+Cluster 1532: cns nervous central metastases brain known active history treated disease
+Cluster 1533: female hrt product year partner diaphragm childbearing bilateral potential condom
+Cluster 1534: hyperleukocytosis leukapheresis wbc signs white cytarabine symptoms ul enrollment blood
+Cluster 1535: dose drug days study prior therapy received following chemotherapy weeks
+Cluster 1536: metformin taking reason insulin doxycycline currently diabetic subjects patients sulfonylureas
+Cluster 1537: adrenal dysfunction pituitary history insufficiency uncontrolled documented malignancy known viral
+Cluster 1538: pugh cirrhosis child liver class score present classification childs patients
+Cluster 1539: prostate cancer chemotherapy prior treatment cytotoxic therapy immunotherapy radiation systemic
+Cluster 1540: surgically sterile month documented screening status post prior hysterectomy menses
+Cluster 1541: refuse patients participate candidates subjects cisplatin chemotherapy deemed eligible therapy
+Cluster 1542: anticancer concurrent agents therapy investigational treatment therapies receiving prostate cancer
+Cluster 1543: ldh lactate dehydrogenase uln serum times normal upper limit level
+Cluster 1544: contraindications mri medical leukapheresis metallic patients pancreatectomy claustrophobia subjects catheterization
+Cluster 1545: mds myelodysplastic aml syndrome syndromes antecedent hypomethylating treatment agent hematologic
+Cluster 1546: immunization attenuated live week receive vaccines period study vaccine entry
+Cluster 1547: aurora kinase alisertib targeted prior including inhibitor agent administration mln
+Cluster 1548: pathologically confirmed cancer breast diagnosis patients metastatic dlbcl gist prostate
+Cluster 1549: invasive malignancy years history prior remission cancer past active primary
+Cluster 1550: cancers active primary patients requiring second skin systemic treatment invasive
+Cluster 1551: colorectal histologically confirmed adenocarcinoma metastatic cytologically cancer unresectable proven locally
+Cluster 1552: bypass artery coronary attack accident transient cerebrovascular ischemic graft peripheral
+Cluster 1553: hepatitis ml copies iu viremic dna virus deoxyribonucleic carrier active
+Cluster 1554: archival tissue tumor biopsy available fresh sample provide undergo willing
+Cluster 1555: cns involvement disease active patients nervous central evidence known eligible
+Cluster 1556: initiative compliant means proximity geographical protocol investigator visits make judged
+Cluster 1557: metastases brain known patients history excluded subjects subject evidence patient
+Cluster 1558: alanine aminotransferase alt upper limit normal times uln institutional age
+Cluster 1559: accessible biopsy tumor biopsies lesion site patients treatment lesions tissue
+Cluster 1560: menses year postmenopausal defined screening menopausal prior post ago menopause
+Cluster 1561: objectives achieving obtaining reliable data circumstances chances decrease condition significantly
+Cluster 1562: provide able consent informed patients understand study cognitively meaningful phase
+Cluster 1563: pugh class child liver function ascites score hepatic disease classified
+Cluster 1564: heparin low molecular weight anticoagulation warfarin therapeutic dose receiving coumadin
+Cluster 1565: gilbert bilirubin uln total syndrome unless documented disease serum patients
+Cluster 1566: pancreatitis acute chronic history year known recent study entry symptomatic
+Cluster 1567: qtcf ms regard average fridericia eligibility meets consecutive qt results
+Cluster 1568: metastasis distant evidence lymph induction organs clavicles liver adenopathy patients
+Cluster 1569: glutamic transaminase aminotransferase pyruvic serum sgpt oxaloacetic sgot alt alanine
+Cluster 1570: gilberts bilirubin unless upper limit normal total uln syndrome institutional
+Cluster 1571: hematopoietic allogeneic transplant stem cell prior hsct previous gvhd days
+Cluster 1572: adjuvant chemotherapy therapy radiation months prior cancer surgery treatment patients
+Cluster 1573: men women age years ages patients adult status country majority
+Cluster 1574: pomalyst rems program registered mandatory comply requirements willing strategy mitigation
+Cluster 1575: corticosteroid decreasing stable dose corticosteroids days prior receiving eligible modify
+Cluster 1576: expression tumor cd cells immunohistochemistry pd wt positive tissue cohort
+Cluster 1577: radiotherapy starting weeks recovered prior toxicities treatment study related bone
+Cluster 1578: prolonged qtc interval qt corrected msec electrocardiogram history rate syndrome
+Cluster 1579: zubrod performance registration status days prior step documented patients study
+Cluster 1580: implanted device pacemaker defibrillator devices electronic stimulator brain pacemakers deep
+Cluster 1581: infection virus active hepatitis immunodeficiency human known hiv positive ongoing
+Cluster 1582: test urine pregnancy negative serum childbearing potential confirmed positive required
+Cluster 1583: thrombosis deep heparin low molecular weight venous dvt vein anticoagulation
+Cluster 1584: currently investigational agents receiving patients intended treatments therapy participants gbm
+Cluster 1585: docetaxel prior treatment cabazitaxel chemotherapy paclitaxel patients received therapy setting
+Cluster 1586: barrier method birth control duration adequate use study contraception abstinence
+Cluster 1587: formulation component hypersensitivity known allergy reaction history drug murine medi
+Cluster 1588: initiation hemoglobin dl mmol days performed treatment labs working nhemoglobin
+Cluster 1589: hiv infection blot western licensed history documentation assay test elisa
+Cluster 1590: capsules swallow able patients inability unable intact patient crushed gastrointestinal
+Cluster 1591: final study administration sperm donate period drug screening subject male
+Cluster 1592: cervical carcinoma cancer situ intraepithelial neoplasia cin stage history colposcopy
+Cluster 1593: uncontrolled cardiovascular conditions arrhythmias current infarction myocardial congestive evidence past
+Cluster 1594: receptor epidermal growth factor human negative breast er positive estrogen
+Cluster 1595: brain metastases symptomatic steroids requiring known patients uncontrolled presence symptoms
+Cluster 1596: chemotherapy allowable cancer different prior systemic note study therapy previous
+Cluster 1597: pectoris illness uncontrolled unstable symptomatic intercurrent limited congestive angina failure
+Cluster 1598: calcium corrected mg dl serum albumin total subjects equal weeks
+Cluster 1599: disease autoimmune thyroiditis vitiligo sclerosis graves lupus multiple hashimotos arthritis
+Cluster 1600: bmi index mass body patients scanner weight greater overweight bore
+Cluster 1601: range bilirubin upper limit total normal uln reference level ulrr
+Cluster 1602: compression spinal cord definitively treated stable surgery radiation diagnosed previously
+Cluster 1603: procedure surgical major weeks prior study days day treatment planned
+Cluster 1604: obtaining existing disorder safety conditions interfere pre unstable compliance psychiatric
+Cluster 1605: mandatory testing hiv immunodeficiency virus human known infection history patient
+Cluster 1606: malignancies unsure indolent consult second melanoma completely history resected cancer
+Cluster 1607: reversible fully effects recovered toxicity failure grade chemotherapy prior regardless
+Cluster 1608: barrier birth study control method abstinence contraception adequate agree men
+Cluster 1609: insulin diabetes mellitus dependent oral requiring patients diabetics gestational uncontrolled
+Cluster 1610: pancreas adenocarcinoma histologically cytologically metastatic confirmed proven advanced ductal resectable
+Cluster 1611: jak inhibitor janus kinase prior ruxolitinib therapy inhibitors treatment indication
+Cluster 1612: angina pectoris infarction myocardial months unstable starting prior drug study
+Cluster 1613: iu sensitivity units hcg chorionic minimum equivalent gonadotropin test pregnancy
+Cluster 1614: pleural effusion malignant mesothelioma significant chest clinically ray effusions fluid
+Cluster 1615: fluorescein allergy reaction known shellfish skin iodine test prior sodium
+Cluster 1616: morbidity severe follows active defined factors score total index investigator
+Cluster 1617: ctla targeted pd therapies excluded prior therapy stimulatory anti allowed
+Cluster 1618: regimens chemotherapy prior received metastatic cytotoxic disease patients treatment setting
+Cluster 1619: objective progression evidence disease entry documented study therapy prior clinical
+Cluster 1620: cva accident cerebrovascular infarction myocardial mi unstable months angina history
+Cluster 1621: crc histologically metastatic confirmed colorectal cytologically msi kras cancer history
+Cluster 1622: visceral crisis metastasis metastases rapid liver disease symptomatic progression organ
+Cluster 1623: cells plasma marrow bone nucleated platelet count plasmacytoma monoclonal biopsy
+Cluster 1624: internet access computer home email smartphone regular web tablet navigate
+Cluster 1625: feeding female breast pregnant patients lactating participants stop patient agree
+Cluster 1626: opioid use pain analgesics daily morphine abuse chronic past history
+Cluster 1627: patient cognitive information compromise complete psychiatric comply study conditions ability
+Cluster 1628: final try study administration agree drug heterosexually pregnant consistently days
+Cluster 1629: deficits neurologic week stable neurological minimum encephalopathy focal research prior
+Cluster 1630: conduct planning involvement study present sponsor center enrolled association previously
+Cluster 1631: reproductive contraceptive effective method agreed potential use duration unless patients
+Cluster 1632: corticosteroid prednisone equivalent mg day dose therapy corticosteroids chronic weeks
+Cluster 1633: protein urine upc ratio creatinine hour proteinuria dipstick screening assessed
+Cluster 1634: women pregnancy test sterilized menopausal menses surgically undergo post year
+Cluster 1635: contraception agree study men duration women use potential adequate childbearing
+Cluster 1636: vitamin antagonists warfarin anticoagulation equivalent requires phenprocoumon antagonist days patients
+Cluster 1637: indicating purpose understands procedures study participate willing required consent informed
+Cluster 1638: pd anti agent received therapy prior treatment merck participated pembrolizumab
+Cluster 1639: carcinoma treated intent modalities curative cell confined uteri malignancy skin
+Cluster 1640: herbal ephedra kava yohimbe ginseng ma gingko biloba dehydroepiandrosterone huang
+Cluster 1641: parenteral antibiotics free requiring infection active patients disorder illness entry
+Cluster 1642: illness medical condition unstable acute concurrent patients cardiovascular major significant
+Cluster 1643: rendering prohibit altered understanding mental dementia significantly compliance requirements protocol
+Cluster 1644: support transfusion hemoglobin dl growth factor days blood product requiring
+Cluster 1645: exon egfr mutation lr insertion deletion mutations activating gx documented
+Cluster 1646: coumadin warfarin derivative anticoagulants anticoagulant sodium therapeutic doses patients taking
+Cluster 1647: traumatic injury major effects surgery significant recovered days treatment dose
+Cluster 1648: uncontrolled heart significant hypertension failure congestive york association disease clinically
+Cluster 1649: exist longer measures unresectable effective standard curative histologically palliative confirmed
+Cluster 1650: abuse alcohol drug known history active current suspected investigator months
+Cluster 1651: consultation exacerbated reasonably toxicity irreversible grade expected unresolved included criteria
+Cluster 1652: sgpt sgot upper limit normal alt ast institutional uln liver
+Cluster 1653: irb approved board document sign understand review able willing written
+Cluster 1654: epidural brain metastases disease treated known cranial treatment stable adequately
+Cluster 1655: toxicities recovered grade prior therapy patients therapies related treatment previous
+Cluster 1656: poorly controlled diabetes hypertension mellitus antihypertensives hbac despite multiple uncontrolled
+Cluster 1657: procedures obtained consent informed written prior screening study specific protocol
+Cluster 1658: form consent sign informed able willing understand specific written appropriately
+Cluster 1659: direct bilirubin mg dl total normal serum check patient elevated
+Cluster 1660: palliative radiation radiotherapy therapy weeks prior treatment study days completed
+Cluster 1661: transmural infarction myocardial months registration ecg prior angina unstable congestive
+Cluster 1662: ptt uln pt inr aptt institutional coagulation normal patients warfarin
+Cluster 1663: ethics iec committee board independent irb review institutional approved consent
+Cluster 1664: tablets swallow unable subject unwilling capsules patients affecting absorb eligible
+Cluster 1665: phenobarbital carbamazepine phenytoin wort inducers rifabutin cypa st rifampin johns
+Cluster 1666: saturation room air effusion oxygen pleural baseline clinically significant zydelig
+Cluster 1667: vaccine prevention infectious therapy administration non oncology diseases ipilimumab dose
+Cluster 1668: prevent signing abnormality condition illness psychiatric medical laboratory consent informed
+Cluster 1669: msec qtc qt corrected interval electrocardiogram ekg baseline prolongation screening
+Cluster 1670: various analogues formulations excipients allergy medications agent known study allergic
+Cluster 1671: probe signals copy average number cep ihc ratio ish dual
+Cluster 1672: form acceptable fathering birth control medically childbearing child use willing
+Cluster 1673: compromise interpretation psychiatric safety study participation follow disorder interfere compliance
+Cluster 1674: receive cytotoxic management persistent recurrent regimen allowed required additional disease
+Cluster 1675: caregivers family patient caregiver identified person patients primary appropriate identify
+Cluster 1676: msecs qtc interval corrected qt formula using bazetts bazett prolongation
+Cluster 1677: family history long syndrome qt personal factors hypokalemia risk pointes
+Cluster 1678: additional progressing malignancy requires known active treatment years required past
+Cluster 1679: autoimmune history disease organ major disorder known current severe hepatitis
+Cluster 1680: transfusions platelets platelet independent transfusion days mcl mm prior receiving
+Cluster 1681: traumatic injury major significant surgery weeks study treatment prior days
+Cluster 1682: leptomeningeal disease manifestation presence evidence patients diffuse spread untreated extracranial
+Cluster 1683: therapeutic participation clinical investigational intent agent days study trial treatment
+Cluster 1684: severely impaired lung function interstitial concurrent condition history severity judged
+Cluster 1685: hsp inhibitor prior treatment braf therapy previously treated mek received
+Cluster 1686: times bilirubin total upper limit normal uln institutional serum age
+Cluster 1687: dvt deep thrombosis embolism venous accident cerebrovascular attack transient ischemic
+Cluster 1688: visits scheduled comply plan able laboratory tests willing treatment schedule
+Cluster 1689: beta chorionic gonadotropin hcg women human pregnant potential childbearing feeding
+Cluster 1690: lines therapy prior received systemic disease treatment chemotherapy line advanced
+Cluster 1691: cytotoxic days retinoic cis procarbazine tamoxifen interferon administration acid agents
+Cluster 1692: major surgery drug weeks dose study administration prior trauma initiation
+Cluster 1693: leukapheresis prior accept willing undergo weeks able months donor cladribine
+Cluster 1694: gated acquisition muga multiple lvef left echocardiogram ejection fraction ventricular
+Cluster 1695: sociological familial geographical psychological schedule potentially hampering follow compliance protocol
+Cluster 1696: dialysis renal hemo requiring peritoneal failure patients currently current dependent
+Cluster 1697: splenic irradiation splenectomy months prior current history mmb immunodeficiency drug
+Cluster 1698: laboratory meet criteria following clinical parameters tests indicated data subject
+Cluster 1699: smear suggestive features myelodysplastic peripheral leukemia blood acute syndrome mds
+Cluster 1700: premenopausal women estradiol range postmenopausal patient status menopausal willing comply
+Cluster 1701: cancer carcinoma cell prostate cured thyroid gleason impact adequately unlikely
+Cluster 1702: hepatic function adequate defined follows evidenced following dysfunction met criteria
+Cluster 1703: hemoglobin biopsy value prior screening anemia week lower enrollment patients
+Cluster 1704: transfusion meet inclusion blood allowed criteria hb hemoglobin platelet mm
+Cluster 1705: therapy embolization dose targeted receipt immunotherapy agent monoclonal antibodies endocrine
+Cluster 1706: infertility exists entire documentation practice study period effective unless contraception
+Cluster 1707: influenza attenuated vaccine live season october march vaccination cycle approximately
+Cluster 1708: fracture wound ulcer healing bone non untreated active nonhealing days
+Cluster 1709: major surgery require course injury traumatic anesthesia general patients study
+Cluster 1710: immunodeficiency combined form primary severe disease acquired aids deficiency syndrome
+Cluster 1711: ptcy mils infusion relapse additional criteria inclusion exclusion gvhd uln
+Cluster 1712: azd structure excipients similar inactive hypersensitivity chemical osimertinib drugs class
+Cluster 1713: umol bilirubin mg dl direct serum total liter gilbert days
+Cluster 1714: seronegative antibody hiv immunodeficiency human virus depends donor treatment intact
+Cluster 1715: inhibitors cypa potent inducers use concomitant cytochrome medications prior strong
+Cluster 1716: hyperbilirubinemia gilbert bilirubin unconjugated syndrome uln total normal upper limit
+Cluster 1717: unresolved toxicity grade previous therapy alopecia anticancer ctcae toxicities prior
+Cluster 1718: components allergy history drug study known hypersensitivity treatment nivolumab benzamide
+Cluster 1719: infection antiviral hepatitis immunodeficiency chronic virus human requiring current hiv
+Cluster 1720: joint ajcc committee american stage cancer staging iv melanoma metastatic
+Cluster 1721: infertility exists fertile documentation practice contraceptive methods men effective unless
+Cluster 1722: azole itraconazole fluconazole systemic drug cycle weeks day treatment antifungals
+Cluster 1723: cells platelet mm count bil dl marrow untransfused anc hemoglobin
+Cluster 1724: radionuclide treatment dose weeks received study subject prior participant drug
+Cluster 1725: pertinent aspects informed dated indicating signed document consent legally trial
+Cluster 1726: discontinued prior weeks therapy previous radiation treatment study cancer treatments
+Cluster 1727: ejection left ventricular fraction cardiac rest ef function greater heart
+Cluster 1728: organ function marrow normal defined requirements patients poor bone acceptable
+Cluster 1729: guardian unwillingness legal representative research inability participant written consent informed
+Cluster 1730: respiratory appropriateness coagulation intravenous pi antibiotics infections cardiovascular immune shall
+Cluster 1731: aim phase ii prisoners sub fluent type outpatient cancer evaluation
+Cluster 1732: glaucoma angle uncontrolled macular degeneration markedly acuity history narrow decreased
+Cluster 1733: albumin initiation dl mg days treatment performed registration cohort dehydration
+Cluster 1734: albumin dl days obtained prior registration study screening treatment dose
+Cluster 1735: burkitt lymphoma leukemia cell mature lymphoblastic patients like morphology precursor
+Cluster 1736: occasional help care karnofsky able performance status patient patients kps
+Cluster 1737: deficiency immune autoimmune history disease known active acquired carnitine disorder
+Cluster 1738: myeloma multiple diagnosis confirmed histologically patients symptomatic criteria diagnosed standard
+Cluster 1739: abdominal prior cavity radiotherapy surgery radiation pelvic patients pelvis received
+Cluster 1740: participation study investigational drug weeks days prior treatment clinical preceding
+Cluster 1741: major surgery effects recovered starting drug considered days biopsy tumor
+Cluster 1742: inclusive age years female male donor older participants time informed
+Cluster 1743: interstitial pneumonitis lung disease history patients cause unresolved clinically presence
+Cluster 1744: hematologic function adequate malignancy organ defined parameters treatment days following
+Cluster 1745: colorectal cancer metastatic prior chemotherapy patients history treatment line breast
+Cluster 1746: grade recovery alopecia toxicity prior excluding therapy neuropathy baseline anorexia
+Cluster 1747: ctla anti antibody adverse immune pd lymphocyte treatment cytotoxic prior
+Cluster 1748: intra thoracic surgery abdominal injury pelvic major starting procedure effects
+Cluster 1749: provision consent informed written signed participate date form sign study
+Cluster 1750: laboratory assessments adequate coagulation hepatic renal hematological baseline function reference
+Cluster 1751: transplant organ solid bone marrow prior hematologic history allogeneic patients
+Cluster 1752: contraception agree use method adequate male study barrier patients potential
+Cluster 1753: coagulation inr normalized international ratio adequate evidenced blood function anti
+Cluster 1754: unwillingness follow inability protocol procedures required outlined return visits study
+Cluster 1755: infiltrates chest pulmonary improving ray presumed fungal progressive attributed infections
+Cluster 1756: permanently assignment study withdrawn enter participation allowed previous subjects treatment
+Cluster 1757: ild interstitial lung pneumonitis history disease induced evidence active drug
+Cluster 1758: glioma grade high diagnosis recurrent patients low histologically malignant confirmed
+Cluster 1759: exist additional criteria exclusion inclusion regarding morbid restrictions illness disease
+Cluster 1760: plasma leukemia diagnosis cell dyscrasia known patients current falling fap
+Cluster 1761: illnesses antibiotics infections requiring disorders bleeding active fallopian falls false
+Cluster 1762: surgery registration major weeks prior recovered minimum prohibited eligible patients
+Cluster 1763: glioblastoma gliosarcoma histologically recurrent confirmed temozolomide glioma radiation patients proven
+Cluster 1764: situation social illness psychiatric requirements compliance limit study ability comply
+Cluster 1765: infection month past evidence active septic shock clinically multi significant
+Cluster 1766: phq questionnaire score mood suicidal health ideation patient question thoughts
+Cluster 1767: virus immunodeficiency human infection hiv history hepatitis current apheresis serology
+Cluster 1768: isolated testicular extramedullary cns relapse nervous limited central recurrent refractory
+Cluster 1769: curatively treated cancer years situ solid adequately evidence skin melanoma
+Cluster 1770: donor age years old matched related sibling morbidity haploidentical score
+Cluster 1771: allowed prior therapy chemotherapy radiation treatment patients use systemic months
+Cluster 1772: hyperbilirubinemia benign bilirubin total congenital unless uln serum hereditary indirect
+Cluster 1773: creatinine hour clearance min ml serum uln hr cr institutional
+Cluster 1774: adt androgen deprivation therapy months prior testosterone treatment prostate ng
+Cluster 1775: live vaccine received days dose prior study drug treatment registration
+Cluster 1776: carfilzomib recent therapy mm dexamethasone containing combination line regimen treatment
+Cluster 1777: pd ctla inhibitors checkpoint received immune prior immunotherapy cd treatment
+Cluster 1778: mental mini physical status mmse exam health state score consent
+Cluster 1779: kind immediate palliative requirement surgery treatment including malignancy prior metastatic
+Cluster 1780: plasma cell amyloidosis leukemia dyscrasia solitary cells plasmacytoma poems extramedullary
+Cluster 1781: ct criteria response tomography measurable solid evaluation recist tumors computed
+Cluster 1782: agent investigational receiving patients currently received study weeks patient days
+Cluster 1783: trauma healing wound major surgery fracture ulcer catheter presence insufficient
+Cluster 1784: provide willing consent able informed capable participate signed patient patients
+Cluster 1785: pregnant planning feeding breast breastfeeding study months pregnancy female lactating
+Cluster 1786: moderate cypa strong inducers inhibitors use dose days study prior
+Cluster 1787: virus hepatitis seropositive hcv hbv immunodeficiency hiv human viral known
+Cluster 1788: signed specific consent informed study form prior entry registration understood
+Cluster 1789: desquamating nodosum characterized erythema rash thalidomide development taking similar drugs
+Cluster 1790: arterial tia ischemic attack transient mi angina cva myocardial cerebrovascular
+Cluster 1791: agents anti cancer investigational receiving therapy patients chemotherapy concomitant prior
+Cluster 1792: unwilling unable consent informed sign provide form document patients written
+Cluster 1793: infection dose requiring drug study antibiotics systemic active days prior
+Cluster 1794: immunosuppressive medications systemic corticosteroids treatment weeks requiring condition prior use
+Cluster 1795: fev pulmonary copd predicted expiratory forced volume obstructive second chronic
+Cluster 1796: sulfamethoxazole trimethoprim ampicillin contraindication penicillin allergy antibiotics sensitivity administration prophylactic
+Cluster 1797: myeloma relapsed multiple refractory therapy lines diagnosis prior disease progressive
+Cluster 1798: carcinomatous meningitis nervous central metastases cns known active untreated clinically
+Cluster 1799: pik inhibitor mtor akt inhibitors treatment prior kinase rapamycin target
+Cluster 1800: positivity hiv immunodeficiency virus human known hepatitis procurement history infectious
+Cluster 1801: diatheses uncontrolled bleeding active including severe diseases hepatitis systemic evidence
+Cluster 1802: parameters laboratory range protocol defined acceptable adequate medical reserve history
+Cluster 1803: complications adequately recovered toxicity intervention major surgery starting prior therapy
+Cluster 1804: therapy hormonal anti approved initiation cancer weeks chemotherapy including treatment
+Cluster 1805: pt warfarin inr prophylactic anticoagulation daily low taking heparinoids episodes
+Cluster 1806: arterial accident cerebrovascular transient thromboembolic ischemic attack infarction myocardial angina
+Cluster 1807: pacemaker defibrillator cardiac presence dependent permanent rhythm patients placement control
+Cluster 1808: ovulation abstinence methods calendar periodic withdrawal symptothermal post acceptable lifestyle
+Cluster 1809: reached hemoglobin transfusion dl level eligibility gm registration days performed
+Cluster 1810: histologically confirmed diagnosis cancer metastatic patients disease melanoma endometrial cytologically
+Cluster 1811: mtor inhibitor inhibitors temsirolimus rapamycin everolimus mammalian prior treatment sirolimus
+Cluster 1812: ability comply condition procedures opinion study investigator impair interfere requirements
+Cluster 1813: maximum creatinine age serum mg dl years male female gender
+Cluster 1814: clinical inflammation concerns intestinal psychological obstruction safety social issues judgment
+Cluster 1815: target lesions population disease radiotherapy measurable exceptions non radiation lumpectomy
+Cluster 1816: malignant disease non treated preclude study active history tumor relapse
+Cluster 1817: liver portal hypertension varices biliary esophageal hepatic fulminant hepatitis synthetic
+Cluster 1818: integrity tract malabsorption lack gastrointestinal physical syndrome upper oral syndromes
+Cluster 1819: compliance non regimens medical history expected patient behavior associated cml
+Cluster 1820: carcinoma cell malignancies cervix situ basal squamous skin free treated
+Cluster 1821: lesion measurable disease cm radiation mm metastatic baseline subjects patients
+Cluster 1822: plus duration instructions wocbp treatment drug method contraception follow half
+Cluster 1823: permit circumstances follow completion required study patients instance issue travel
+Cluster 1824: tremelimumab durvalumab excipient hypersensitivity history excipients donate medi combination infusion
+Cluster 1825: nivolumab predisposition hepatoxicity caution drugs used containing regimen treated hepatotoxicity
+Cluster 1826: score ecog performance status patients acceptable subjects cgvhd good lung
+Cluster 1827: strenuous exercise muscular ck embarking increases avoided planning plasma activities
+Cluster 1828: hodgkin expansion lymphoma cohort participants enrollment weeks prior dl serum
+Cluster 1829: withstand compromise organ major ability disease therapy patients chair discussed
+Cluster 1830: infections active uncontrolled clinically patients evidence systemic known grade conditions
+Cluster 1831: cbc differential blood count complete obtained registration function days prior
+Cluster 1832: recovering surgery major prior procedure surgical investigator days dose defined
+Cluster 1833: flat lie tolerate pet unable minutes inability ct position hold
+Cluster 1834: resolved toxicity grade related prior alopecia therapy treatment acute significant
+Cluster 1835: radiation marrow bone therapy prior weeks pelvic received considered study
+Cluster 1836: rems revlimid program strategy mitigation registered evaluation mandatory comply risk
+Cluster 1837: osteoporosis spine hip score dexa femoral right fracture lumbar left
+Cluster 1838: pressure antihypertensive mmhg blood bp medications controlled dbp sbp hypertension
+Cluster 1839: extramedullary disease isolated leukemia cns relapse patients marrow active bone
+Cluster 1840: currently agents receiving anti eligible cancer patients prior cypa subjects
+Cluster 1841: ventilation mechanical oxygen supplemental requiring saturation room air higher respiratory
+Cluster 1842: receptor negative er ihc hybridization pr fish progesterone estrogen immunohistochemistry
+Cluster 1843: agrees method contraception male acceptable use duration study subject entire
+Cluster 1844: neuroblastoma catecholamines demonstration verification urinary cells increased marrow histologic bone
+Cluster 1845: neuropathy grade greater patients time significant pain enrollment dose subjects
+Cluster 1846: transurethral turp prostate resection prior surgery prostatic cryotherapy including previous
+Cluster 1847: sibling donor identical hla offspring parent matched genotypically haploidentical transplant
+Cluster 1848: planned period radiation biological current chemotherapy agents investigational treatment use
+Cluster 1849: postmenopausal women status defined patient year woman menstrual months eligible
+Cluster 1850: gilbert syndrome history known disease diagnosis patients eligible bilirubin glucuronidation
+Cluster 1851: vomiting nausea bowel refractory absorption resection inflammatory gastrointestinal significant preclude
+Cluster 1852: transplant organ stem solid allogeneic cell prior marrow bone allogenic
+Cluster 1853: noncompliance regimens medical history haart unreliable protocol comply unable therapy
+Cluster 1854: fertile contraception use effective patients male female study agree willing
+Cluster 1855: malignancy years history prior primary remission evidence patients treatment previous
+Cluster 1856: unlikely restrictions patient comply study procedures participate requirements judgment investigator
+Cluster 1857: methods ovulation contraception abstinence practice agree periodic symptothermal calendar withdrawal
+Cluster 1858: step randomization prior criteria registration eligibility days ii patients dl
+Cluster 1859: abnormalities cardiac significant history gastrointestinal cardiovascular presence clinically relevant certain
+Cluster 1860: cytological histological evidence solid advanced metastatic participant tumor cancer malignancy
+Cluster 1861: specific study provide entry consent informed patient prior able patients
+Cluster 1862: total bilirubin serum uln institutional grade days date ctcae study
+Cluster 1863: histology squamous cell mixed carcinoma nsclc patients predominant non adenosquamous
+Cluster 1864: trm mortality simplified model score related calculated treatment induction intensive
+Cluster 1865: age wheelchair years walk ambulatory assessing paralysis patients lansky score
+Cluster 1866: infection uncontrolled eligible patients subjects judged controlled active opinion investigator
+Cluster 1867: pyruvate sgpt glutamate transaminase alt alanine aminotransferase serum uln institutional
+Cluster 1868: olaparib hypersensitivity excipients product known patients tremelimumab cabazitaxel composition chemical
+Cluster 1869: dlcocorr monoxide carbon capacity corrected diffusing diffusion lung pfts pulmonary
+Cluster 1870: melanomatous invasive malignancy free skin non cancer years unless minimum
+Cluster 1871: uln alkaline phosphatase ast alt ineligible bilirubin aminotransferase concomitant eligible
+Cluster 1872: hemoptysis teaspoon weeks dose drug excess red ml study blood
+Cluster 1873: agent investigational registration days treatment prior protocol therapy registered study
+Cluster 1874: recist measurable disease presence site assessed phase patients investigator radiographically
+Cluster 1875: hiv immunodeficiency virus human positive known serology patients infection patient
+Cluster 1876: ps ecog subjects screening score patients patient equals scale ib
+Cluster 1877: pulmonary fibrosis idiopathic silicosis sarcoidosis pneumonitis history interstitial slowly hypersensitivity
+Cluster 1878: asa anesthesiologists society american score status class anesthesiology physical iv
+Cluster 1879: therapy herbal week cycle day anticancer prior weeks radiotherapy intended
+Cluster 1880: contraceptives acceptable methods use spermicide sold medically unprotected iud birth
+Cluster 1881: aids hiv known illness related positive history positivity excluded underlying
+Cluster 1882: tissue tumor availability sample archived archival biopsy fresh freshly collected
+Cluster 1883: aspect complying subject unacceptable likely prevent judgment physician treating condition
+Cluster 1884: method discontinuation effective contraception time signed barrier consent willing use
+Cluster 1885: inclusion pre registration criteria cohort tissue leukapheresis doctor transplant turbt
+Cluster 1886: administration pregnancy test women product enrollment positive investigational prior study
+Cluster 1887: pgg exposure previous excipients allergy known previously received patients fancd
+Cluster 1888: improve lvef exercise asymptomatic rest left ejection ventricular fraction symptomatic
+Cluster 1889: recent completed requiring infection systemic drug days treatment dose study
+Cluster 1890: carcinoma cell basal skin squamous malignancy years excluding cancer invasive
+Cluster 1891: contraception methods female contraceptive male effective bearing child patch potential
+Cluster 1892: allogenic transplant umbilical cord double marrow bone transplantation ducbt blood
+Cluster 1893: cancers melanoma skin non years malignancy situ treated malignancies exception
+Cluster 1894: prednisone equivalent daily mg corticosteroid excess chronic use day corticosteroids
+Cluster 1895: cyp cytochrome strong inhibitor requires treatment inhibitors inducers inducer subfamily
+Cluster 1896: lower limit normal magnesium institutional potassium supplementation lln institution range
+Cluster 1897: bilirubin mg dl equal ml unless considered tumor enrollment levels
+Cluster 1898: severe infection weeks sepsis prior randomization initiation treatment septicemia patients
+Cluster 1899: lethal antiretroviral suppressive increased combination therapy infections hiv pharmacokinetic interactions
+Cluster 1900: world organization health eastern cooperative oncology group ecog performance status
+Cluster 1901: participants agents receiving investigational study days stratum treatment cancer enrollment
+Cluster 1902: interpretation affect results compliance protocol malignancy significant concomitant diseases history
+Cluster 1903: platelet count transfusion days mm support prior counts administration study
+Cluster 1904: calculated clearance min ml creatinine measured days estimated calc prior
+Cluster 1905: functions adequate renal organ marrow bone liver hepatic defined conducted
+Cluster 1906: designee length enrolling entire comply determined procedures understand physician study
+Cluster 1907: cns metastases asymptomatic nervous central leptomeningeal steroids carcinomatosis treated requirement
+Cluster 1908: ovarian cancer epithelial platinum patients breast prior treatment recurrent chemotherapy
+Cluster 1909: abstinent agreement remain period contraceptive rate dose year refrain methods
+Cluster 1910: presence infection uncontrolled active hours disease cancer chronic invasion systemic
+Cluster 1911: haemoglobin dl hb transfused function count white glycated platelets hematology
+Cluster 1912: line therapy chemotherapy prior received treatment second patients disease systemic
+Cluster 1913: illness unwarranted high considered risk investigational investigator disease acute intercurrent
+Cluster 1914: btk inhibitor bruton ibrutinib tyrosine kinase prior exposure pik therapy
+Cluster 1915: surgery major enrollment weeks prior study undergone visit radiation patients
+Cluster 1916: granulocyte count mm ul starting peripheral days therapy total enrollment
+Cluster 1917: psa rising doubling value apart time ng months values week
+Cluster 1918: member family staff directly involved friend site members immediate spouse
+Cluster 1919: female employing reproductive birth effective control feeding pregnant male potential
+Cluster 1920: measurable neuroblastoma lesions mibg disease fluid detected gallium bone collections
+Cluster 1921: accountability portability insurance hipaa act consent health willingness understand sign
+Cluster 1922: hematological function adequate renal hepatic liver kidney acceptable defined malignancies
+Cluster 1923: stress cad doubt angiography define cardiac st abnormal imaging present
+Cluster 1924: minute creatinine clearance ml calculated formula cockcroft gault measured using
+Cluster 1925: condom intercourse males sexually stopping father taking child use period
+Cluster 1926: narrow therapeutic substrates cypa index metabolized cypd indices window substrate
+Cluster 1927: healing illness exertion shortness uncontrolled breath significant infection mild rest
+Cluster 1928: creatinine clearance min ml uln serum calculated measured levels obtained
+Cluster 1929: tki egfr treatment prior erlotinib therapy generation progression gefitinib previous
+Cluster 1930: likely interfere illness psychiatric participation medical clinical study patients opinion
+Cluster 1931: hepatitis immunodeficiency virus human hiv infection active known chronic history
+Cluster 1932: unable oral swallow medications medication receive patients malabsorption gastrointestinal capsules
+Cluster 1933: user illicit abuse regular recreational alcohol substance recent drugs including
+Cluster 1934: aminotransferase times aspartate ast upper normal limit alanine alt serum
+Cluster 1935: measures avoidance male producing agree female use study potential dose
+Cluster 1936: bilirubin upper limit normal uln serum direct equal patients age
+Cluster 1937: allow compromise disorder compliance psychiatric appropriate does protocol consent informed
+Cluster 1938: diathesis bleeding history known evidence coagulation patients anticoagulation correctable warfarin
+Cluster 1939: pain uncontrolled related tumor cancer tumour does farber fap fanconi
+Cluster 1940: amylase grade serum pancreatitis pancreatic pancreas suggesting findings elevated injury
+Cluster 1941: ckd epi epidemiology collaboration kidney min creatinine ml chronic equation
+Cluster 1942: methods ovulation devices intrauterine rate year abstinence sterilization contraceptive failure
+Cluster 1943: shorter days lives half whichever investigational dose preceding minimum drugs
+Cluster 1944: blast count hydroxyurea peripheral blood circulating marrow bone mm ul
+Cluster 1945: transplantation stem organ allogeneic cell solid prior history including marrow
+Cluster 1946: clear cell histology serous carcinosarcoma carcinoma histologies endometrioid endometrial mixed
+Cluster 1947: marrow transplantation bone stem cell prior hematopoietic reserves allogeneic extensive
+Cluster 1948: nrt contraindications contraindication nicotine use patches fda replacement worsening angina
+Cluster 1949: cardiac significant clinically disease uncontrolled history arrhythmias active months including
+Cluster 1950: medi sickness angioedema nhistory laryngeal anaphylaxis humanized edema asthma olaparib
+Cluster 1951: uncontrolled hepatitis heart severe chronic quantifiable severely disease symptomatic congestive
+Cluster 1952: ul cells absolute neutrophil anc count days treatment obtained prior
+Cluster 1953: fallopian tube peritoneal ovarian primary cancer platinum stage patients chemotherapy
+Cluster 1954: activity physical moderate engage minutes intensity week vigorous questionnaire sedentary
+Cluster 1955: testosterone ng nmol castrate dl level serum levels screening prostate
+Cluster 1956: autoimmune disease vitiligo active history hypothyroidism systemic thyroiditis requiring disorder
+Cluster 1957: calculated formula cockcroft gault clearance min creatinine ml using obtained
+Cluster 1958: seizure disorder history uncontrolled seizures patients active epilepsy disorders neurologic
+Cluster 1959: day cycle hemoglobin dl days prior treatment obtained study albumin
+Cluster 1960: bbi capsules unwilling swallow daily unable arq napabucasin complete dose
+Cluster 1961: castration resistant prostate cancer metastatic chemotherapy disease crpc prior testosterone
+Cluster 1962: connective tissue scleroderma lupus disorders active disease history dermatomyositis treating
+Cluster 1963: suitable intent curative administered local therapy disease urothelial cancer carcinoma
+Cluster 1964: stage iv cancer iii ovarian ii diagnosed diagnosis pancreatic advanced
+Cluster 1965: nursing pregnant patient subjects pregnancy mothers subject intends non wishing
+Cluster 1966: cholesterol mg dl fasting serum total level triglyceride triglycerides mmol
+Cluster 1967: xanthine rasburicase oxidase allergy inhibitors known contraindication allopurinol tls lysis
+Cluster 1968: valid benefits capable understanding nature risks consent informed provide able
+Cluster 1969: administration drug study prior weeks days investigational treatment therapy completed
+Cluster 1970: brain metastases dexamethasone treated hemorrhage treatment cns requirement progression metastasis
+Cluster 1971: females pregnancy negative test childbearing potential serum urine prior days
+Cluster 1972: grapefruit juice seville oranges fruits study containing days avoid dose
+Cluster 1973: quality prolong survival state proven curative therapy acceptable life current
+Cluster 1974: excipients drugs hypersensitivity known study allergy history afatinib drug trial
+Cluster 1975: liver significant clinically disease known history renal evidence participants chronic
+Cluster 1976: sex having condom woman use drug study pregnant agrees dose
+Cluster 1977: cancer center anderson md active patients treatment history mdacc years
+Cluster 1978: coagulopathy diathesis anticoagulation bleeding therapeutic absence evidence significant thromboembolic permitted
+Cluster 1979: strong cypa inhibitors requires treatment cytochrome cypd chronic concomitant taking
+Cluster 1980: fcbp lenalidomide consecutive pregnancy childbearing effective potential days method agree
+Cluster 1981: authorization release information health research written obtained use consent study
+Cluster 1982: responsive accepted care relapse progressive therapy curative standard non surgery
+Cluster 1983: medi phase cohort ii eligibility cancer criteria study ovarian colorectal
+Cluster 1984: borderline ovarian malignant epithelial tumors low potential ascites mullerian tumor
+Cluster 1985: confound situation significantly results subject study condition participation interfere risk
+Cluster 1986: infectious specialist referred seropositivity result disease testing physician increase previously
+Cluster 1987: stress cardiac test coronary ischemia artery echocardiogram thallium patients history
+Cluster 1988: macroglobulinemia waldenstrom courses failed immunoglobulin clinicopathological ig workshop consensus panel
+Cluster 1989: cdk inhibitor prior treatment received palbociclib inhibitors therapy ribociclib patient
+Cluster 1990: hrt menopausal hormone use cessation replacement estradiol fsh therapy study
+Cluster 1991: transfusion independent platelet ul count factors growth days prior support
+Cluster 1992: deciliter grams hemoglobin dl gram liter albumin millimoles transfusion equal
+Cluster 1993: pancreatic cancer disease metastatic acute prior chronic treatment resection acinar
+Cluster 1994: colitis crohn ulcerative disease bowel inflammatory gastrointestinal coloproctitis history hemorrhagic
+Cluster 1995: eastern cooperative oncology ecog group performance status patient randomization grade
+Cluster 1996: meq potassium serum sodium hyponatremia bicarbonate magnesium value defined evening
+Cluster 1997: carcinoma situ breast ductal lobular invasive cancer lcis dcis diagnosis
+Cluster 1998: aspartate ast aminotransferase upper limit normal uln days registration prior
+Cluster 1999: block degree av atrioventricular rd nd ecg type abnormalities significant
+Cluster 2000: swallowing difficulty malabsorption hamper absorption capable conditions gastrointestinal pills compliance
+Cluster 2001: formulated polysorbate drugs hypersensitivity docetaxel reaction severe history reactions taxotere
+Cluster 2002: strong cypa inhibitors posaconazole nefazodone ginkgo subfamily telithromycin voriconazole biloba
+Cluster 2003: member matched family haplotype donor single hla partially suitable leukocyte
+Cluster 2004: leptomeningeal brain metastases disease uncontrolled glucocorticoids symptomatic continue require patients
+Cluster 2005: barrier effective methods diaphragms condoms kill gels creams female spermicides
+Cluster 2006: inclusion registration criteria step randomization prior secondary mcl phase hemoglobin
+Cluster 2007: endocrine therapy breast cancer prior adjuvant chemotherapy treatment received tamoxifen
+Cluster 2008: radiotherapy days prior study dose randomization treatment drug received enrollment
+Cluster 2009: potassium limits magnesium normal calcium serum levels sodium supplementation institution
+Cluster 2010: pdl pd anti inhibitor prior ctla treatment checkpoint patients antibody
+Cluster 2011: encephalopathy hepatic ascites history clinically months refractory liver diuretic evidence
+Cluster 2012: inclusion criteria phase screening patients treatment specific arm cohort patient
+Cluster 2013: autoimmune immunosuppressive requiring disease active systemic therapy steroids history documented
+Cluster 2014: comply ability protocol judgment limitation consent informed investigator study follow
+Cluster 2015: partner sexually nonsterilized final female childbearing potential active effective dose
+Cluster 2016: rcc advanced metastatic nephrectomy prior systemic therapy received treated localized
+Cluster 2017: il interferon concomitant therapies regimens immunotherapy immunosuppressive non interleukin following
+Cluster 2018: pd inhibitor therapy prior treatment anti ctla disease patients agent
+Cluster 2019: curatively primary outcome cancer affect setting resected opinion solid present
+Cluster 2020: entire pregnancy unwilling avoid unable period acceptable wocbp method study
+Cluster 2021: appendix performance ecog status karnofsky refer adequate randomization rating ii
+Cluster 2022: radiotherapy weeks prior dose study treatment received palliative patients therapy
+Cluster 2023: consciousness loss seizure brain arteriovenous injury malformation head history attack
+Cluster 2024: acupuncture near treatment deformities accurate infection indication location previous currently
+Cluster 2025: antibodies monoclonal hypersensitivity reactions history severe allergy humanized prior weeks
+Cluster 2026: version recist measurable disease defined criteria patient revised patients lesions
+Cluster 2027: vs host graft transplant stem elapsed disease cell active evidence
+Cluster 2028: randomization hemoglobin dl days obtained prior transfusion weeks factors growth
+Cluster 2029: times creatinine uln serum renal institutional prior atlcar kinase donor
+Cluster 2030: percentile height th gender pressure age blood bp hypertension medication
+Cluster 2031: psychological substance abuse interfere social conditions study evaluation results participation
+Cluster 2032: immunostimulatory ifn interleukin interferon il alpha limited agents systemic cycle
+Cluster 2033: unreasonably hazardous make opinion uncontrolled physician protocol treating infection patient
+Cluster 2034: amylase lipase institutional uln equal standards pancreatic times age function
+Cluster 2035: proteasome inhibitor imid immunomodulatory prior therapy lenalidomide refractory lines received
+Cluster 2036: rt prior anthracyclines treatment infarction myocardial cardiac thoracic heart history
+Cluster 2037: beats bpm minute rate heart bradycardia resting hr tachycardia baseline
+Cluster 2038: metastases brain evidence returned enlarging neurologic trial symptoms imaging meningitis
+Cluster 2039: altered prohibit dementia mental informed status consent understanding giving entry
+Cluster 2040: positivity antiretroviral combination hiv immunodeficiency virus human known therapy know
+Cluster 2041: apl promyelocytic leukemia acute diagnosed aml diagnosis patients subject atra
+Cluster 2042: virus hepatitis hbv hcv infection hiv immunodeficiency human active known
+Cluster 2043: nitrosoureas mitomycin weeks chemotherapy prior radiotherapy study entering patients received
+Cluster 2044: willing able informed consent schedules adhere visit written guidelines meet
+Cluster 2045: values range laboratory defined having patient outside function protocol screening
+Cluster 2046: bleeding risk high active pathologic carries coagulopathy condition carry vessels
+Cluster 2047: smoking cigarette prolonged respiratory tested expiratory fev forced predicted dysfunction
+Cluster 2048: pancreatic adenocarcinoma histologically confirmed cytologically metastatic ductal advanced diagnosis locally
+Cluster 2049: specimens provide research willingness blood correlative mandatory submitted protocol tumor
+Cluster 2050: intrathecal chemotherapy cns nervous central cytarabine methotrexate involvement therapy hydroxyurea
+Cluster 2051: childbearing potential bilateral hysterectomy test pregnancy oophorectomy negative tubal women
+Cluster 2052: bearing child female pregnancy test potential negative patients serum urine
+Cluster 2053: parenteral antibiotics infection requiring active infective requires anti oral ongoing
+Cluster 2054: assessments complete study follow protocol able lack availability screening interfere
+Cluster 2055: prestudy physical obtained registration history days prior exam pre study
+Cluster 2056: alkaline phosphatase normal upper limit times institutional limits liver unless
+Cluster 2057: transplantation marrow bone organ solid history tuberculosis primary previous immunodeficiency
+Cluster 2058: institutional bilirubin upper limit total normal direct age serum registration
+Cluster 2059: aspirate marrow bone biopsy peripheral undergo blood willing blasts flow
+Cluster 2060: corticosteroid systemic therapy use days prior chronic study dose week
+Cluster 2061: gated multi muga acquisition fraction ejection left ventricular echocardiogram lvef
+Cluster 2062: toxicities grade alopecia previous recovered neuropathy therapy resolved ctcae anticancer
+Cluster 2063: acidosis lactic metabolic history meq bicarbonate risk ketoacidosis increase chronic
+Cluster 2064: spermicidal suppository film cream gel foam caps cap vault occlusive
+Cluster 2065: systemic therapy prior received treatment days patients weeks disease chemotherapy
+Cluster 2066: kps greater score modified definitions rpa equal subject worse class
+Cluster 2067: planned surgery therapy treatment radiation chemotherapy weeks study course dental
+Cluster 2068: investigational device participation agent study current planned using weeks glioma
+Cluster 2069: heart association angina class york infarction new myocardial failure iii
+Cluster 2070: cerebrovascular transient ischemic accident attack months history attacks past prior
+Cluster 2071: sterile surgically postmenopausal effective contraception using compliant methods sexually contraceptive
+Cluster 2072: toxicity hearing exacerbated reasonably irreversible loss unresolved expected peripherally ctcae
+Cluster 2073: play lansky score performance karnofsky scale pediatric years status older
+Cluster 2074: dexamethasone mg day equivalent dose daily corticosteroid corticosteroids systemic days
+Cluster 2075: amyloidosis al light amyloid chain primary non myeloma diagnosis complicated
+Cluster 2076: world organization grade health glioma confirmed iv histologically diagnosis iii
+Cluster 2077: toxicities alopecia grade related prior treatment ctcae exception time therapy
+Cluster 2078: patient study treatment protocol disease parent therapy investigator consent permanently
+Cluster 2079: score eastern cooperative performance oncology group ecog status karnofsky lansky
+Cluster 2080: hcv hepatitis hbv virus positive antibody rna surface antigen test
+Cluster 2081: increases arrhythmia ventricular cardiac opinion risk presence investigator heart disease
+Cluster 2082: hc hepatitis positive hcab serology immunoblot riba reflexively test assay
+Cluster 2083: remission cr leukemia risk high acute complete aml relapse cytogenetics
+Cluster 2084: irradiation pelvic prior body brain total previous cranial tbi craniospinal
+Cluster 2085: hepatitis pcr positive polymerase chain reaction virus antibody antigen surface
+Cluster 2086: dysplasia bone nf tibial marrow esophagus confirmed hyperplasia grade distinctive
+Cluster 2087: myelodysplastic syndrome mds known myeloproliferative leukemia diagnosis history presence patients
+Cluster 2088: tuberculosis active hepatitis known patients infection clinically patient hiv incompletely
+Cluster 2089: mr imaging magnetic resonance contraindication metallic devices compatible mri contrast
+Cluster 2090: cgy radiation tbi delivered therapy prior ineligible centigray therapeutic patients
+Cluster 2091: stage iv breast cancer metastatic diagnosis disease patients iii diagnosed
+Cluster 2092: histologically breast invasive confirmed cancer carcinoma primary diagnosis cytologically metastatic
+Cluster 2093: tomography emission positron pet ct computed disease scan chest fdg
+Cluster 2094: blockers beta arrhythmic digoxin anti cardiac channel angiotensin requiring arrhythmias
+Cluster 2095: flow angiographic maa duodenum technetium macroaggregated tc stop application detectable
+Cluster 2096: confounds interpret data condition ability study subject investigator medial interpretation
+Cluster 2097: access venous adequate central leukapheresis inadequate poor peripheral administration iv
+Cluster 2098: antineoplastic expected require form therapy localized systemic study patient trial
+Cluster 2099: ul obtained platelet registration days plt count prior randomization platelets
+Cluster 2100: sarcoma soft tissue ewing rhabdomyosarcoma tumor kaposi diagnosis synovial gist
+Cluster 2101: lie inability scanning minutes pet imaging entire supine time cough
+Cluster 2102: kinase mitogen mek activated protein inhibitor braf raf prior inhibitors
+Cluster 2103: preclude participation medical psychiatric investigator study condition disorder safe opinion
+Cluster 2104: vaccines previous received tumor agents investigational weeks currently receiving infusion
+Cluster 2105: carcinoma curatively situ cell basal treated skin malignancy squamous years
+Cluster 2106: grades pain neuropathy significant grade days prior enrollment randomization day
+Cluster 2107: anc ul mcl platelets liter hematology ml cohort familial families
+Cluster 2108: research purposes tissue provide samples willingness blood willing consent biopsy
+Cluster 2109: cluster differentiation cd hiv count positive immunodeficiency virus human patients
+Cluster 2110: undergo biopsy willing biopsies tumor treatment pre willingness research mandatory
+Cluster 2111: coagulopathy uncorrectable known existing uncontrolled history inr uncorrected disorder platelet
+Cluster 2112: illnesses infective coagulation infections disorders active major medical systemic requiring
+Cluster 2113: malignancy carcinoma cell curative basal low prostate situ squamous resection
+Cluster 2114: talimogene laherparepvec oncolytic individuals treatment virus unwilling immunosuppressed fluids dose
+Cluster 2115: fasting thresholds exceeded lipid lowering cholesterol triglycerides case mmol included
+Cluster 2116: signs interstitial symptoms lung ongoing time informed consent disease screening
+Cluster 2117: tolerance impair opinion investigator significant diseases treatment example trial inflammatory
+Cluster 2118: cll sll iwcll diagnosis treatment therapy prior patients criteria received
+Cluster 2119: hepatitis active known patients hepatic history virus patient subject disorder
+Cluster 2120: phos alk alkaline phosphatase uln upper normal limit ast alt
+Cluster 2121: combination following use simultaneously considered methods used therapy fanconi fancd
+Cluster 2122: pregnancy test positive women pregnant serum lactating females breastfeeding wocbp
+Cluster 2123: transfusions provided red known counts evaluable platelet hematologic meet receive
+Cluster 2124: spoken english written understand language patient fluency proficient inability unable
+Cluster 2125: psa progression bone pcwg prostate disease ng defined criteria new
+Cluster 2126: qt heart ventricular cardiac history coronary significant left clinically screening
+Cluster 2127: cavitating lesion radiographic pulmonary evidence subject centrally vessel nsclc abutting
+Cluster 2128: hematopoietic transplantation stem cell allogeneic hsct autologous prior eligible patients
+Cluster 2129: mmhg pressure optimal despite management hypertension medical diastolic uncontrolled systolic
+Cluster 2130: hypersensitivity history reaction severe reactions patients hydrogel trastuzumab cremophor dacarbazine
+Cluster 2131: molecule small investigational dose treatment chemotherapy weeks half anticancer monoclonal
+Cluster 2132: mellitus diabetes induced steroid history controlled poorly patients insulin gestational
+Cluster 2133: malignancy concurrent active treatment presence patients patient actively skin donor
+Cluster 2134: focbp test pregnancy negative registration days prior urine study serum
+Cluster 2135: suicidal ideation disorder homicidal attempt schizophrenia history bipolar depressive active
+Cluster 2136: american college pathologists society asco cap guidelines clinical oncology breast
+Cluster 2137: method contraception methods final childbearing potential effective male responsible product
+Cluster 2138: isolated palliative intent local lesions surgery acceptable major procedure surgical
+Cluster 2139: correction fridericia formula qtcf msec interval qt qtc corrected screening
+Cluster 2140: lymphocytes mm mcl absolute donor count cells xe able engineered
+Cluster 2141: karnofsky greater equal performance status kps score ps zubrod lansky
+Cluster 2142: surgery major effects recovered weeks starting study treatment patients prior
+Cluster 2143: multiforme glioblastoma gbm gliosarcoma histologically patients extensively disseminated confirmed astrocytoma
+Cluster 2144: apnea sleep sleepiness daytime excessive result supplemental obstructive conditions oxygen
+Cluster 2145: institute national common grade nci adverse alopecia ctcae version events
+Cluster 2146: creatinine levels clearance institutional min ml normal patients uln iuln
+Cluster 2147: heart unstable optimized ventricular left ejection fraction disease lvef artery
+Cluster 2148: agitated bodies incompatible severely metal pacemaker contraindication material device allergy
+Cluster 2149: procedure surgical major anticipation cycle day course need days prior
+Cluster 2150: iodine allergy contrast radioactive history intravenous hypersensitivity materials iodide diet
+Cluster 2151: prison residing patients zydelig families fap fanconi fancd fancc fanca
+Cluster 2152: procedures specific consent informed written study provide prior willing assessments
+Cluster 2153: rule females urine pregnancy childbearing blood test potential pregnant feeding
+Cluster 2154: hg pressure mm optimal despite management hypertension repeated measurement diastolic
+Cluster 2155: histologically confirmed solid cytologically tumor malignant mesothelioma pleural diagnosis metastatic
+Cluster 2156: saturation air room oxygen baseline ambulatory pulmonary hypoxia function sp
+Cluster 2157: mcl platelet count cells days pembrolizumab step prior thrombocytosis treatment
+Cluster 2158: vaccination live vaccine days prior start treatment minimum received randomization
+Cluster 2159: coronary acute angioplasty stenting myocardial infarction syndromes angina months bypass
+Cluster 2160: creatine phosphokinase ck cpk uln kinase plasma upper limit normal
+Cluster 2161: dependence alcohol abuse substance drug current history active past year
+Cluster 2162: spinal cord compression tumor cauda imminent impending equina fracture clinical
+Cluster 2163: aged older years male female females time males men adult
+Cluster 2164: substances subfamily cytochrome family polypeptide inducers cypa inhibitors medications strong
+Cluster 2165: progenitor transplantation organ solid marrow bone allogeneic cell history prior
+Cluster 2166: candidate surgery curative treating definitive suitable physician patient appropriate surgeon
+Cluster 2167: hct autologous eligible nhl high failed aggressive curative lymphomas histologies
+Cluster 2168: polysorbate hypersensitivity history docetaxel glycol severe polyethylene cremophor reaction peg
+Cluster 2169: contraindication mri known pacemaker medical concomitant therapy anticoagulation prophylaxis patients
+Cluster 2170: mother breastfeeding discontinued pregnant treated excluded women study lactating olaparib
+Cluster 2171: myelogenous crisis blast leukemia chronic cml intolerant refractory failed phase
+Cluster 2172: leptomeningeal metastasis brain suspected disease known active history patients presence
+Cluster 2173: cirrhosis hepatic ascites known meaningful clinical evidence resulting history insufficiency
+Cluster 2174: mds aml secondary diagnosis related hypomethylating treatment patients therapy hypoplastic
+Cluster 2175: aware nature indicating consent informed sign investigational keeping policies study
+Cluster 2176: uncontrolled medical concurrent condition significant severe clinically neurological pulmonary including
+Cluster 2177: hepatitis hiv testing required immunodeficiency virus human known baseline positivity
+Cluster 2178: rucaparib defect absorption stent disorder gastrointestinal duodenal interfere existing investigator
+Cluster 2179: composition compounds chemical attributed similar reactions allergic biologic history nivolumab
+Cluster 2180: internal mucosal bleeding evidence platelet transfusion refractory active maintain cells
+Cluster 2181: stroke history months month past tia year enrollment cerebral prior
+Cluster 2182: hodgkin lymphoma non nhl cell relapsed refractory autologous confirmed histologically
+Cluster 2183: equal expectancy life greater weeks months investigator opinion patients subjects
+Cluster 2184: locally advanced metastatic disease cancer breast patients therapy treatment systemic
+Cluster 2185: thorax radiation prior radiotherapy therapy abdomen breast ipsilateral treatment stratified
+Cluster 2186: gastrointestinal bleeding gi significant months clinically history prior active bleed
+Cluster 2187: cmv cytomegalovirus seropositive infection recipient viremia anti antiviral cidofovir ganciclovir
+Cluster 2188: final highly consisting continue spouse effective study male forms subject
+Cluster 2189: paraffin slides unstained tumor embedded formalin block fixed blocks tissue
+Cluster 2190: cd cells cell positive cll negative leukemia diagnosis expression lymphoma
+Cluster 2191: schedule comply follow able treatment visit plan consent willing protocol
+Cluster 2192: anti therapy cancer prior concurrent systemic treatment days tumor investigational
+Cluster 2193: protected abide authorization disclosure restrictions return information assessments health study
+Cluster 2194: cessation smoking program tobacco nicotine current medications use bupropion varenicline
+Cluster 2195: cns untreated metastases nervous central symptomatic progressing actively active control
+Cluster 2196: fvc vital forced capacity predicted pulmonary value corrected hemoglobin room
+Cluster 2197: provide written informed consent willingness voluntarily study participant agree participate
+Cluster 2198: refusal informed consent sign participate patient randomization inability receive contraception
+Cluster 2199: hg mm bp hypertension diastolic systolic uncontrolled readings defined pressure
+Cluster 2200: block degree heart ventricular av bundle branch tachycardia atrioventricular second
+Cluster 2201: willing able undergo study patients follow complete biopsies blood provide
+Cluster 2202: obstruction bowel medications oral unable radiological partial complete evidence clinical
+Cluster 2203: response partial complete disease pr achieved cr therapy stable patients
+Cluster 2204: chemotherapy adjuvant prior metastatic disease therapy neoadjuvant months received advanced
+Cluster 2205: ascites paracentesis clinically requiring significant trace clinical evident medical presence
+Cluster 2206: seropositivity immunodeficiency virus human hiv known history infection hepatitis active
+Cluster 2207: nursing females pregnant discontinue agree mmb intend lactating pregnancy dose
+Cluster 2208: sct autologous allogeneic stem cell prior transplant transplantation allo auto
+Cluster 2209: dvt thrombosis deep vein pe embolism pulmonary history thromboembolic months
+Cluster 2210: uncontrolled disease diabetes active chronic medical pulmonary infection renal mellitus
+Cluster 2211: cns epileptic completion stable inducing enzyme metastases brain receiving involvement
+Cluster 2212: complicates interferes undue data interpretation participate ability places condition reason
+Cluster 2213: dictated criteria having unresolved toxicities resolved alopecia ctcae version exclusion
+Cluster 2214: jeopardize safety condition unstable patient compliance study subject opinion medical
+Cluster 2215: procurement inclusion criteria time expectancy life exclusion weeks patients blood
+Cluster 2216: cycle investigational day therapeutic administration agent days treatment weeks prior
+Cluster 2217: concurrently investigational receiving agents study patients days treatment drug participation
+Cluster 2218: protein dl serum monoclonal iga spep igg mg gram liter
+Cluster 2219: sufficient involved field days interval small radiotherapy considered administration ixazomib
+Cluster 2220: hiv immunodeficiency virus positive human patients excluded ineligible serology tested
+Cluster 2221: bevacizumab component hypersensitivity known osimertinib patients eligible sensitivity formulation contraindication
+Cluster 2222: limits creatinine normal upper serum uln times sgpt alt institutional
+Cluster 2223: metastasis nervous central known history evidence malignancy metastases liver clinical
+Cluster 2224: unreliable entire potentially regimens compliance complete considered medical able non
+Cluster 2225: radiation therapy prior days registration patients received allowed treatment history
+Cluster 2226: excluding access placement vascular surgery major weeks study biopsies procedures
+Cluster 2227: compression carcinomatous meningitis spinal cord brain metastases leptomeningeal evidence seizure
+Cluster 2228: stage iv disease iii ii patients diagnosed lymphoma inoperable figo
+Cluster 2229: implantable defibrillator cardioverter pacemaker cardiac electronic stimulators automatic device arrhythmia
+Cluster 2230: resected completely cell basal squamous skin recurred exceptions type treated
+Cluster 2231: untreated infection active previously patients uncontrolled hepatitis disease presence systemic
+Cluster 2232: torsades pointes medications risk known qt associated prolongation causing drugs
+Cluster 2233: creatinine cockcroft calculated gault clearance min ml equation serum mg
+Cluster 2234: pugh child liver classification disease status patients cirrhosis findings stage
+Cluster 2235: interested smoking quitting behavior change treatment daily dcis consider willing
+Cluster 2236: cns metastases nervous central patients stable brain treated neurologically weeks
+Cluster 2237: injected contraception implanted hormonal oral methods use established hormone transdermal
+Cluster 2238: probability months melanoma recurrence skin malignancy non cancer estimated survival
+Cluster 2239: qt long risk sudden syndrome unexplained arrhythmic prolongation death interval
+Cluster 2240: effusions pleural ascites malignant pericardial symptomatic exudative patients significant peritoneal
+Cluster 2241: tolerate able unable mri patients ascorbate position dose procedure flexible
+Cluster 2242: modifying disease autoimmune agents systemic immunosuppressive corticosteroids drugs past years
+Cluster 2243: currently receiving treatment therapy chemotherapy patients patient participating radiation study
+Cluster 2244: immunosuppressive therapy systemic receiving chronic steroids treatment patients drugs agents
+Cluster 2245: hybridization fish situ ihc fluorescence immunohistochemistry negative fluorescent positive amplification
+Cluster 2246: unable provide consent informed patients written study subjects adults complete
+Cluster 2247: study behavior ideation suicidal inappropriate interpretation make increase judgment including
+Cluster 2248: measurable ct cm tomography computed disease dimension longest scan lesion
+Cluster 2249: phone smart access text mobile messages willing messaging internet receive
+Cluster 2250: equal age greater years subjects time old participants patients adult
+Cluster 2251: compression brain cord spinal metastases stable unless asymptomatic steroids treatment
+Cluster 2252: scanning monitored anesthesia adult require pet patients mri imaging claustrophobia
+Cluster 2253: procedures surgical minor days placement major cath waiting beginning port
+Cluster 2254: progressive massive thrombocytopenia lymphadenopathy evidence anemia splenomegaly doubling lymphocytosis month
+Cluster 2255: heparin molecular weight low warfarin aspirin anticoagulants lmwh dose anti
+Cluster 2256: restrictive obstructive illnesses respiratory coagulation infections arrhythmias cardiovascular immune pulmonary
+Cluster 2257: peptic ulcer disease active gastritis history esophagitis months bleeding gastrointestinal
+Cluster 2258: creatinine estimation clearance gault cockcroft min ml basis glomerular filtration
+Cluster 2259: complying understanding capable signed document protocol informed consent requirements subject
+Cluster 2260: breastfeed infants lactating females agreed plan unless eligible study female
+Cluster 2261: consecutive undergone childbearing potential orientation months naturally meets sexual regardless
+Cluster 2262: free disease years malignancies unless history malignancy subject cancer prior
+Cluster 2263: equation estimated creatinine gault cockcroft min clearance ml using serum
+Cluster 2264: contrast steroid systemic steroids doses anaphylaxis allergies prevent use reaction
+Cluster 2265: infarction myocardial months history prior registration past patients ischemic screening
+Cluster 2266: creatinine clearance calculated crcl uln place gfr institutional glomerular filtration
+Cluster 2267: organization world health classification diagnosis aml criteria according confirmed mds
+Cluster 2268: randomization investigational agent days prior use treatment exposure drug date
+Cluster 2269: inability tolerate procedures imaging opinion treating investigator physician claustrophobia thromboprophylaxis
+Cluster 2270: year expectancy life greater group patients dementia end lgl malignancy
+Cluster 2271: satisfy criteria following enrolled subjects patient patients study portion sos
+Cluster 2272: evaluable measurable disease patients radiographically presence phase parts participants evidence
+Cluster 2273: context ancillary investigation utilized fda indication research food approved immunotherapy
+Cluster 2274: neoadjuvant adjuvant chemotherapy prior months therapy setting treatment received disease
+Cluster 2275: transaminase aminotransferase aspartate alanine ast alt uln normal upper limit
+Cluster 2276: treatment prior inhibitor patients months trastuzumab trc enrollment trabectedin study
+Cluster 2277: pathology national nci institute cancer laboratory confirmed confirmation diagnosis center
+Cluster 2278: toxicities grade related prior resolved treatment therapy recovery baseline significant
+Cluster 2279: able consent informed patients patient subjects study participants eligible donors
+Cluster 2280: maoi meperidine linezolid methylene blue monoamine oxidase maois activity significant
+Cluster 2281: ventricular arrhythmia requiring mechanical medication unstable stroke infarction myocardial control
+Cluster 2282: leukemia nervous central cns active known clinically subject patients clinical
+Cluster 2283: unable supportive tests research care follow guardian comply appropriate protocol
+Cluster 2284: nonmalignant objectives compromise opinion sponsor disease protocol investigator hydronephrosis conditions
+Cluster 2285: glomerular filtration rate creatinine mg dl min ml gfr serum
+Cluster 2286: qt ms qtc corrected interval baseline prolonged long screening syndrome
+Cluster 2287: impairs pills swallow ability condition patients severely patient tubes intractable
+Cluster 2288: requires malignant radiation systemic chemotherapy primary disease treatment active concurrently
+Cluster 2289: dermatomyositis scleroderma lupus collagen erythematosus active rash vascular systemic cpk
+Cluster 2290: childbearing correctly consistently potential use highly agreement partners rate continue
+Cluster 2291: androgen deprivation therapy prior anti prostate cancer months patients treatment
+Cluster 2292: form willingness understand sign ability consent informed written initiation procedures
+Cluster 2293: myeloma involvement multiple nervous central meningeal signs known exhibiting clinical
+Cluster 2294: proteins murine allergy mouse history hypersensitivity egg trastuzumab intolerance antibodies
+Cluster 2295: medications oral ability inability tolerate record absorb ingest product daily
+Cluster 2296: undesirable makes participate jeopardize trial compliance opinion investigators evidence protocol
+Cluster 2297: heart unstable york association new angina congestive infarction myocardial failure
+Cluster 2298: molecule targeted therapy small chemotherapy prior weeks radiation day study
+Cluster 2299: illness active uncontrolled gastritis diatheses including peptic pectoris ulcer intercurrent
+Cluster 2300: fl grade lymphoma follicular dlbcl histologically confirmed aggressive transformation diagnosis
+Cluster 2301: ipsilateral breast radiation cancer history prior dcis previous contralateral invasive
+Cluster 2302: aspects comply willing able protocol subject informed participant consent participants
+Cluster 2303: varices esophageal bleeding gastric history months portal known hypertension evidence
+Cluster 2304: transplant autologous stem cell prior asct patients months received allogeneic
+Cluster 2305: component hypersensitivity known allergy study formulations product drug reaction investigational
+Cluster 2306: screening prior months time hospitalization date positive days patient subject
+Cluster 2307: inflammatory autoimmune documented disorders active prior exceptions years disease past
+Cluster 2308: given written consent informed subjects patient study procedures participate understands
+Cluster 2309: jaw osteonecrosis dental osteomyelitis oral extraction surgery tooth current evidence
+Cluster 2310: colon rectum adenocarcinoma histologically rectal confirmed cancer metastatic cytologically diagnosis
+Cluster 2311: taking currently patients medications medication treatment anti hydroxychloroquine days months
+Cluster 2312: bleeding active history significant predisposition months hemoptysis major thrombosis gastrointestinal
+Cluster 2313: pt uln inr aptt investigator compliant times team capable grade
+Cluster 2314: access venous inability tolerate achieve donor adequate undergo false fanconi
+Cluster 2315: neoplastic anti therapy agents investigational agent days biologic systemic treatment
+Cluster 2316: extending capable definitely expectancy standard life potentially curative known therapy
+Cluster 2317: fast maintain mln hours hour oral administration medication required able
+Cluster 2318: mm anc count platelets dl hemoglobin marrow absolute adequate neutrophil
+Cluster 2319: hcc fibrolamellar cholangiocarcinoma mixed hepatocellular carcinoma histology diagnosis sarcomatoid known
+Cluster 2320: platelet count obtained registration days mm prior randomization mcl untransfused
+Cluster 2321: corneal keratopathy keratitis disorder epitheliopathy active history eye current bullous
+Cluster 2322: agrees treatment wocbp female childbearing potential guidance contraception dose period
+Cluster 2323: gault cockcroft clearance creatinine min ml estimated calculated cc measured
+Cluster 2324: deteriorate autoimmune hypo hyperthyroid agent immunostimulatory stimulatory receiving psoriasis vitiligo
+Cluster 2325: beam external radiation therapy prior weeks brachytherapy radiotherapy received gy
+Cluster 2326: partner vasectomized male sole female azoospermia sterilization months confirmed tubal
+Cluster 2327: pregnancy childbearing test women screening potential negative urine serum visit
+Cluster 2328: interfere conditions psychiatric medical treatment protocol procedures related compliance illness
+Cluster 2329: blockade checkpoint immune agonists therapies cd prior treatment differentiation progression
+Cluster 2330: sgpt alt sgot uln ast liver metastases institutional present hepatic
+Cluster 2331: identified registration mutation inclusion gps criteria wash location certified clia
+Cluster 2332: alcoholism addiction confuse hinder illness psychiatric follow evaluation drug active
+Cluster 2333: scale karnofsky performance kps status score higher lansky minimum greater
+Cluster 2334: hbv hepatitis virus surface dna infection viral positive hcv antigen
+Cluster 2335: disorders bleeding history psychiatric known uncontrolled patients acquired significant major
+Cluster 2336: cytological histological confirmation diagnosis prostate adenocarcinoma metastatic cancer nsclc advanced
+Cluster 2337: egg allergy eggs products known gentamicin aminoglycoside tobramycin antibiotics example
+Cluster 2338: inactive autoimmune process active syndrome subjects disease family farber fap
+Cluster 2339: cycle day prior weeks days therapy treatment anti chemotherapy cancer
+Cluster 2340: gnrh orchiectomy releasing hormone gonadotropin androgen analogue deprivation antagonist castration
+Cluster 2341: elevation thought hemolysis unless infiltration bilirubin gilberts normal hepatic upper
+Cluster 2342: postmenopausal hormone age estradiol fsh follicle range menopausal stimulating oophorectomy
+Cluster 2343: pain scale score worst patients cancer rating nrs narcotic medication
+Cluster 2344: aortic aneurysm vascular dissection significant disease peripheral clinically stenosis history
+Cluster 2345: guidelines according informed consent obtained institutional written assent signed appropriate
+Cluster 2346: unwillingness inability comply protocol informed participate consent procedures duration study
+Cluster 2347: contraceptives sexes adults potential reproductive effective feeding birth trial control
+Cluster 2348: laboratory organ function values adequate following determined indicated tests defined
+Cluster 2349: entry study anti agents receiving cancer time radiotherapy patients days
+Cluster 2350: stimulating colony granulocyte factor csf factors erythropoietin gcsf weeks growth
+Cluster 2351: contraceptive partner vaginal female product intrauterine estrogenic dose male progestogen
+Cluster 2352: severe bacteremia pneumonia hospitalization complications infection infections limited including weeks
+Cluster 2353: inflammatory breast cancer diagnosis patients including carcinoma tumors subjects patient
+Cluster 2354: immunosuppression significant chronic autoimmune immunosuppressive organ transplant requiring transplantation patients
+Cluster 2355: iuln aminotransferase ast alt aspartate alanine liver metastases registration days
+Cluster 2356: pathological prostate consistent finding carcinoma small cell diagnosis neuroendocrine criteria
+Cluster 2357: clinically significant uncontrolled disease investigator judged infection active heart infections
+Cluster 2358: lesions inactive radiated brain fully asymptomatic resected provided steroids carcinomatous
+Cluster 2359: ctc nci grade toxicity common criteria version neuropathy institute national
+Cluster 2360: psoriasis eczema requiring systemic treatment subjects diseases history patients personal
+Cluster 2361: aphasia paresis cerebellar brain psychosis injuries dementia epilepsy organic cns
+Cluster 2362: transfusions hemoglobin dl hgb allowed receive blood permitted days permissible
+Cluster 2363: mean ecgs electrocardiograms ms correction corrected qt qtc interval rate
+Cluster 2364: corticosteroids sprays drops applications airways eye articular rash uses obstructive
+Cluster 2365: times liver metastases uln presence demonstrable aminotransferase unconjugated bilirubin upper
+Cluster 2366: involvement leptomeningeal amyloid nodal lymphoma patients evidence tumor cardiac known
+Cluster 2367: calcium mg dl serum mmol adjusted albumin hypercalcemia ca corrected
+Cluster 2368: practice agree contraception effective male study barrier entire true subjects
+Cluster 2369: preclude oral illnesses absorption gastrointestinal olaparib medications able cediranib tolerate
+Cluster 2370: past years malignancy history second active diagnosed cancer diverticulosis chemotherapy
+Cluster 2371: symptoms signs related disease clinical infection following brain neurological patients
+Cluster 2372: glucose blood fasting random limits normal age uln draw upper
+Cluster 2373: cancer melanoma skin non malignancy years history concurrent active past
+Cluster 2374: sexual end partner male wocbp contraception adequate willing use weeks
+Cluster 2375: nature benefits willingly alternatives risks aware informed discomforts experimental neoplastic
+Cluster 2376: macroglobulinemia waldenstrm wm waldenstroms lpl lymphoplasmacytoid lymphoma workshop criteria international
+Cluster 2377: anticancer therapies currently receiving therapy start received radiation antibody chemotherapy
+Cluster 2378: defects congenital heart patients cranial known shunts disease patient cardiac
+Cluster 2379: vessel major blood invasion encasement evidence radiologically tumor radiographic documented
+Cluster 2380: platelet transfusions independent count transfusion receiving mm enrollment defined days
+Cluster 2381: brentuximab vedotin prior bv treatment received previous bendamustine hypersensitivity nivolumab
+Cluster 2382: unsupported platelets days mm transfusions hemoglobin platelet count transfusion ul
+Cluster 2383: catheter central picc inserted peripherally placement indwelling access venous port
+Cluster 2384: reaction adverse drug components history allergies allergy hypersensitivity monoclonal antibody
+Cluster 2385: body weight kg ideal kilogram greater lbs significantly pounds patients
+Cluster 2386: pomalidomide prior therapy exposure treatment previous combination received dexamethasone patients
+Cluster 2387: nitrosourea weeks mitomycin chemotherapy therapy prior drug starting antibodies received
+Cluster 2388: half lives agents investigational prior treatment days study drug therapy
+Cluster 2389: nonsteroidal nsaids inflammatory aspirin drugs anti use antiinflammatory agents day
+Cluster 2390: pregnant study inform immediately suspect participating woman barrier method physician
+Cluster 2391: cohorts expansion participants enrolled criteria patients combination dose disease prior
+Cluster 2392: studies imaging performed correlative enrolled patients participation study investigational patient
+Cluster 2393: terminology common ctcae adverse events toxicities grade alopecia criteria unresolved
+Cluster 2394: inducer cypa strong inhibitor potent cytochrome medication enzyme days use
+Cluster 2395: prothrombin normalized inr ratio international pt time uln normal seconds
+Cluster 2396: grapefruit seville oranges star fruit cypa hybrids days strong medications
+Cluster 2397: flow cytometry cd expression cells immunohistochemistry marrow bone blood peripheral
+Cluster 2398: pneumonitis noninfectious steroids required history current evidence active treatment crossover
+Cluster 2399: banking offered future specimens opportunity specimen studies participate patients translational
+Cluster 2400: carcinoma cell adequately basal squamous skin treated malignancy situ cancer
+Cluster 2401: echocardiogram ejection fraction left ventricular lvef echo muga assessed radionuclide
+Cluster 2402: antivirals antifungals antibiotics requiring infection acute systemic active prior days
+Cluster 2403: situ cancer carcinoma cervical cell basal skin squamous years malignancy
+Cluster 2404: compromise safety complete ability concomitant patient disorders investigator study discretion
+Cluster 2405: radical prostatectomy prostate cancer cryosurgery scheduled surgery adenocarcinoma undergo radiation
+Cluster 2406: wall chest breast radiation ipsilateral prior cancer radiotherapy skin mastectomy
+Cluster 2407: neck head cancer patients dissection primary radiation history prior lung
+Cluster 2408: elapsed weeks therapy prior radiation chemotherapy minimum surgery dose days
+Cluster 2409: phobia needed reasons examinations claustrophobia inability complete care standard imaging
+Cluster 2410: adenocarcinoma prostate proven histologic biopsy diagnosis histologically confirmation histopathological evidence
+Cluster 2411: myeloablative conditioning transplant stem allogeneic cell hematopoietic non months reduced
+Cluster 2412: standard histologically cytologically solid therapy advanced confirmed tumor available metastatic
+Cluster 2413: anticipated survival months patient incompatible transplant organ month illness major
+Cluster 2414: investigational participated device participating agent currently using study weeks dose
+Cluster 2415: medications use affect patients following receiving study prior known inhibit
+Cluster 2416: leukemia acute biphenotypic diagnosis lineage lymphoblastic chronic refractory myeloid myelogenous
+Cluster 2417: radiologic definitive evidence metastatic clinical disease local imaging nodal node
+Cluster 2418: birth control effective women potential method agree men use childbearing
+Cluster 2419: contained formulation excipient hypersensitivity drug known proteins recombinant tesirine rovalpituzumab
+Cluster 2420: improve thoracentesis paracentesis causes dyspnea respiratory effusion ascites pleural compromise
+Cluster 2421: increase toxicity risk medical potentially condition opinion illness investigator concomitant
+Cluster 2422: detained involuntarily compulsorily prisoners incarcerated infectious illness psychiatric physical subjects
+Cluster 2423: glioblastoma gliosarcoma world organization iv health grade histologically glioma confirmed
+Cluster 2424: appendix eastern oncology ecog group cooperative performance status ps score
+Cluster 2425: bleeding hemorrhage event terminology common ctcae events adverse grade criteria
+Cluster 2426: biological therapy chemotherapy radiation investigational agents weeks concurrent immunotherapy receiving
+Cluster 2427: junction gastroesophageal adenocarcinoma gastric esophagus histologically stomach confirmed metastatic cytologically
+Cluster 2428: cell carcinoma basal squamous malignancies skin years cancer past exception
+Cluster 2429: dyspnea rest oxygen evidence exertion complications continuous average scale numeric
+Cluster 2430: number therapies prior limit allowed received patients participants line permitted
+Cluster 2431: adverse recovery events toxicities ctcae terminology common grade related supportive
+Cluster 2432: options treatment standard informed curative therapeutic available exhausted refractory patients
+Cluster 2433: authorized legally representative consent informed provide patient written study signed
+Cluster 2434: pills swallow unable patients ineligible capsules unwilling men suspension prohibits
+Cluster 2435: concurrent chemotherapy radiation therapy allowed receiving immunotherapy cytotoxic patients biologic
+Cluster 2436: entry eastern cooperative oncology ecog group performance status study days
+Cluster 2437: reproductive contraception potential effective use female agree study male women
+Cluster 2438: esophageal cancer gastric carcinoma gastro adenocarcinoma esophagectomy patients variceal prior
+Cluster 2439: gastrointestinal vomiting diarrhea malabsorption nausea ulcerative impairment disease significantly uncontrolled
+Cluster 2440: dose treatment study radiation days site received thoracic cavity metastasis
+Cluster 2441: cpi treatment weeks initiation past cancer prior received investigational immunotherapy
+Cluster 2442: ongoing infection active evidence uncontrolled systemic presence entry pleural pi
+Cluster 2443: unacceptably places toxicities condition high medical risk opinion investigator subject
+Cluster 2444: written informed consent provides obtained able patients patient study gives
+Cluster 2445: surgery diagnostic major weeks recovery day prior complete cycle registration
+Cluster 2446: entering prior radiotherapy study chemotherapy weeks patients therapy recovered events
+Cluster 2447: common terminology ctcae adverse events grade criteria version diarrhea toxicity
+Cluster 2448: qt points resting msec ecg qtc family hour long electrocardiogram
+Cluster 2449: lymphoma large cell diffuse dlbcl transformation follicular mediastinal primary nhl
+Cluster 2450: gp inhibitors inducers strong glycoprotein cypa inhibitor drugs concomitant known
+Cluster 2451: smokers current smoking tobacco cigarette non quit year years users
+Cluster 2452: eligibility criteria infusion step registration lymphodepletion tvs ctl proceed meet
+Cluster 2453: research participate form sign willing informed consent subject patient participant
+Cluster 2454: swallow ability medication oral dosage impaired patients form solid medicines
+Cluster 2455: autoimmune subjects excluded syndrome atopy systemic childhood bronchodilators intermittent injections
+Cluster 2456: performing evaluations authorization procedures hipaa written obtained related protocol informed
+Cluster 2457: viral bacterial hepatitis fungal infection hiv immunodeficiency active virus human
+Cluster 2458: serologically hiv positive immunodeficiency virus human immunocompromised known patients testing
+Cluster 2459: intolerance allergy known history steroid therapy prior lactose excipients dexamethasone
+Cluster 2460: urothelial carcinoma bladder tract muscle cell invasive histologically upper metastatic
+Cluster 2461: measurable recist lesion target defined disease criteria according presence patients
+Cluster 2462: threshold seizure lower substituted medications discontinued known prior entry weeks
+Cluster 2463: allografts organ patients renal transplant excluded subjects subject history participant
+Cluster 2464: cardiac disease following history conditions shunts criteria patients known condition
+Cluster 2465: small cell histology mixed non variant cancer squamous lung tumors
+Cluster 2466: metabolites whichever lives half longer compound kinase received active agents
+Cluster 2467: cardiovascular significant disease uncontrolled history including evidence risk following pulmonary
+Cluster 2468: idiosyncrasy delayed chemically immediate reaction hypersensitivity drugs related known gsk
+Cluster 2469: cypc strong cypa inducers substrates inhibitors cytochrome medications treatment cyp
+Cluster 2470: fgfr inhibitor selective fgf prior receipt treatment alterations amplification gene
+Cluster 2471: aml mds cmml patients therapy prior hypomethylating relapsed blasts marrow
+Cluster 2472: gammopathy significance undetermined monoclonal smoldering mgus myeloma multiple amyloidosis macroglobulinemia
+Cluster 2473: provide understand ability informed consent willingness written signed procedures participate
+Cluster 2474: pills swallow able ability patient patients mouth capsules participant participants
+Cluster 2475: dexamethasone dose mg stable days initiation prior treatment glucocorticoid daily
+Cluster 2476: wocbp shall highly contraception effective sexually methods investigators male pregnancy
+Cluster 2477: hemorrhage event nci bleeding ctcae grade weeks start medication study
+Cluster 2478: cd anti prior therapy monoclonal antibody treatment directed car cell
+Cluster 2479: iuln bilirubin institutional upper normal limit total gilberts registration syndrome
+Cluster 2480: negligible death metastasis risk malignancies years exception malignancy screening prior
+Cluster 2481: arm patients study nivolumab exclusion combination enrolled prior treatment criteria
+Cluster 2482: wbc white blood mm count cell cells total equal neutrophil
+Cluster 2483: myelosuppressive chemotherapy days nitrosourea dose prior therapy cytotoxic received protocol
+Cluster 2484: curable apparently cured cancers locally malignancy cancer years previous superficial
+Cluster 2485: heart mmhg pressure blood hypertension uncontrolled systolic diastolic myocardial infarction
+Cluster 2486: comorbidity ci hct index score hematopoietic age years transplant cell
+Cluster 2487: brain mri metastases imaging ct resonance magnetic contrast prior weeks
+Cluster 2488: autoimmune past documented years active disease prior disorder requiring participant
+Cluster 2489: meningeal brain tumors metastatic symptomatic asymptomatic leptomeningeal allowed definitive treated
+Cluster 2490: asthma persistent history uncontrolled severe moderate controlled years classification known
+Cluster 2491: histological diagnosis subtype cancer inhl confirmed histologically tumor cell limited
+Cluster 2492: receptor er progesterone pr estrogen positive pgr negative staining breast
+Cluster 2493: uncompensated respiratory severe unstable renal uncontrolled cardiac hepatic diseases disease
+Cluster 2494: successfully malignancy resected completely carcinoma treated free situ skin subjects
+Cluster 2495: blasts raeb anemia refractory excess mds myelodysplastic high ipss leukemia
+Cluster 2496: ph philadelphia chromosome positive abl bcr kinase tyrosine patients tki
+Cluster 2497: pheochromocytoma patients concurrent diagnosis metastatic regorafenib biochemically phases untreated hyper
+Cluster 2498: tolerate oral able medications inability medication swallow malabsorption patients enteral
+Cluster 2499: pregnancy testing agree ongoing fcbp practice females childbearing potential contraception
+Cluster 2500: performed written related provide obtained procedures informed consent participation ability
+Cluster 2501: addictive preclude disorders psychiatric meeting conditions requirements opinion patient investigator
+Cluster 2502: promyelocytic pml leukemia rar retinoic apl acute rara alpha acid
+Cluster 2503: unl bilirubin aminotransferase ast metastases aspartate liver case serum transaminase
+Cluster 2504: women amenorrhea childbearing potential bilateral possibly menarche months suppression amenorrheic
+Cluster 2505: radiation toxicities recovered radiotherapy related corticosteroids pneumonitis require weeks prior
+Cluster 2506: expecting conceive children projected father breastfeeding duration pregnant study dose
+Cluster 2507: disease infiltrating autoimmune vasculitis erythematosus unacceptable possible lupus inflammatory bowel
+Cluster 2508: steroids topical inhaled systemic corticosteroids immunosuppressive permitted use allowed doses
+Cluster 2509: proton pump ppi inhibitors inhibitor study days receiving taken dose
+Cluster 2510: transaminase uln ast aspartate upper normal alanine limit alt serum
+Cluster 2511: enrolled protocol subjects currently investigational radiation completed subject treatment intensification
+Cluster 2512: adenocarcinoma carcinoma epithelial cell endometrioid serous histologic undifferentiated clear mixed
+Cluster 2513: pregnancy urine test negative reproductive female serum potential pregnant days
+Cluster 2514: umol creatinine mg dl serum plasma min days liter clearance
+Cluster 2515: colitis ulcerative inflammatory disease bowel crohns documented active prior crohn
+Cluster 2516: led permanent experienced discontinuation immunotherapy toxicity prior irae event immune
+Cluster 2517: neutrophils absolute mm count neutrophil cells apc mcl monocytes platelets
+Cluster 2518: obstruction bowel history symptoms partial signs complete small evidence months
+Cluster 2519: anaphylactic recombinant proteins allergic excipients severe hypersensitivity reaction reactions history
+Cluster 2520: type diabetes ii patients hbac uncontrolled neurofibromatosis fitzpatrick disease hyperglycemic
+Cluster 2521: initiation neutrophil mcl absolute anc count days treatment nabsolute prior
+Cluster 2522: neutrophil ml absolute count sorafenib equal cells arm fancc fascia
+Cluster 2523: pneumonitis history induced ongoing active drug immune mediated years requiring
+Cluster 2524: neuroendocrine small cell prostate carcinoma differentiation features adenocarcinoma histologically confirmed
+Cluster 2525: ihc immunohistochemistry positive fish tumor expression eso ny staining ini
+Cluster 2526: transplantation organ allogeneic history liver prior patients autologous tissue undergone
+Cluster 2527: values laboratory clinical specified screening protocol study adequate following bladder
+Cluster 2528: nutrition parenteral tpn hydration total dependency iv intravenous gastrostomy current
+Cluster 2529: therapies prior cancer anti received treatment patients approved systemic targeted
+Cluster 2530: psychiatric illness medical consent informed significant treatment compliance follow prevent
+Cluster 2531: reasons palliative radiotherapy weeks chemotherapy receiving systemic treatment study prior
+Cluster 2532: grapefruit ketoconazole juice itraconazole inhibitors erythromycin cypa clarithromycin miconazole ritonavir
+Cluster 2533: ul count lymphocyte cycle day days obtained treatment study prior
+Cluster 2534: wbc white blood mm cell days registration obtained prior expansion
+Cluster 2535: lower ejection fraction left ventricular normal limit lvef lln institutional
+Cluster 2536: restrictions apply men birth control study practicing regulations dose regarding
+Cluster 2537: inhalers excluding dose week steroids corticosteroids oral iv administration receiving
+Cluster 2538: diabetes uncontrolled history controlled patients ac diagnosed subjects hemoglobin diagnosis
+Cluster 2539: diarrhea chronic grade persistent uncontrolled resulting gastrointestinal greater gi baseline
+Cluster 2540: expansion escalation dose patients enrolled stage ii enrollment combination tumor
+Cluster 2541: portal vein main thrombosis invasion occlusion thrombus hepatic cava vena
+Cluster 2542: alternative cause menses medical age months years iu fsh level
+Cluster 2543: neck head radiation prior therapy cancer region chemotherapy previous patients
+Cluster 2544: responders recurred disease effective progressive standard salvage previously regimens non
+Cluster 2545: triple negative breast cancer cohort tnbc metastatic patients advanced histologically
+Cluster 2546: wounds ulcers unhealed healing fractures surgical non open patients incomplete
+Cluster 2547: contraception conjunction jelly intrauterine spermicidal sterile method barrier device surgically
+Cluster 2548: specific sign study informed consent entry prior patient patients understand
+Cluster 2549: alimentation affecting requirement gastrointestinal absorption inability disease tract oral intravenous
+Cluster 2550: current agents investigational use anticipated study participating therapy cohort receipt
+Cluster 2551: platelets mcl registration days prior obtained study performed step dose
+Cluster 2552: pregnant participating inform immediately suspect woman physician treating study partner
+Cluster 2553: breast diagnosis cancer current years invasive hr primary patients past
+Cluster 2554: equal greater platelets mm mcl ul grade ctcae creatinine treatment
+Cluster 2555: marrow involvement bone count unless anc platelet neutrophil absolute lymphoma
+Cluster 2556: bilirubin upper limit normal serum total uln performed tbl twice
+Cluster 2557: dated signed informed consent written provide procedures study voluntarily able
+Cluster 2558: recurrence local disease evidence progression cancer therapy patients treatment regional
+Cluster 2559: gleason score biopsy prostate cores higher cancer pattern grade core
+Cluster 2560: implants breast metal metallic mri bilateral patients contraindicated flap pacemakers
+Cluster 2561: retardation mental organic deficit dementia sensory brain diagnosis concurrent syndrome
+Cluster 2562: highly women effective contraception methods bearing child physiologically potential capable
+Cluster 2563: amylase uln serum institutional pancreatitis institutions ceritinib pancreatic fasting signs
+Cluster 2564: hypo hyperthyroid psoriasis requiring vitiligo diabetes type immunosuppressive disease replacement
+Cluster 2565: hepatitis positive antibody serology immunization indicative hbsab virus hbcab criterion
+Cluster 2566: foam spermicidal jelly diaphragm methods contraceptive childbearing intrauterine potential effective
+Cluster 2567: negligible outcome death expected malignancies curative metastasis treated risk exception
+Cluster 2568: renal acceptable function liver hematologic coagulation follows exhibit tests assessed
+Cluster 2569: concurrently using antineoplastic patient approved investigational agent anti agents cancer
+Cluster 2570: neurologic confound dysfunction brain evaluation develop adverse prognosis events metastases
+Cluster 2571: csf gm filgrastim sargramostim erythropoietin stimulating weeks factors colony prior
+Cluster 2572: longer whichever half lives drug investigational days study dose prior
+Cluster 2573: causes dyspnea effusion ascites pleural respiratory compromise grade ctcae version
+Cluster 2574: mouse antibody human hama anti products murine reaction hypersensitivity antibodies
+Cluster 2575: hysterectomy bilateral oophorectomy salpingo prior ligation tubal surgical salpingectomy sterile
+Cluster 2576: prednisolone prednisone corticosteroid contraindicated condition make medical use infection active
+Cluster 2577: pancreatic cancer chemotherapy radiation prior therapy radiotherapy treatment investigational systemic
+Cluster 2578: diffusing monoxide carbon dlco capacity predicted corrected lung hemoglobin lungs
+Cluster 2579: mental compromise impairment comply ability requirements informed consent study deficits
+Cluster 2580: function cardiac adequate assessed normal physical examination history clinically pulmonary
+Cluster 2581: unwilling fertile use contraceptives men post women months contraception transplant
+Cluster 2582: anticoagulation therapeutic receiving patients therapy stable require anticoagulant oral anticoagulants
+Cluster 2583: recovered surgery radiation toxicities therapy weeks prior major chemotherapy treatment
+Cluster 2584: diseases autoimmune history conditions medical concomitant concurrent uncontrolled active chronic
+Cluster 2585: vaccine attenuated live administration weeks anticipation study day cycle prior
+Cluster 2586: breast cancer metastatic prior therapy patients treatment history received positive
+Cluster 2587: pagets nipple disease bone breast history diagnosis patients inflammatory diagnosed
+Cluster 2588: asthma remote mild erythematosis rheumatoid arthritis lupus active history autoimmune
+Cluster 2589: gated multi acquisition muga fraction echocardiogram ejection scan cardiac normal
+Cluster 2590: equal eastern cooperative oncology performance group status ecog karnofsky greater
+Cluster 2591: mabs hypersensitivity severe reactions antibodies monoclonal history excipients patient treatment
+Cluster 2592: liver inherited alcoholic fatty disease cirrhosis viral hepatitis clinically significant
+Cluster 2593: optic nerve chiasm glioma pathway apparatus nf tumor medulla midbrain
+Cluster 2594: nitrosoureas weeks chemotherapy dose tazemetostat elapsed previous minimum date received
+Cluster 2595: unwillingness inability comply procedures follow study outlined cooperate protocol instructions
+Cluster 2596: hiv testing immunodeficiency virus human required known infection positive note
+Cluster 2597: dipg stratum progressive progressed recurrent non patients pons transfusions glioma
+Cluster 2598: noninfectious pneumonitis interstitial lung evidence active disease history known clinically
+Cluster 2599: protocol concurrent treatment participating defined patients participation allowed enrollment patient
+Cluster 2600: marginal zone lymphoma splenic nodal extranodal mzl follicular malt mucosa
+Cluster 2601: warfarin therapeutic use anticoagulants concurrent doses requires current inr heparin
+Cluster 2602: mi myocardial infarction months infraction history heart arq congestive angina
+Cluster 2603: pemetrexed cisplatin carboplatin prior platinum chemotherapy mesothelioma received regimen treatment
+Cluster 2604: significantly absorption interfere metabolism excretion distribution condition presence gastrointestinal drugs
+Cluster 2605: diarrhea ctcae grade patients persistent management despite nci medical active
+Cluster 2606: antiviral antifungal antibiotics chronic infection requiring systemic active bronchiectasis infectious
+Cluster 2607: autografting nonmyeloablative chemotherapy consolidation hct myeloma multiple permitted prior received
+Cluster 2608: fully effects corticosteroids currently recovered starting drug receiving systemic received
+Cluster 2609: compromise safety opinion condition investigator abnormality patient medical patients data
+Cluster 2610: recovery complete start major surgery weeks laparoscopy treatment study excluding
+Cluster 2611: corticosteroids systemic weeks patients use treatment receiving prior days immunosuppressive
+Cluster 2612: comparator hypersensitivity combination agent history designated applicable choices drugs ip
+Cluster 2613: standard therapy exists progressed solid advanced patients tumors despite disease
+Cluster 2614: operate requirements inability protocol entire schedule visit comply study able
+Cluster 2615: english unable read speak understand language questions respond patients complete
+Cluster 2616: scheduled surgery undergo receive chemotherapy patients study procedure patient weeks
+Cluster 2617: zubrod oncology eastern group cooperative ecog status performance karnofsky level
+Cluster 2618: uncontrolled disorder medical poor prohibits malignant obtaining risk disease examples
+Cluster 2619: places unacceptable participate condition risk laboratory subject abnormalities study presence
+Cluster 2620: wort st johns john rifampin rifampicin herbal discontinue use taking
+Cluster 2621: switched prolong medication different qt interval treatment discontinued currently receiving
+Cluster 2622: explained paracentesis air abdominal free recent procedure surgical evidence patients
+Cluster 2623: dehydration grade nci ctcae exacerbated version conditions opinion registration investigator
+Cluster 2624: hearing loss grade impairment sensorineural significant existing cisplatin clinically patients
+Cluster 2625: cellulose microcrystalline stearate colloidal silicon magnesium dioxide crospovidone mannitol excipients
+Cluster 2626: steroid steroids topical inhaled use nasal dose prednisone systemic mg
+Cluster 2627: uncontrolled heart malnutrition ischemic severe illness hypertension disease diabetes active
+Cluster 2628: amylase lipase uln serum normal limits days range registration upper
+Cluster 2629: extensive resection crohn colitis ulcerative gastric disorder gastrointestinal small significant
+Cluster 2630: mm repeated accurately suitable accurate measurements axis longest irradiated lesion
+Cluster 2631: crushing chewing dissolving oral tablets able medication breaking altering opening
+Cluster 2632: metastases leptomeningeal brain active cerebral treated subjects patients allowed nervous
+Cluster 2633: cystectomy radical candidate patients undergo urologic attending medically diversion patient
+Cluster 2634: gbm recurrent histologically recurrence confirmed proven diagnosis treatment gliosarcoma prior
+Cluster 2635: oral medication able swallow consume inability patient subjects patients swallowed
+Cluster 2636: parp olaparib inhibitor including previous treatment veliparib rucaparib talazoparib prior
+Cluster 2637: gilbert bilirubin uln upper normal limit total syndrome unless institutional
+Cluster 2638: hepatitis factors risk hbv hcv virus screening medical acid history
+Cluster 2639: pancytopenia cytopenias reversible neoplastic judged underlying potentially disease studies results
+Cluster 2640: weight lbs scanner table pounds weighing limit fit gantry subjects
+Cluster 2641: anticancer approved investigational concurrent therapeutics therapy therapeutic steroids agents use
+Cluster 2642: phaeochromocytoma patients zydelig family fascia farber fap fanconi fancd fancc
+Cluster 2643: hormonal therapy prior treatment cancer chemotherapy weeks tamoxifen study received
+Cluster 2644: csf cerebrospinal fluid cytology cns leptomeningeal disease nervous lumbar central
+Cluster 2645: radionuclide fraction angiogram ejection echocardiogram shortening gated study function cardiac
+Cluster 2646: thromboplastin normalized inr partial ratio international ptt time uln seconds
+Cluster 2647: transfusion hemoglobin dl permitted days allowed blood erythropoietin reach meet
+Cluster 2648: drugs supportive contraindication hydration treatments concomitant preexisting intolerance impairment required
+Cluster 2649: chorionic hcg gonadotropin beta human pregnant positive breastfeeding serum test
+Cluster 2650: hospitalization requiring exacerbation respiratory registration precluding obstructive illness chronic pulmonary
+Cluster 2651: aids cdc definition acquired deficiency immune protocol centers based current
+Cluster 2652: bone metastases scan disease lesions metastatic paget metastasis new progression
+Cluster 2653: needle biopsy core fine aspiration fna diagnosis breast tumor biopsies
+Cluster 2654: cerebellum involving tumors cerebral patients families farber fap fanconi fancd
+Cluster 2655: pi principal investigator discretion patients study determined opinion patient designee
+Cluster 2656: immunodeficiency virus human hiv infection known history patient regardless based
+Cluster 2657: start radiotherapy weeks treatment study prior received palliative completed lesions
+Cluster 2658: competent mentally consent informed sign understand form willingness ability irb
+Cluster 2659: curative intent surgery resection radiation amenable treatment therapy surgical eligible
+Cluster 2660: potassium range correctable supplements normal start institutional corrected days serum
+Cluster 2661: cured carcinoma situ skin years malignancy malignancies cancer cervical treated
+Cluster 2662: study agree accepted sexually course medically barrier methods use contraception
+Cluster 2663: infection requiring active systemic treatment therapy acute prior ongoing admission
+Cluster 2664: igm subtype myeloma multiple immunoglobulin level minimum times measurable serum
+Cluster 2665: spermicide methods contraception method barrier condom intrauterine plus male hormonal
+Cluster 2666: ischemia symptomatic myocardial evidence peripheral ecg infarction electrocardiogram significant electrocardiography
+Cluster 2667: grade hematologic toxicity resolved non therapy previous prior acute exception
+Cluster 2668: versus host graft transplant allogeneic stem cell disease active months
+Cluster 2669: affect poorly crohns gastrointestinal colitis ulcerative absorption disorders controlled malabsorption
+Cluster 2670: gi alter significantly impairment absorption gastrointestinal everolimus function oral disease
+Cluster 2671: donor matched unrelated related sibling available hla identified suitable mismatched
+Cluster 2672: benefit clinical confer intolerant therapies provide available known therapy standard
+Cluster 2673: pills injections contraception intrauterine implants iud birth device control effective
+Cluster 2674: stages cancer iii breast diagnosed disease participate willing iv geographically
+Cluster 2675: line refractory relapsed therapy prior treatment disease chemotherapy aml patients
+Cluster 2676: steroid immunosuppressive form medication chronic excess systemic doses replacement therapy
+Cluster 2677: progression disease evidence therapy documented treatment radiographic prior patients months
+Cluster 2678: resolution alopecia toxic grade effect recent therapy prior chemotherapy surgery
+Cluster 2679: viral hepatitis active infection hiv virus immunodeficiency human known chronic
+Cluster 2680: hipaa authorization health informed consent release separately information personal portability
+Cluster 2681: start surgery major weeks study treatment prior days cycle therapy
+Cluster 2682: palmetto saw herbal decrease psa levels products spes pc prostate
+Cluster 2683: malignancies hematologic non epithelial sarcoma lymphoma cancers killer patients natural
+Cluster 2684: perforatum hypericum remedy wort st herbal johns use john interrupt
+Cluster 2685: prohibited bisphosphonates use huang yohimbe ephedra kava ginseng concurrent treatment
+Cluster 2686: apecsc actionable assignment match choice given mutation analysis molecular enrolled
+Cluster 2687: infections antibiotics active requiring systemic intravenous controlled patients therapy chronic
+Cluster 2688: mek inhibitor braf prior treatment therapy raf inhibitors previous vemurafenib
+Cluster 2689: severely expectancy life limited diseases illness malignancy concomitant patients disease
+Cluster 2690: specified protocol therapy concomitant use chemotherapy immunotherapy meet radiation prior
+Cluster 2691: nodes lymph axillary regional cm positive disease metastatic patients pelvic
+Cluster 2692: adjuvant neo chemotherapy therapy prior treatment months setting metastatic received
+Cluster 2693: serology hiv positive antiviral negative htlv viral infection known nucleic
+Cluster 2694: arrhythmias uncontrolled ventricular ischemia conduction severe electrocardiographic angina acute abnormalities
+Cluster 2695: carfilzomib bortezomib treatment prior proteasome lenalidomide therapy received inhibitor refractory
+Cluster 2696: major surgery days registration prior study patients treatment entering undergone
+Cluster 2697: birth control use methods acceptable study potential agree method female
+Cluster 2698: aspartate aminotransferase ast normal range reference limits institutional infusion alk
+Cluster 2699: inducing enzyme epileptic eiaed anti drugs eiaeds phenobarbital carbamazepine phenytoin
+Cluster 2700: flt itd mutation tkd activating aml positive mutations patients local
+Cluster 2701: immunotherapy vaccines type completion tumor days weeks completed initiation subjects
+Cluster 2702: vaccines live attenuated typhoid polio tya rubella mumps yellow varicella
+Cluster 2703: cart hiv copies mrna mm meet stavudine messenger zidovudine antiretroviral
+Cluster 2704: urinalysis abnormalities clinically significant results days studied patient demonstrating urinary
+Cluster 2705: study course dose contraception adequate willing childbearing potential female participants
+Cluster 2706: lesions endobronchial infiltrating vessels pulmonary major known bronchi hemorrhage increase
+Cluster 2707: interfere cooperate likely deemed participate ability mental condition investigator substance
+Cluster 2708: state current curative disease known option therapy hypercoagulable lymphoid currently
+Cluster 2709: autoimmune asthma atopy childhood vitiligo resolved disease history documented active
+Cluster 2710: acidosis associated lactic alcoholic beverages heart metformin habitual intake increased
+Cluster 2711: lower muga acquisition ejection fraction left lvef echocardiogram ventricular gated
+Cluster 2712: ventricular arrest sudden syncope etiology fibrillation tachycardia personal cardiovascular conditions
+Cluster 2713: recurrent disease cancer metastatic patients breast progressive chemotherapy refractory treatment
+Cluster 2714: host versus graft transplantation allogeneic gvhd stem cell disease hematopoietic
+Cluster 2715: myeloma imwg working international multiple group criteria diagnosis diagnostic according
+Cluster 2716: radiation received therapy patients chemotherapy prior weeks study treatment gy
+Cluster 2717: cancer basal squamous skin cell years malignancy invasive history treated
+Cluster 2718: tablet swallow able drug capsule study ability unable drugs pill
+Cluster 2719: transplantation allogeneic organ solid marrow prior bone patients transplant autologous
+Cluster 2720: perflutren hypersensitivity known definity suspected lipid patients agent component microspheres
+Cluster 2721: vaccines flu influenza live allowed mist seasonal inactivated generally intranasal
+Cluster 2722: trial start treatment investigational days concomitantly therapy drug agents past
+Cluster 2723: lymphocyte count ul absolute mm days cells registration cd obtained
+Cluster 2724: days infusion growth xrt elapsed therapy myelosuppressive dose prior events
+Cluster 2725: contraindicate undue place complications disorder physician drugs treating subject opinion
+Cluster 2726: gemcitabine cisplatin prior received hypersensitivity treatment chemotherapy patients therapy adjuvant
+Cluster 2727: individuals antiretroviral combination hiv ineligible positive immunodeficiency virus human therapy
+Cluster 2728: modification mdrd diet renal min ml glomerular filtration creatinine rate
+Cluster 2729: marrow bone biopsy patients involvement cells cellularity disease blood peripheral
+Cluster 2730: participate consent informed study written able provide procedures understand patients
+Cluster 2731: colony granulocyte stimulating csf factor macrophage gm factors erythropoietin weeks
+Cluster 2732: steroid prednisone equivalent mg day systemic therapy chronic dose physiologic
+Cluster 2733: glomerular filtration gfr rate min ml estimated creatinine renal calculated
+Cluster 2734: coagulation adequate profile defects function parameters jaundice functioning defined normal
+Cluster 2735: fev expiratory forced volume second predicted pulmonary corrected lung value
+Cluster 2736: renal liver acute chronic disease pancreatitis severe unrelated patients considered
+Cluster 2737: tentorium vault cranial detected foci metastases tumor evidence gbm outside
+Cluster 2738: malignant tumors advanced hepatic patients solid excluded presence known low
+Cluster 2739: specific criteria eligibility phase cohort subprotocols protocol exclusion inclusion restriction
+Cluster 2740: starting surgery major weeks treatment radiation study therapy days prior
+Cluster 2741: invasive breast cancer diagnosed prior bilateral currently history biopsy lobular
+Cluster 2742: oncologist treating medical radiation determined patients patient attending surgeon study
+Cluster 2743: inclusive corticosteroids metastases concurrent limited symptomatic brain requiring radiation surgery
+Cluster 2744: protein dyscrasia polyneuropathy organomegaly endocrinopathy poems changes plasma monoclonal skin
+Cluster 2745: hematologic visit factors growth screening values laboratory obtained days transfusions
+Cluster 2746: encasement mesenteric sma superior artery smv vein abutment celiac degrees
+Cluster 2747: invasive cancer non melanoma skin years cancers malignancies past exception
+Cluster 2748: hemorrhagic history stroke thrombotic hereditary telangiectasia cystitis months disorders disorder
+Cluster 2749: dementia parkinsons neurological disease history neurologic disorders psychosis disorder psychiatric
+Cluster 2750: participate study interventional agrees willing patient subject cognitively able patients
+Cluster 2751: gi diarrhea vomiting alter nausea ulcerative significantly malabsorption diseases absorption
+Cluster 2752: hepatitis active patients liver tests infection abnormal tuberculosis function carriers
+Cluster 2753: investigational agents received days receiving patients past prior day treatment
+Cluster 2754: heat hsp shock deacetylase dac protein hdac valproic histone inhibitors
+Cluster 2755: feeding breast donor time study patients currently patient lactation applicable
+Cluster 2756: delayed weeks regimens chemotherapy toxicity continuously weekly basis given limited
+Cluster 2757: refrain sperm study donating dose drug period male days donation
+Cluster 2758: antibody monoclonal prior therapy lives half elapsed weeks days dose
+Cluster 2759: cns leukemia active fluid cerebrospinal known nervous patients central intrathecal
+Cluster 2760: er estrogen receptor positive breast cancer invasive staining negative cells
+Cluster 2761: embolism pulmonary months entry prior study previous history symptomatic acute
+Cluster 2762: porphyria porphyrins porphyrin photosensitivity patients hypersensitivity like compounds psoriasis history
+Cluster 2763: kg weight weighing weighs patients lb age patient bmi equal
+Cluster 2764: potentially curative therapy amenable patients resection available disease standard undergone
+Cluster 2765: measurable ct mri disease recist assessed registration scan lesion imaging
+Cluster 2766: inhibitors cypa boosted boceprevir telaprevir ritonavir cobicistat ciprofloxacin diltiazem olaparib
+Cluster 2767: alcoholism drug history abuse illicit diagnosis active addiction use recent
+Cluster 2768: nasopharyngeal carcinoma primary sinus paranasal salivary gland cancer site patients
+Cluster 2769: induction chemotherapy bcg patients therapy consolidation intensive regimen standard received
+Cluster 2770: abdominal abscess fistula intra obstruction perforation bowel including gastrointestinal appendicitis
+Cluster 2771: cancer cell adequately treated basal squamous skin situ malignancy free
+Cluster 2772: phase ib expansion portion treatment eligibility study patients prior trial
+Cluster 2773: impairment renal severe function cardiac existing hydration gastrointestinal visual contraindicated
+Cluster 2774: involvement cns nervous central active malignancy cells disease patients symptomatic
+Cluster 2775: hypersensitivity severe asthma monoclonal reactions antibodies nci anaphylaxis ctcae known
+Cluster 2776: lymphocytic lymphoma sll small leukemia cll chronic cell follicular marginal
+Cluster 2777: gej adenocarcinoma gastric confirmed stomach histologically metastatic siewert advanced junction
+Cluster 2778: crossover step registration optional arm days patients prior iuln criteria
+Cluster 2779: chemotherapeutic lymphotoxic agents leukapheresis bendamustine cyclophosphamide cytotoxic lymphodepletion elapsed lives
+Cluster 2780: malignancy cancer melanomatous adequately exception concurrent basal skin squamous treated
+Cluster 2781: immunotherapy anticancer chemotherapy weeks therapy day cycle radiation prior systemic
+Cluster 2782: performance status oncology group ecog eastern cooperative exhibit expectancy life
+Cluster 2783: kilograms weight body kg donor donors pounds years weighing related
+Cluster 2784: bright hemoptysis teaspoon red blood episode month history prior day
+Cluster 2785: study men agree duration contraception participation adequate pregnant use suspect
+Cluster 2786: swallow medications oral ability able inability patient condition reliably precludes
+Cluster 2787: myelomonocytic cmml leukemia chronic mds juvenile mpn myeloproliferative diagnosis myelodysplastic
+Cluster 2788: ambulatory walking non assistive aid walk able ecog devices self
+Cluster 2789: equation cockcroft gault clearance min ml creatinine calculated using obtained
+Cluster 2790: bowel small condition modify study enzymes pancreas inappropriate interpretation make
+Cluster 2791: follow available study duration willing reliable procedures make patients treatment
+Cluster 2792: platelets mm registration cells days prior obtained study protocol weeks
+Cluster 2793: involvement nervous cns central known aml active patients leptomeningeal participant
+Cluster 2794: strong cytochrome subfamily cypa family inhibitors treatment polypeptide requires chronic
+Cluster 2795: clinical follow immunological exam patients evidence disease availability lack nodal
+Cluster 2796: heart ventricular screening mmhg degree pressure nyha class months systolic
+Cluster 2797: tissue biomarker provide tumor analyses consent biopsy archival willing analysis
+Cluster 2798: apply exclusion criteria protocol defined inclusion pregnant nursing lactating women
+Cluster 2799: eighteen older years age old sm proven day progressive refractory
+Cluster 2800: able understand sign consent informed document read patients patient person
+Cluster 2801: nab paclitaxel gemcitabine hypersensitivity treatment prior known arm history excipients
+Cluster 2802: jeopardize reasonable outlined safety ability receive illness infection concurrent medical
+Cluster 2803: oxidase monoamine inhibitors mao maoi serotonin tricyclic inhibitor antidepressants clonidine
+Cluster 2804: lymphedema group head neck cancer iii treatment therapists primary extremity
+Cluster 2805: comply procedures willingness follow ability study interventions stated unable duration
+Cluster 2806: pulmonary obstructive chronic copd disease severe asthma lung moderate requiring
+Cluster 2807: troponin normal baseline bnp levels limit cardiac limits uln ctn
+Cluster 2808: nyha class iv iii failure heart congestive classification ii cardiac
+Cluster 2809: irradiated previously measurable lesions recist lesion progression disease situated considered
+Cluster 2810: mm calipers exam ray recorded accurately longest dimension chest diameter
+Cluster 2811: declining itp thrombocytopenic purpura hemolytic resulting anemia idiopathic evidenced hgb
+Cluster 2812: antimicrobial responding infection therapy active appropriate uncontrolled infections adequately requiring
+Cluster 2813: allograft organ history prior transplantation allogeneic immunosuppression transplanted transplant recipient
+Cluster 2814: men wocbp sexually contraception instructed nivolumab azoospermic active adhere method
+Cluster 2815: bilirubin gilberts uln upper normal total limit syndrome disease institutional
+Cluster 2816: egfr epidermal receptor growth factor kinase alk anaplastic lymphoma mutations
+Cluster 2817: celiac bowel disease colitis diarrhea gastrointestinal inflammatory history irritable chronic
+Cluster 2818: abstinence contact heterosexual true interruption study commit agree interruptions monthly
+Cluster 2819: cns radiographic completion directed metastases hemorrhage interim optic provided anticonvulsants
+Cluster 2820: activator ligand kappa nuclear rank receptor factor bisphosphonates rankl denosumab
+Cluster 2821: cell renal carcinoma clear rcc component confirmed histologically metastatic histological
+Cluster 2822: serology hepatitis positive infection active test vaccination passive unless viral
+Cluster 2823: ich gcp conference local good written harmonization international consent informed
+Cluster 2824: hemolysis bilirubin gilberts mg dl syndrome unless total gilbert direct
+Cluster 2825: time ptt inr prothrombin thromboplastin pt partial normalized ratio international
+Cluster 2826: time prothrombin thromboplastin pt ptt partial normal uln upper limit
+Cluster 2827: hospice care receiving currently pc services enrolled enroll patient home
+Cluster 2828: alp alkaline phosphatase uln liver metastases aminotransferase bone ast alt
+Cluster 2829: contraceptive use study methods effective method agree oral hormonal implant
+Cluster 2830: candidate surgical patient resection appropriate surgeon deemed therapy good medical
+Cluster 2831: medication study suppressive interfere corticosteroids inhalers prior immuno days patients
+Cluster 2832: physician treating determined patients opinion judged discretion deemed disease patient
+Cluster 2833: stem transplant cell allogeneic prior autologous received patients months eligible
+Cluster 2834: transplant liver prior post days enrollment patients history study months
+Cluster 2835: uncontrolled infection patients concurrent systemic hepatitis grade excluded randomization evidence
+Cluster 2836: aminotransferase obtained uln aspartate ast registration days alanine alt prior
+Cluster 2837: gvhd host versus graft disease acute active grade chronic immunosuppressive
+Cluster 2838: research participants consent study actively treated active blood biopsies participating
+Cluster 2839: ago years malignancy eligible malignancies prior patients evidence diagnosed cancer
+Cluster 2840: allergens allergic unknown severe reactions components history drugs vaccines anaphylaxis
+Cluster 2841: atrial ventricular presence tachyarrhythmia history significant fibrillation clinically tachyarrhythmias sustained
+Cluster 2842: interstitial pneumonitis living activities affecting intervention daily lung therapeutic clinically
+Cluster 2843: retroviral hiv anti positive immunodeficiency human virus excluded receiving therapy
+Cluster 2844: techniques fertile contraceptive unwilling men use months women following treatment
+Cluster 2845: allergic reactions history attributed patients components hypersensitivity known paclitaxel product
+Cluster 2846: speak english able understand comprehend ability interpreter patients assistance questionnaires
+Cluster 2847: intravascular disseminated coagulation dic leukostasis evidence cns bleeding leukemia uncontrolled
+Cluster 2848: received prior patients therapy treatment chemotherapy days inhibitor agent eligible
+Cluster 2849: inhibitors flt kinase hydroxyurea biological hematopoietic targeted factors therapy growth
+Cluster 2850: brain seizures history subarachnoid controlled stroke cns tia examination primary
+Cluster 2851: skin carcinoma cell progressing potentially requires exceptions additional curative basal
+Cluster 2852: pd anti programmed death ligand cell agent receptor prior therapy
+Cluster 2853: arthritis autoimmune rheumatoid lupus systemic erythematosus disease sclerosis inflammatory vasculitis
+Cluster 2854: prednisone equivalent day mg corticosteroids dose systemic steroids weeks prior
+Cluster 2855: oxaloacetic glutamic sgot transaminase serum normal upper limit times uln
+Cluster 2856: serous ovarian peritoneal grade high fallopian tube cancer primary epithelial
+Cluster 2857: ppd purified derivative tuberculosis protein history tb test positivity positive
+Cluster 2858: grade sensory alopecia neuropathy recovered related toxicities stable severity events
+Cluster 2859: herbal supplements medications use dietary preparations study alternative stop remedies
+Cluster 2860: signed document consent informed assent understand capability appropriate patient documents
+Cluster 2861: aml secondary therapy prior chemotherapy patients diagnosis relapsed related novo
+Cluster 2862: mibg avid neuroblastoma uptake patients therapy weeks disease evaluable site
+Cluster 2863: cyclosporine tacrolimus immunosuppressive mycophenolate mofetil chronic corticosteroids sirolimus methotrexate immunosuppressants
+Cluster 2864: impair disorder opinion medical investigator study receive uncontrolled protocol ability
+Cluster 2865: instructions staff comply unable compliance medical given unwilling regimens non
+Cluster 2866: surgery minor major placement weeks procedures days insertion access biopsy
+Cluster 2867: randomization surgery major days prior weeks date radiotherapy time elapsed
+Cluster 2868: neuropathic pain symptoms scale neuropathy grade questionnaire minimum numeric existing
+Cluster 2869: carcinoma malignancy situ skin treated melanomatous non years adequately cervix
+Cluster 2870: transfusion platelets platelet days mcl support mm prior ul weeks
+Cluster 2871: donor mismatch homozygous allele hla pairs mismatched pra patient cross
+Cluster 2872: cva accident cerebrovascular months cerebral vascular history stroke multiple severe
+Cluster 2873: plasma leukemia cell circulating cells differential active standard remission partial
+Cluster 2874: skull base defect tumor missing tumors targeted bone brain replacement
+Cluster 2875: scan ct pet mri bone tomography computed evidence prior disease
+Cluster 2876: alkaline phosphatase uln metastases liver bone documented involvement present patients
+Cluster 2877: vismodegib partners condoms intercourse vasectomy sexual reproductive male times female
+Cluster 2878: appropriately treated cancer carcinoma skin melanoma cervical stage malignancy endometrial
+Cluster 2879: sensitivity known products components administered allergy dosing derived product vitamin
+Cluster 2880: volunteers healthy cohorts normal enhancement sub patient contrast group adult
+Cluster 2881: intent curative treated years malignancy cancer disease situ carcinoma allowed
+Cluster 2882: asthma mild history severe inhaled medications chronic requiring eligible presently
+Cluster 2883: ventricular pacemaker cardiac arrhythmias contractions medication requiring premature supraventricular pericarditis
+Cluster 2884: severe disease uncontrolled concurrent medical infection history illness heart patients
+Cluster 2885: women wocbp menarche postmenopausal defined potential amenorrhea experienced sterilization bilateral
+Cluster 2886: british french fab american promyelocytic leukemia aml acute classification mds
+Cluster 2887: amino transferase uln alt ast aspartate alanine aminotransferase liver times
+Cluster 2888: grade enter anticancer toxicities alopecia ctcae therapies version terminology recovered
+Cluster 2889: carcinoma situ cervix cancer skin years melanoma non treated malignancy
+Cluster 2890: er pr breast positive negative cancer ihc pgr tumor biopsy
+Cluster 2891: gog performance status patients grade gynecological oncology refer group appendix
+Cluster 2892: potential birth pregnancy agree control childbearing conception test negative impregnating
+Cluster 2893: provision procedures specific informed consent study prior written dated signed
+Cluster 2894: safety interfere investigator opinion compromise evaluation illness condition efficacy drug
+Cluster 2895: blasts peripheral blood marrow bone leukemic circulating aml presence detected
+Cluster 2896: carcinoma situ cervix basal cell skin malignancy squamous years treated
+Cluster 2897: irb board review approved institutional consent informed sign document written
+Cluster 2898: cells kg cd stem autologous cell collection cryopreserved minimum peripheral
+Cluster 2899: effective contraception sterile surgically agree female use postmenopausal period patients
+Cluster 2900: cfr code donor regulations federal eligibility agency outlined donors donation
+Cluster 2901: remission complete cr patients partial second leukemia disease pr lymphoma
+Cluster 2902: hematocrit hemoglobin anemia donor dl reached males transfusion females initiation
+Cluster 2903: limits normal supplements magnesium outside corrected phosphorus institutional sodium serum
+Cluster 2904: beneficiary security france affiliated category social french inclusion subject eligible
+Cluster 2905: childbearing potential amenorrheic women postmenopausal pregnancy test months considered negative
+Cluster 2906: swallowing capsules difficulty participate procedures willing able including evaluations capable
+Cluster 2907: alcoholic liver cirrhosis steatohepatitis hepatitis induced chronic biliary caused cholelithiasis
+Cluster 2908: contraceptive device methods barrier intrauterine double iud women bearing child
+Cluster 2909: radiotherapy prior cranial treatment received gy allowed external brain hemibody
+Cluster 2910: lipase serum uln normal upper limit institutional inclusion registration capmatinib
+Cluster 2911: meningeal spinal progressive new brain metastases subjects falling fallopian falls
+Cluster 2912: cancers situ required melanoma dysplasia colon bladder achieved gastric malignancies
+Cluster 2913: ova final study donate female drug administration period screening breastfeed
+Cluster 2914: axis cm short diameter lymph node nodes lesion measurable long
+Cluster 2915: vaccinations live attenuated influenza vaccines days weeks given treatment study
+Cluster 2916: abstinence methods lifestyle usual preferred ovulation acceptable true periodic symptothermal
+Cluster 2917: hsct gvhd host graft versus post immunosuppressive hematopoietic transplant time
+Cluster 2918: mucositis oral current presence grade patients therapy prevention currently study
+Cluster 2919: ugta polymorphism homozygous udp diclofenac imipramine glucuronosyltransferase inhibitor mefenamic probenecid
+Cluster 2920: reserve inadequate marrow bone organ function demonstrated laboratory values following
+Cluster 2921: nt probnp troponin pro pg terminal threshold natriuretic ng ml
+Cluster 2922: age consent appropriate informed pediatric guardian assent years discussion included
+Cluster 2923: unwilling contraception adequate unable use year start protocol women methods
+Cluster 2924: size cm tumor breast lesion greater primary diameter patients imaging
+Cluster 2925: vascular transient ischemic attack accident cerebrovascular outpatient disease angina unstable
+Cluster 2926: immunodeficiency hiv virus human known history patients hepatitis disease active
+Cluster 2927: bearing child females pregnancy test potential negative serum study urine
+Cluster 2928: predicted expectancy life months weeks greater subject patient patients ace
+Cluster 2929: marrow pediatric cycles blasts failed patients having aml high risk
+Cluster 2930: smoking pack cigarettes tobacco years history year quit smoker smoked
+Cluster 2931: transplant marrow bone allogeneic stem cell prior previous autologous history
+Cluster 2932: form sign specific consent study patients informed patient prior able
+Cluster 2933: signed specific procedures informed consent study prior obtained initiation written
+Cluster 2934: ability consent informed willingness donor patients lack demonstrate read willing
+Cluster 2935: lab values creatinine surgeon results uln performed prior prevent serum
+Cluster 2936: surgery obtain diagnostic removal major undergone biopsy diagnosis organ day
+Cluster 2937: lifespan anticipated greater expected month weeks months assessment investigator fap
+Cluster 2938: lumbar puncture cns involvement nervous central required symptoms diagnostic leukemic
+Cluster 2939: illness uncontrolled heart social compliance psychiatric congestive situations failure cardiac
+Cluster 2940: cd major surgery weeks days prior dosing scheduled anticancer agent
+Cluster 2941: hemoglobin mg dl thrombocytopenia platelets obtain phosphorus dosing transfusion hours
+Cluster 2942: met hgf inhibitor pre requirements criteria entry patients treatment prior
+Cluster 2943: age years potential menses bearing child pregnancy negative test onset
+Cluster 2944: scale eastern cooperative group oncology ecog performance status equal according
+Cluster 2945: endotracheal endobronchial tumor evidence anus invading rectum esophagus cabozantinib tract
+Cluster 2946: directed therapy discontinued tumor malignant prior immunologic registration hormonal agents
+Cluster 2947: bilirubin uln gilbert total direct syndrome patients normal upper limit
+Cluster 2948: curative treated intent prostate cancer situ surgically carcinoma ductal negligible
+Cluster 2949: investigation participated clinical dosing month investigational currently drug prior patients
+Cluster 2950: heart class failure york ejection fraction association nyha new congestive
+Cluster 2951: healthy volunteer controls pilot control group female criteria participants exclusion
+Cluster 2952: intratumoral injection accessible percutaneously tumor site sd diameter lesion ep
+Cluster 2953: lymphoma cns involvement nervous central known active patients leptomeningeal cerebrospinal
+Cluster 2954: medication screening antihypertensive heart arrhythmias hg pressure controlled blood cardiac
+Cluster 2955: inactivated vaccines vaccination avelumab prohibited administration weeks dose trial trials
+Cluster 2956: significant tolerate compromise clinically dysfunction illness infections organ results ability
+Cluster 2957: inability comply protocol requirements procedures study assessments follow available willing
+Cluster 2958: claustrophobia severe anxiolytics unresponsive history oral mri symptomatic subjects inability
+Cluster 2959: heart classification york association new iv iii functional failure nyha
+Cluster 2960: strontium samarium radium rhenium weeks radiopharmaceuticals prior treatment therapy systemic
+Cluster 2961: score years lansky age karnofsky performance status scale lps kps
+Cluster 2962: breast cancer conserving surgery biopsy imaging mammogram patients multicentric erythema
+Cluster 2963: ind covered investigational receiving study monitor sponsor medications actively pi
+Cluster 2964: range lower times upper limit normal gender reference test hemoglobin
+Cluster 2965: protein level myeloma serum paraprotein dl urine hours multiple mg
+Cluster 2966: plexus dental stent work celiac biliary minor placement block dosing
+Cluster 2967: sugar blood diabetes fasting mg dl uncontrolled substitute random mellitus
+Cluster 2968: past months days year history use cigarettes chemotherapy weeks month
+Cluster 2969: predominant lymphocyte nodular hodgkin lymphoma hl classical hodgkins diagnosis world
+Cluster 2970: brainstem cerebellum spinal cord leptomeningeal evidence disease multifocal radiological growing
+Cluster 2971: cerebrovascular accident stroke history months movement known past seizures prior
+Cluster 2972: gleason psa prostate score risk ng stage tb intermediate ml
+Cluster 2973: inability oral unwillingness swallow tolerance comply medication absorption requirements administration
+Cluster 2974: parameters undergoing seconds hematology biopsy meeting patients lupus anticoagulant normalized
+Cluster 2975: consciousness loss seizure attack transient ischemic history predispose months cortical
+Cluster 2976: maintained corticosteroid stable regimen baseline increase days decreasing scan patients
+Cluster 2977: proteinuria grade urinalysis hours dipstick gm greater hematuria hrs mg
+Cluster 2978: protected release authorization information health sign aware indicating nature patients
+Cluster 2979: prothrombin pt time uln normal seconds upper limit control anticoagulation
+Cluster 2980: mmol sodium mg dl normalize levels despite intervention serum electrolyte
+Cluster 2981: motor sensory neuropathy grade ctcae equal peripheral preexisting existing pre
+Cluster 2982: problem feels pose unacceptable underlying addition dysfunction organ condition risk
+Cluster 2983: tissue needle tumor specimens biopsy core acceptable samples slides blocks
+Cluster 2984: finding laboratory physical medical investigator illness study increase opinion condition
+Cluster 2985: affect absorption gastrointestinal malabsorption drug condition bypass gastric lenvatinib conditions
+Cluster 2986: contents voluntarily explained fully signed policies informed consent accordance institutional
+Cluster 2987: intestinal obstruction enteropathy diarrhea signs inflammatory history gastro vomiting extensive
+Cluster 2988: arrhythmic anti arrhythmias ventricular cardiac requiring therapy fibrillation drugs controlled
+Cluster 2989: ffpe tissue slides tumor block formalin unstained fixed paraffin embedded
+Cluster 2990: years age time adult patients enrollment diagnosis adults study months
+Cluster 2991: immunodeficiency diagnosis congenital inherited participants acquired autoimmune condition active prior
+Cluster 2992: hepatitis chronic history active acute known type viral undergoing positive
+Cluster 2993: rankl atezolizumab denosumab discontinue treatment inhibitor requiring patients require fallopian
+Cluster 2994: focbp undergone celibate remaining orientation choice months naturally meets sexual
+Cluster 2995: ms qtc interval males females prolonged ecg prolongation qt qtcb
+Cluster 2996: products pregnancy women wocbp potential contraceptives mechanical practicing spermicides using
+Cluster 2997: checkpoint immune inhibitor inhibitors prior therapy treatment cell immunotherapy pathways
+Cluster 2998: pose interfere condition study risk investigator opinion conduct unacceptable patient
+Cluster 2999: platinum therapy compound surgical intraperitoneal organoplatinum carboplatin management extended cisplatin